Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation. by Stevenson, M. et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 20 ISSUE 46 JUNE 2016
ISSN 1366-5278
DOI 10.3310/hta20460
Sepsis: the LightCycler SeptiFast Test MGRADE®, 
SepsiTest™ and IRIDICA BAC BSI assay for rapidly 
identifying bloodstream bacteria and fungi –  
a systematic review and economic evaluation
Matt Stevenson, Abdullah Pandor, Marrissa Martyn-St James,  
Rachid Rafia, Lesley Uttley, John Stevens, Jean Sanderson,  
Ruth Wong, Gavin D Perkins, Ronan McMullan and Paul Dark

Sepsis: the LightCycler SeptiFast Test
MGRADE®, SepsiTest™ and IRIDICA BAC BSI
assay for rapidly identifying bloodstream
bacteria and fungi – a systematic review
and economic evaluation
Matt Stevenson,1* Abdullah Pandor,1
Marrissa Martyn-St James,1 Rachid Rafia,1
Lesley Uttley,1 John Stevens,1 Jean Sanderson,1
Ruth Wong,1 Gavin D Perkins,2,3 Ronan McMullan4,5
and Paul Dark6,7
1School of Health and Related Research, University of Sheffield, Sheffield, UK
2Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
3Heart of England NHS Foundation Trust, Coventry, UK
4Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK
5Belfast Health and Social Care Trust, The Royal Hospitals, Belfast, UK
6Institute of Inflammation and Repair, University of Manchester, Manchester, UK
7Salford Royal NHS Foundation Trust, Salford, UK
*Corresponding author
Declared competing interests of authors: Gavin D Perkins is a member of the Health Services and
Delivery Research (researcher-led) panel. Ronan McMullan reports grant funding (2012–17) as a member
of the Innovate UK-funded consortium, with industry partner (Randox Ltd), to develop and validate a novel
point-of-care diagnostic test for sepsis. Paul Dark reports grants from Innovate UK (Technology Strategy
Board) during the conduct of the study.
Published June 2016
DOI: 10.3310/hta20460
This report should be referenced as follows:
Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, et al. Sepsis: the
LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying
bloodstream bacteria and fungi – a systematic review and economic evaluation. Health Technol
Assess 2016;20(46).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment NICE TAR and DAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.027
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number
14/69/04. The protocol was agreed in May 2015. The assessment report began editorial review in August 2015 and was accepted for
publication in November 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up
their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for
their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material
published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a
commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials
and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor John Norrie Health Services Research Unit, University of Aberdeen, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research and
Development Group, University of Winchester, UK
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™
and IRIDICA BAC BSI assay for rapidly identifying
bloodstream bacteria and fungi – a systematic review and
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Background: Sepsis can lead to multiple organ failure and death. Timely and appropriate treatment can
reduce in-hospital mortality and morbidity.
Objectives: To determine the clinical effectiveness and cost-effectiveness of three tests [LightCycler
SeptiFast Test MGRADE® (Roche Diagnostics, Risch-Rotkreuz, Switzerland); SepsiTestTM (Molzym Molecular
Diagnostics, Bremen, Germany); and the IRIDICA BAC BSI assay (Abbott Diagnostics, Lake Forest, IL, USA)]
for the rapid identification of bloodstream bacteria and fungi in patients with suspected sepsis compared
with standard practice (blood culture with or without matrix-absorbed laser desorption/ionisation time-of-
flight mass spectrometry).
Data sources: Thirteen electronic databases (including MEDLINE, EMBASE and The Cochrane Library) were
searched from January 2006 to May 2015 and supplemented by hand-searching relevant articles.
Review methods: A systematic review and meta-analysis of effectiveness studies were conducted.
A review of published economic analyses was undertaken and a de novo health economic model was
constructed. A decision tree was used to estimate the costs and quality-adjusted life-years (QALYs)
associated with each test; all other parameters were estimated from published sources. The model was
populated with evidence from the systematic review or individual studies, if this was considered more
appropriate (base case 1). In a secondary analysis, estimates (based on experience and opinion) from seven
clinicians regarding the benefits of earlier test results were sought (base case 2). A NHS and Personal Social
Services perspective was taken, and costs and benefits were discounted at 3.5% per annum. Scenario
analyses were used to assess uncertainty.
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Results: For the review of diagnostic test accuracy, 62 studies of varying methodological quality were
included. A meta-analysis of 54 studies comparing SeptiFast with blood culture found that SeptiFast had
an estimated summary specificity of 0.86 [95% credible interval (CrI) 0.84 to 0.89] and sensitivity of 0.65
(95% CrI 0.60 to 0.71). Four studies comparing SepsiTest with blood culture found that SepsiTest had an
estimated summary specificity of 0.86 (95% CrI 0.78 to 0.92) and sensitivity of 0.48 (95% CrI 0.21 to
0.74), and four studies comparing IRIDICA with blood culture found that IRIDICA had an estimated
summary specificity of 0.84 (95% CrI 0.71 to 0.92) and sensitivity of 0.81 (95% CrI 0.69 to 0.90).
Owing to the deficiencies in study quality for all interventions, diagnostic accuracy data should be treated
with caution. No randomised clinical trial evidence was identified that indicated that any of the tests
significantly improved key patient outcomes, such as mortality or duration in an intensive care unit or
hospital. Base case 1 estimated that none of the three tests provided a benefit to patients compared with
standard practice and thus all tests were dominated. In contrast, in base case 2 it was estimated that all
cost per QALY-gained values were below £20,000; the IRIDICA BAC BSI assay had the highest estimated
incremental net benefit, but results from base case 2 should be treated with caution as these are not
evidence based.
Limitations: Robust data to accurately assess the clinical effectiveness and cost-effectiveness of the
interventions are currently unavailable.
Conclusions: The clinical effectiveness and cost-effectiveness of the interventions cannot be reliably
determined with the current evidence base. Appropriate studies, which allow information from the tests to
be implemented in clinical practice, are required.
Study registration: This study is registered as PROSPERO CRD42015016724.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Aliquot A portion of a total amount of a solution.
Amplicon A piece of deoxyribonucleic acid or ribonucleic acid that is the source and/or product of natural
or artificial amplification or replication events.
Antigen Any structural substance that serves as a target for the receptors of an adaptive
immune response.
Antimicrobial medications Drugs used to treat infections, such as antibiotics and antifungal and
antiviral drugs.
Bacteraemia The presence of bacteria in the blood.
Bloodstream infection The presence of bacteria in the blood.
Broad-spectrum antibiotic An antibiotic that acts against a wide range of disease-causing bacteria.
Colony-forming unit A unit used to estimate the number of viable bacteria or fungal cells in a sample.
Conformité Européenne mark A manufacturer’s declaration that the product meets the requirements of
the applicable Electronic Commerce directives.
Dominated Of an intervention, more expensive and providing the same or fewer additional quality-adjusted
life-years than another intervention, or equally expensive and providing fewer quality-adjusted life-years than
another intervention.
Dominating Of an intervention, less expensive and providing the same or more quality-adjusted
life-years than another intervention, or equally expensive and providing more quality-adjusted life-years
than another intervention.
Empiric treatment A therapy based on clinical experience in the absence of complete information.
Gram-indeterminate bacteria Bacteria that do not respond predictably to Gram staining and, therefore,
cannot be determined as either Gram positive or Gram negative.
Gram-negative bacteria Bacteria that give a negative result in the Gram stain test.
Gram-positive bacteria Bacteria that give a positive result in the Gram stain test.
Gram staining Differentiates bacteria by the chemical and physical properties of their cell walls by
detecting peptidoglycan, which is present in a thick layer in Gram-positive bacteria.
Incremental cost-effectiveness ratio The additional cost per unit increase in effectiveness (often
measured in quality-adjusted life-years).
Incremental net monetary benefit A measure of the cost-effectiveness of a test at a given cost per
quality-adjusted life-year gained threshold. The greater the incremental net monetary benefit, the more
cost-effective the test.
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Index test The test of which the performance is being evaluated.
Lysis The breaking down of the membrane of a cell, often by viral, enzymic or osmotic mechanisms that
compromise its integrity.
Maximum acceptable incremental cost-effectiveness ratio The largest value that society is assumed
to be willing to spend to purchase a one-unit increase in effectiveness.
Narrow-spectrum antibiotic An antibiotic effective against specific families of bacteria.
Nosocomial infection Hospital-acquired infection.
Polymerase chain reaction A technology in molecular biology used to amplify a single copy or a few
copies of a piece of deoxyribonucleic acid across several orders of magnitude, generating thousands to
millions of copies of a particular deoxyribonucleic acid sequence.
Propensity score matching A statistical matching technique that attempts to estimate the effect of a
treatment, policy or other intervention by accounting for the covariates that predict receiving
the treatment.
Quality-adjusted life-year A measure of both the longevity and quality of life. The higher the
quality-adjusted life-years, the longer a person is likely to live for and/or the better the quality of life the
person is predicted to have.
Reference standard The best test currently available.
Sanger sequencing A method of deoxyribonucleic acid sequencing.
Sensitivity The proportion of people with the target condition that receive a positive test result. It is not
uncommon for the true status of the patient to be determined by the reference standard even if that is an
imperfect test.
Sepsis A condition characterised by the body’s inflammatory response to an infection.
Septic shock Persistent sepsis-induced hypotension (low blood pressure) despite adequate
fluid resuscitation.
Severe sepsis Occurs when the body’s response to infection interferes with the functioning of vital
organs, such as the heart, kidneys, lungs or liver.
Single gate A study design in which only patients with the target condition are recruited.
Specificity The proportion of people without the target condition who receive a negative test result. It is
not uncommon for the true status of the patient to be determined by the reference standard, even if that
is an imperfect test.
Superinfection A second infection superimposed on an earlier one, especially by a different microbial
agent of exogenous or endogenous origin, which is resistant to the treatment used against the
first infection.
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List of abbreviations
APACHE Acute Physiology And Chronic
Health Evaluation
CE Conformité Européenne
cfu colony-forming unit
CI confidence interval
CrI credible interval
DNA deoxyribonucleic acid
EDTA ethylenediaminetetraacetic acid
ICER incremental cost-effectiveness ratio
ICU intensive care unit
MAICER maximum acceptable incremental
cost-effectiveness ratio
MALDI-TOF matrix-absorbed laser desorption/
ionisation time of flight
MS mass spectrometry
NICE National Institute for Health and
Care Excellence
NMB net monetary benefit
PCR polymerase chain reaction
QALY quality-adjusted life-year
QUADAS Quality Assessment of Diagnostic
Accuracy Studies
RCT randomised controlled trial
SAPS Simplified Acute Physiology Score
SD standard deviation
SIRS systemic inflammatory
response syndrome
SIRS-SS systemic inflammatory response
syndrome with suspected sepsis
SOFA Sequential Organ Failure
Assessment
VAT value-added tax
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full
report was used by the Appraisal Committee at NICE in their deliberations. The full report
with each piece of confidential data removed and replaced by the statement ‘confidential
(or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Sepsis is estimated to cause 37,000 deaths per year in the UK. Early and appropriate treatment canreduce the risk of sepsis-related death. New tests can detect bacteria and fungi in the blood much
quicker than standard practice, allowing treatment changes to occur faster.
This report looked at the clinical effectiveness and cost-effectiveness of three tests: LightCycler SeptiFast
Test MGRADE® (Roche Diagnostics, Risch-Rotkreuz Switzerland); SepsiTest™ (Molzym Molecular
Diagnostics, Bremen, Germany); and the IRIDICA BAC BSI assay (Abbott Diagnostics, Lake Forest, IL, USA).
These tests are designed to provide the clinician with a result regarding whether or not a patient has sepsis
and which bacterium or fungus is the cause, and are much quicker than current methods. A review of the
published literature showed that the tests are better at correctly identifying patients without sepsis than
those with sepsis, but that all three tests are imperfect.
However, because of limitations in reporting and study quality, these data should be treated with caution.
A review of the published literature showed that the tests can decrease the time at which the clinician
received the result and decrease the time at which some patients changed to a better treatment within
clinical trials. However, these benefits may not be realised in clinical practice. Furthermore, key benefits
(reduced mortality, reduced length of stay in intensive care units and hospital, and reduced costs of
treatment) of the new tests had yet to be proven within clinical trials. Expert clinicians were asked to
provide estimates of these benefits and the answers were, on average, positive, although individual
clinicians held widely different views.
Given the markedly different results produced when the published evidence of benefits were used and
when the estimates from the clinicians were used, no firm conclusions could be made regarding the likely
cost or benefits associated with the three tests. In order to provide better estimates, studies should be
undertaken where information from the tests is allowed to change clinical practice and for these results to
be compared with those from current practice.
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Scientific summary
Background
Sepsis is a condition characterised by the body’s inflammatory response to a bacterial, viral or fungal
infection. In the UK, sepsis is estimated to be responsible for 100,000 hospital admissions and 37,000
deaths per year. As a consequence, the cost to the NHS is considerable. Current standard practice for
detecting pathogens in those patients with a suspected bloodstream infection or sepsis consists of clinical
assessment in conjunction with blood culture [with or without matrix-absorbed laser desorption/ionisation
time-of-flight (MALDI-TOF) mass spectrometry (MS)]. However, positive blood culture results for bacteria
or fungi can take several days. Several new tests have been developed that can detect minute amounts
of pathogens’ deoxyribonucleic acid in patients’ whole-blood samples, with results available within
approximately 6 hours under optimal conditions, although this time is likely to be increased if the tests are
introduced routinely into clinical practice. It is noted that recently published guidelines, if followed, are
likely to reduce the consequences of sepsis.
Objectives
To evaluate the clinical effectiveness and cost-effectiveness of three tests [LightCycler SeptiFast Test
MGRADE® (Roche Diagnostics, Risch-Rotkreuz, Switzerland), SepsiTest™ (Molzym Molecular Diagnostics,
Bremen, Germany) and the IRIDICA BAC BSI assay (Abbott Diagnostics, Lake Forest, IL, USA)] for the rapid
identification of bloodstream bacteria and fungi compared with standard practice.
Methods
Clinical evidence review
A systematic review was conducted in accordance with established guidelines. Thirteen electronic
databases and research registers were searched (including MEDLINE, EMBASE and The Cochrane Library)
from January 2006 to May 2015. Searches were supplemented by hand-searching of relevant articles
(including citation searching and screening company submissions) and contacting experts in the field.
The methodological quality of each included study was performed using the Quality Assessment of
Diagnostic Accuracy Studies tool. Data were extracted at the pathogen level, where reported in the
published literature, otherwise data were extracted at the patient level. Results were summarised in tables
and text. Data analysis comprised a narrative synthesis and pairwise meta-analysis.
Cost-effectiveness assessment
A systematic review of evidence relating to the cost-effectiveness of the interventions was undertaken.
A mathematical model was constructed with two key scenarios evaluated: base case 1, in which only
published statistically significant data were used within the model; and base case 2, in which data provided
by clinical experts were used. Further analyses were conducted where studies had compared interventions
where MALDI-TOF MS was used in conjunction with blood culture and where studies had compared two
of the interventions simultaneously. Evaluations were undertaken assuming a range (2.4–68) of blood
samples that need analysing per day for all scenarios. Threshold analyses were also undertaken to provide
further information for the Diagnostic Appraisal Committee on the gains required in reduced mortality,
reduced intensive care unit length of stay and in reduced costs of antimicrobial drugs.
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Results
Clinical effectiveness results
The literature searches identified 2892 citations. Of these, 66 studies met the inclusion criteria.
The methodological quality of the included studies was variable, with the majority having deficiencies in
reporting and study quality. For the review of diagnostic test accuracy, a meta-analysis of 54 studies
comparing SeptiFast with blood culture found that SeptiFast had an estimated specificity of 0.86
[95% credible interval (CrI) 0.84 to 0.89] and sensitivity of 0.65 (95% CrI 0.60 to 0.71). However, there
was substantial heterogeneity between studies, particularly for sensitivity. Reasons for the observed
heterogeneity in sensitivity and specificity between studies were explored using metaregression for several
potentially relevant characteristics: age category (adults, and children and neonates), antibiotic use at the
time of blood sampling, community- or health-acquired infection, patients with febrile neutropenia and
studies with inclusion/exclusion of contaminants. There was no evidence to suggest that the pooled
sensitivity and specificity was affected by these subgroups. Comparison with blood culture plus MALDI-TOF
MS in a single study showed higher specificities than sensitivity [0.74, 95% confidence interval (CI) 0.64 to
0.85, and 0.58, 95% CI 0.30 to 0.86, respectively]. Pooled effects across four studies comparing SepsiTest
with blood culture suggest that SepsiTest had an estimated specificity of 0.86 (95% CrI 0.78 to 0.92) and a
sensitivity of 0.48 (95% CrI 0.21 to 0.74). Although there was substantial heterogeneity between studies,
analyses for potential causes of this heterogeneity could not be explored because of the small number of
included studies. Comparison with blood culture plus MALDI-TOF MS in a single study also showed higher
specificities than sensitivity (0.96, 95% CrI 0.92 to 1.00 and 0.11, 95% CrI 0.00 to 0.23, respectively). A
meta-analysis of four studies comparing IRIDICA with blood culture found that IRIDICA had an estimated
specificity of 0.84 (95% CrI 0.71 to 0.92) and a sensitivity of 0.81 (95% CrI 0.69 to 0.90). However, there
was substantial heterogeneity between studies. Moreover, owing to the deficiencies in study quality for all
interventions, diagnostic accuracy data may not be reliable and should be treated with caution.
For the review of other intermediary and clinical outcome measures, 41 studies across the three
interventions reported data on time to pathogen identification (SeptiFast only, n= 21); time to treatment
(SeptiFast only, n= 3); test failure rates [SeptiFast, n= 7 (confidential information has been removed)];
duration of stay in hospital or critical care units (SeptiFast only, n= 13); duration of broad- and
narrow-spectrum antimicrobial therapy (SeptiFast only, n= 1); changes in antimicrobial treatment plan
(SeptiFast, n= 14; and IRIDICA, n= 1); and mortality (SeptiFast, n= 17; SepsiTest, n= 1; IRIDICA, n= 1;
and SeptiFast/SepsiTest, n= 1). The majority of studies reported data for the whole patient cohort, as
opposed to comparative data for the index and reference test. As a result, the effects of the individual test
on these outcomes remain unclear. Of the comparative studies, a small number of low-methodological-
quality randomised controlled trials (all SeptiFast studies) indicated no statistically significant between-
group differences for SeptiFast compared with blood culture in length of hospital stay (n= 3), length of
intensive care unit stay (n= 2), duration of antimicrobial therapy (n= 1) or mortality (n= 3).
Cost-effectiveness results
Four economic evaluations were identified, three evaluating SeptiFast and one evaluating a hybrid of IRIDICA
and an earlier system PLEX-ID, but none was deemed to adequately address the decision problem. The results
produced by the de novo model were highly variable. In base case 1, all interventions were dominated as the
tests were not assumed to provide benefit. In base case 2, all interventions were estimated to have cost per
quality-adjusted life-year (QALY) gained values of < £20,000 when using the average values provided by the
clinicians; however, these estimates differed markedly between individual clinicians, with a non-negligible
proportion believing the tests had a cost per QALY gained in excess of £30,000. IRIDICA was estimated to have
the greatest net monetary benefit, followed by SepsiTest and then SeptiFast. The additional analyses undertaken
using the results from multitest studies that compared SeptiFast, SepsiTest and blood culture, when the data
provided by clinicians were used, were concordant with base case 2. However, the indirect results produced
when using studies directly comparing the three tests with MALDI-TOF MS produced contrary results, with
SeptiFast estimated to dominate SepsiTest. Within the threshold analyses it was seen that relatively small
mortality gains would be required for the interventions to achieve a cost per QALY gained of £20,000
compared with standard practice.
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Discussion
SeptiFast, SepsiTest and IRIDICA appear to have higher specificity values than sensitivity values. However,
given the potentially fatal consequences of removing treatment from patients with sepsis, it is not
anticipated that negative tests in isolation would be acted on in clinical practice were an intervention
introduced. This is because the sensitivity of the tests is not high enough to allow them to be used in a
‘rule-out’ manner, such that clinicians can be reassured that a negative test is associated with a very low
probability of the patient having the disease. Furthermore, because of the deficiencies in study design and
poor reporting of the included studies, test characteristic data may not be reliable and should be treated
with caution.
The pooled estimates of sensitivity and specificity for each test were estimated assuming that the reference
standard was 100% sensitive and specific; however, this is unlikely to be the case. In practice, a wide
range of factors are known to influence the diagnostic accuracy of blood cultures. For example, this may
include antimicrobial treatment prior to blood sampling, low blood sample volumes, lack of replicate blood
culture sets, delays in incubation and contamination during sampling. As a result, the reported estimates of
sensitivity and specificity are likely to be biased (underestimated) compared with those that would be
obtained using a perfect reference standard. In addition, diagnostic metrics in the included studies were
measured using different units: patients, sample episodes or species/pathogen level. Such analyses create a
‘unit of analyses’ error and may have contributed to the heterogeneity in the results.
Although there are no existing systematic reviews of diagnostic accuracy for SepsiTest or IRIDICA, the
present review includes more studies than previous reviews on SeptiFast and is therefore more
comprehensive. Although an extensive literature search was conducted, it is possible that some studies
may have been missed. However, such omissions are likely to have been minimal as the search included all
identifiable publications in the grey literature (including contact with clinical experts in the field and
checking evidence submitted by the companies that manufacture the tests). Statistical evaluation of
diagnostic test accuracy was undertaken using rigorous methods, allowing for the correlation between
sensitivity and specificity, and between-study heterogeneity. Reasons for the heterogeneity in sensitivity
and specificity between studies were further explored using metaregression. Parameter estimates were
produced using Markov chain Monte Carlo simulation.
There are no head-to-head comparisons of all these tests and there are limited robust data that report the
impact of interventions on hard clinical outcomes, such as mortality and length of stay in critical care units.
The data that do exist have not shown any intervention to produce a non-confounded statistically
significant improvement. In addition, the three interventions provide very limited data regarding
antimicrobial sensitivity. Definitive data on this need to be determined, if possible, via standard culture
methods undertaken in parallel with the interventions. In order to produce a definitive conclusion on the
clinical effectiveness of these interventions, appropriate studies need to be conducted.
The results from the cost-effective analyses are fundamentally limited by the lack of appropriate evidence.
As such, little credence should be given to any result. However, the results from base case 2 show that
there appears to be clinical support for the effectiveness of the interventions even though these data have
not been proven. This lack of data results in all of the tests being dominated in base case 1. Pragmatic
studies assessing the benefits of the interventions in changing real-world decisions are required to provide
appropriate data.
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Conclusions
Based on the current evidence, no definitive conclusions regarding either the clinical effectiveness or the
cost-effectiveness of the interventions can be made. However, evidence based on expert clinical judgement
suggests that the tests are likely to be beneficial to patients but this needs to be proven within
appropriate studies.
Study registration
This study is registered as PROSPERO CRD42015016724.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem
Background to sepsis and bloodstream infection
Sepsis is a condition characterised by the body’s inflammatory response to an infection. Sepsis is diagnosed
where there is evidence of systemic inflammation, in addition to a documented or presumed bloodstream
infection. Systemic illness often occurs when bacteria or fungi invade normally sterile parts of the body.
One example of this is the invasion of bacteria or fungi into the bloodstream, a process that often causes
an inflammatory immune response. A pictorial representation of the relationship between systemic
inflammatory response syndrome (SIRS), infection, sepsis and severe sepsis is provided in Figure 1.
If sepsis is not treated with antibiotics it can progress to severe sepsis or septic shock and can lead to
multiple organ failure and death. Severe sepsis occurs when the body’s response to infection interferes
with the functioning of vital organs, such as the heart, kidneys, lungs or liver. Severe sepsis has historically
been defined as infection and the presence of at least two SIRS criteria;2 however, a recent paper suggests
that the need for two or more SIRS criteria excludes one in eight patients with infection, organ failure
and substantially increases mortality risk.3 SIRS criteria are a fever of > 38 °C or < 36 °C; heart rate of
> 90 beats per minute; respiratory rate of > 20 breaths per minute or arterial carbon dioxide tension
of < 32mmHg; or an abnormal white blood cell count [> 12,000 cells per µl or < 4000 cells per µl,
or > 10% immature neutrophils (bands)].4
Septic shock occurs in severe cases of sepsis and is defined as persistent sepsis-induced hypotension (low
blood pressure) despite adequate fluid resuscitation. Septic shock prevents organs from receiving enough
oxygenated blood. Complications of septic shock can include respiratory failure, heart failure, kidney injury
or failure, and abnormal blood clotting. Severe sepsis is a time-critical condition and delays in recognition
and the subsequent administration of appropriate treatment can adversely impact on outcomes. It has
been reported that the survival rate of untreated patients with sepsis decreases by the hour.5
FIGURE 1 The relationship between SIRS, infection, sepsis and severe sepsis.1 Reproduced with permission from the
Royal College of Physicians.
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The cost implications of sepsis are considerable. The consequences, in terms of mortality and morbidity, are
severe, with Levy et al.6 reporting a mortality rate of 46% for septic patients with both hypotension and a
blood lactate concentration ≥ 4mmol/l. However, compliance with the 2004 Surviving Sepsis Guidelines7
appears to reduce both mortality and length of stay outcomes; Levy et al.8 report that mortality was lower
(29.0%) in those with high compliance with the resuscitation bundle than in those with low compliance
(38.6%). Hospital mortality rates dropped 0.7% for every 3 months of participation with the campaign, and
hospital and intensive care unit (ICU) length of stay decreased 4% for every 10% increase in site compliance –
all of these reductions were statistically significant. An estimate of mortality in patients with early septic shock
was 29% at 90 days.9 Lower estimates of mortality have been provided in a recent study of patients with
hospital-acquired infection with 13% mortality at 28 days,10 and in data from Australia and New Zealand which
report in-hospital mortality as approximately 10% for SIRS-positive sepsis and 20% for SIRS-negative sepsis.3
Severe sepsis is one of the most common reasons for admission to a critical care unit, accounting for
almost one-third of all admissions. In the UK, sepsis is estimated to be responsible for 100,000 hospital
admissions and 37,000 deaths per year.11
Bacterial infections are the most common cause of bloodstream infection; however, they can also be
caused by viral and fungal infections. The most common sites of infection leading to sepsis are the lungs,
urinary tract, abdomen and pelvis. Other sources of infection leading to sepsis include skin infections (such
as cellulitis), post-surgical infections and infections of the nervous system (such as meningitis or
encephalitis). Bacteria can be categorised into three groups: Gram-positive bacteria, Gram-negative
bacteria and, very rarely, Gram-indeterminate bacteria.
Patients who are currently, or have recently been, hospitalised are at risk of acquiring a health-care-
associated infection and are, therefore, at increased risk of sepsis and bloodstream infection. It is thought
that the increasing number of invasive procedures (such as catheterisation), immunosuppressive therapy,
antibiotic therapy and life support measures has resulted in an increase in health-care-associated
bloodstream infections.12 In 2011, an estimated 6.4% [95% confidence interval (CI) 4.7% to 8.7%] of
patients in acute care hospitals were diagnosed with a health-care-associated infection, with the largest
proportion (23.4%) within the ICU.13 Of patients with a health-care-associated infection, it was estimated
that 7.6% had a bloodstream infection.13 Septic shock is most commonly associated with Gram-negative
bacterial bloodstream infections, but shock can also be associated with bloodstream infections caused by
Gram-positive bacteria, particularly with fulminant pneumococcal, Lancefield group A streptococcal and
Staphylococcus aureus infections.14 Community-acquired bloodstream infections occur in people who have
not had recent contact with health-care services. The spectrum of pathogens isolated from these people
may differ from those associated with health-care-acquired bloodstream infection.12
Bloodstream infection is also a risk for people who are immunocompromised, particularly among people
with neutropenia (abnormally low neutrophil levels in the blood), who are at risk of developing
neutropenic sepsis. People who are immunocompromised have a higher incidence of infections caused by
pathogens that pose low risk to those whose immune system is not impaired, such as Pseudomonas
species, Listeria monocytogenes, Corynebacterium species, Candida species, coagulase-negative
staphylococci, enterococci and viridans streptococci. Polymicrobial infections are also more common
among people who are immunocompromised.12
The bacteria most commonly associated with bloodstream infection in adults in England, Wales and
Northern Ireland are outlined in Table 1.
The types of pathogens causing bloodstream infection in children can also be slightly different from those
isolated from adults with bloodstream infection. Pathogens particularly associated with community-acquired
bloodstream infection in children include Streptococcus pneumoniae, Neisseria meningitidis, S. aureus and
Escherichia coli. The profile of pathogens associated with health-care-associated infections in children is
thought to be similar to that associated with health-care-associated infections in adults; however,
polymicrobial infection and anaerobic bacteraemia are thought to occur less frequently among children.12
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Diagnosis of sepsis
Diagnostic criteria for sepsis are listed in the Surviving Sepsis Campaign guidelines16 (adapted from Levy
et al.17). In summary, regular observations of all vital signs should be taken and recorded, kidney and liver
function tests should be performed, and inflammatory biomarkers and serum lactate concentration should
be measured. These guidelines state that a diagnosis of sepsis should be based on infection, documented
or suspected, in conjunction with hyperthermia or hypothermia, tachycardia and at least one indication of
altered organ function (see below). The diagnostic criteria for sepsis include the following variables:
l General variables – temperature of > 38.3 °C or < 36 °C, heart rate > 90 beats per minute, rapid
breathing, altered mental status, significant oedema or high blood sugar concentration in the absence
of diabetes.
l Inflammatory variables – low or high white blood cell count or more than 10% of immature forms,
raised plasma C-reactive protein or raised plasma procalcitonin.
l Haemodynamic and tissue perfusion variables – low blood pressure or raised blood lactate
(a concentration of ≥ 4mmol/l suggests tissue hypoperfusion).
l Organ dysfunction variables – low blood oxygen, reduced urine output, increased creatinine levels
(indicating impaired kidney function), coagulation abnormalities, absent bowel sounds, reduced platelet
count or raised plasma bilirubin levels.
TABLE 1 The bacteria most commonly associated with bloodstream infection in adults in England, Wales and
Northern Ireland between April 2011 and March 2012
Name of bacteria
Percentage of all bacteria associated
with bloodstream infection Group of bacteria
Escherichia coli 36 –
Staphylococcus aureus (MSSA) 9.7 +
Klebsiella spp. 7.8 –
Non-pyogenic streptococci 7.1 +
Other Gram negative 6.4 –
Enterococcus spp. 6.3 +
Pseudomonas spp. 4.3 –
Streptococcus pneumoniae 4.2 +
Other Gram positive 4.2 +
Proteus spp. 3.1 –
Enterobacter spp. 2.2 –
Staphylococcus aureus (MRSA) 1.6 +
Bacteroides spp. 1.5 –
Group B streptococci 1.4 +
Group A streptococci 1.4 +
Diphtheroids 1.2 +
Serratia spp. 1.0 –
Acinetobacter spp. 0.7 –
–, Gram negative; +, Gram positive; MRSA, meticillin-resistant Staphylococcus aureus; MSSA, meticillin-sensitive
Staphylococcus aureus.
Adapted from Davies15 under the Open Government Licence (v3.0) for public sector information (www.nationalarchives.
gov.uk/doc/open-government-licence/version/3/).
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Current standard of care for patients with suspected
bloodstream infections or sepsis
The diagnostic work-up of sepsis and bloodstream infection is described in several guidelines:
l the National Institute for Health and Care Excellence (NICE) Clinical Guideline 151: Prevention and
Management of Neutropenic Sepsis in Cancer Patients18
l the Royal College of Obstetricians and Gynaecologists: Green-Top Guideline 64a. Bacterial Sepsis
in Pregnancy19
l the Royal College of Obstetricians and Gynaecologists: Green-Top Guideline 64b. Bacterial Sepsis
following Pregnancy20
l Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and
Septic Shock.16
In addition, a NICE Clinical Guideline, Sepsis: The Recognition, Diagnosis and Management of Severe
Sepsis, is currently in development with an estimated publication date of July 2016.21 Furthermore, the
Commissioning for Quality and Innovation, which is currently developing a payment framework, has
announced new sepsis mandates to monitor adherence to the sepsis care pathway across the NHS.22
The Surviving Sepsis Campaign guidelines make the following specific recommendations relating to the
detection of localised and bloodstream infection:16
l At least two sets of blood cultures should be collected (aerobic and anaerobic) before antimicrobial
therapy is initiated, provided this does not significantly delay (> 45 minutes) the start of antimicrobial
administration. At least one sample should be drawn percutaneously and one drawn through each
vascular access device, unless the device was recently (< 48 hours) inserted. The blood cultures can be
drawn at the same time if they are obtained from different sites. Cultures of other fluids, such as urine,
cerebrospinal fluid, wound exudate, respiratory secretions or other bodily fluids, which may be the
source of infection should be obtained before initiation of antimicrobial therapy, as long as doing so
does not significantly delay the start of antimicrobial administration.
l Imaging studies such as computerised tomography or radiography should be performed in order to
confirm a potential source of infection.
l Assays to diagnose systemic fungal infection should be used if available, and invasive candidiasis
is suspected.
The Surviving Sepsis Campaign guidelines recommend care ‘bundles’ which should be initiated during the
diagnostic work-up of a patient. The 3-hour bundle should be completed within 3 hours of a patient
developing symptoms that are indicative of sepsis:
(a) measure blood lactate levels to identify tissue hypoperfusion
(b) obtain blood cultures prior to administration of antibiotics
(c) administer broad-spectrum antibiotics
(d) administer 30ml/kg of crystalloid for hypotension or lactate ≥ 4mmol/l.
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The 6-hour bundle should be completed within 6 hours of presentation in the emergency department or
recording of symptoms if in hospital when sepsis starts:
(e) apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain a
mean arterial pressure of ≥ 65mmHg
(f) in the event of persistent arterial hypotension despite volume resuscitation (septic shock) or initial
lactate concentration of ≥ 4mmol/l:
– measure central venous pressure
– measure central venous oxygen saturation
(g) remeasure lactate concentration, if initial lactate was elevated.
The treatment of sepsis varies based on the initial infection, the organs affected and the extent of tissue
damage. The management of severe sepsis and septic shock is described by the Surviving Sepsis Campaign
in its International Guidelines for the Management of Severe Sepsis and Septic Shock.16 All patients with
severe sepsis or septic shock will require initial resuscitation, antimicrobial therapy, source control (where
appropriate) and fluid therapy. Some patients may require additional treatment with vasopressors,
inotropic therapy, corticosteroids or other supportive therapy.
It is recommended that intravenous empiric antimicrobials should be administered within the first hour of
recognition of septic shock and severe sepsis. The initial antimicrobial therapy should include one or more
drugs that have activity against all likely pathogens (bacterial and/or fungal or viral) and that penetrate
in adequate concentrations into the tissues presumed to be the source of sepsis.16 Such treatment is
typically referred to as broad spectrum. Frequently used broad-spectrum antibiotics for more serious
infections include beta-lactams and aminoglycosides. Carbapenems are often the last option in patients
with hard-to-treat infections.23
The choice of empirical antimicrobial therapy is often based on:
l the patient’s history, including drug intolerances
l recent treatment with antibiotics
l underlying disease
l the clinical syndrome
l susceptibility patterns of pathogens in the local community and hospital
l microbiology reports identifying pathogens that have previously colonised or infected the patient.
Clinicians should also consider whether or not a fungus is a likely causative pathogen when selecting initial
therapy and administer, when appropriate, empirical antifungal therapy.
The use of antimicrobials varies between hospitals, as prescribing choices are influenced by local resistance
and susceptibility patterns. The choice of antimicrobials is also influenced by the suspected source of the
infection and local prescribing protocols may be developed for:
l urinary tract infections
l upper respiratory tract infections
l lower respiratory tract infections
l soft-tissue infections
l central nervous system infections
l gastrointestinal infections and genital tract infections
l bloodstream infections
l eye, ear, nose and throat infections
l sepsis of unknown origin.
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Current practice for detecting pathogens in those with
suspected bloodstream infection or sepsis
The current practice for detecting pathogens in those with suspected bloodstream infection or sepsis
consists of clinical assessment in conjunction with blood culture. However, within the NICE scope
for this project,24 an additional comparator of clinical assessment in conjunction with blood culture and
matrix-absorbed laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS) was
included in recognition of the fact that some hospitals are incorporating MALDI-TOF MS within their
standard practice. MALDI-TOF MS has an advantage of shortening the time required for identifying the
causative pathogen when a blood culture becomes positive.
Blood culture
Blood culture is required for the detection and subsequent identification of bloodstream bacteria and
fungi, and to provide potential definitive antimicrobial susceptibility data. Standards for the investigation
of blood cultures are available from Public Health England.12 A blood culture set for the diagnosis of
bloodstream infection is defined as one aerobic and one anaerobic bottle.12 For adult patients it is
recommended that 20–30ml of blood be cultured per set, and that two consecutive blood culture sets
from two separate sites should be collected during any 24-hour period for each septic episode. The first set
should be taken prior to the administration of antimicrobial treatment as the presence of antibiotics or
antifungals may inhibit the growth of pathogens in the blood culture.12 Blood culture bottles should be
incubated within 4 hours of the blood sample being taken, with many laboratories now using automated
culture systems such as the BACTEC (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA)
or BacT/ALERT (Oganon Teknika Corp., Durham, NC, USA) systems, which alert laboratory staff once
growth has been detected.
The time taken for a blood culture bottle to show positivity is variable and can depend on the individual
pathogen, the volume of cultured blood, the concentration of organisms in the sample, whether or not
there are multiple pathogens and whether or not the patient had recently received antibiotics prior to the
blood being sampled.25,26 A median time to positivity of approximately 15 hours has been reported, but
with a wide range for individual samples.25,26
When a blood culture bottle has been detected as positive, it is recommended that:
l Gram staining and rapid antigen testing should be performed within 2 hours.
l Direct or automated isolate identification should be performed within 24 hours (extending to 48 hours
if traditional microbiology techniques, such as morphological identification are used). Rapid species
identification may be done following blood culture using techniques such as MALDI-TOF MS.
l Identification should be followed by susceptibility testing to determine to which antimicrobials the
identified pathogen is susceptible. A preliminary report should be made within 24 hours.
l A preliminary positive report is made within 2 hours of identification and susceptibility testing, and a
final positive report should be made within 5 days of the sample arriving in the laboratory.12
The first target is not typically met by laboratories because if the blood culture is detected as positive
during the night, Gram staining would not occur until the laboratory opened in the morning.
If a blood culture is not positive within 48 hours of sample receipt in the laboratory it is recommended that
a preliminary negative report is provided with a final negative report issued within 5 days, unless extended
culture is being undertaken, for example if fungi or unusual, fastidious or slow-growing organisms
are suspected.12
Blood culture results may not detect pathogens within an individual’s bloodstream because of the transient
nature of bloodstream infections and a low number of organisms present in a blood sample; there can
often be fewer than 1 × 103 colony-forming units (cfus) per litre in adults with a bloodstream infection.12
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The presence of antibiotic treatment prior to the blood being sampled can also result in pathogens not
being detected. Conversely, blood culture results may identify a pathogen that is not in an individual’s
bloodstream as pathogens transferred from the skin during the drawing of blood can contaminate the
culture. To reduce the incidence of such false-positive results, current standards recommended that
contamination rates are no higher than 3%.12 In addition, several criteria may be used to differentiate
between contamination and true bloodstream infection, which include the identity and clinical significance
of the pathogen, the number of positive blood culture sets and positive culture bottles, and the quantity of
growth detected.
Blood culture sample collection differs for infants and neonates, for whom a single aerobic bottle or
low-volume blood culture bottle may be requested.12 Criteria for calculating total blood culture volumes in
neonates and children are based on weight rather than age, and relate to total patient blood volume.
It has been suggested that the volume of blood drawn should be no more than 1% of the patient’s
total blood volume.12 The magnitude of bacteraemia is usually higher in infants and children than that in
adults and, therefore, the sensitivity of detection is not believed to be significantly reduced by lower
blood-to-medium ratios.12
Although blood culture is considered the gold standard, a number of limitations regarding its use were
identified; for example, it has been estimated that only 30–60% of blood cultures taken from patients
with sepsis are positive.27 This may indicate poor sensitivity, which may be attributed to commencement of
antimicrobial therapy prior to sample collection, low pathogen levels in blood and inadequate blood
sampling. Additionally, blood culture does not always pick up fungal pathogens.28
Matrix-absorbed laser desorption/ionisation time-of-flight
mass spectrometry
Following a blood culture becoming positive, it is possible to use MALDI-TOF MS to provide an
identification of the pathogen more quickly than by standard phenotypic techniques alone. Details on
MALDI-TOF MS have been provided by Schubert et al.,29 where pathogens were identified from an agar
plate. Recently, however, Sepsityper (Bruker, Billerica, MA, USA), a preparation method prior to MALDI-TOF
MS, has been developed, allowing MALDI-TOF MS to be used directly on a positive blood culture bottles
without the need for growing pathogens on an agar plate. The use of Sepsityper can thus provide a result
more quickly than standard culture-based identification techniques or MALDI-TOF MS used in conjunction
with agar plates. Morgenthaler and Kostrzewa30 report that ‘the use of the Sepsityper sample preparation
kit leads to a reduction in overall time to results from 8 to > 48 hours (in some studies > 100 hours),
depending on the microorganism growth rate on solid phase culture plates’. The level of Sepsityper use in
England is currently unknown.
A recently completed National Institute for Health Research-funded study RAPIDO (A Prospective
Randomised, Multicentre Trial to Assess the Impact of Laboratory based Rapid Diagnosis on Outcome in
patients with Blood Stream Infections) has compared MALDI-TOF MS with standard practice having recruited
4536 patients from the UK.31 However, at the time of writing, the data analysis had not been fully conducted.
The primary outcome measure within the randomised controlled trial (RCT) is the 28-day all-cause mortality
between the two arms. Following personal communication with Dr Leeming (Dr John Leeming, North Bristol
NHS Trust, 2015, personal communication), it was identified that Sepsityper had been used in the MALDI-TOF
MS arm in all centres bar Newcastle upon Tyne, where the centre used its own method.
The risk of antimicrobial resistance
Broad-spectrum antibiotics administered to patients with suspected sepsis are a mainstay of treatment;
however, these interventions cannot be used indiscriminately without risking unwanted consequences.
Antimicrobial resistance describes the development of resistance to existing antimicrobial medications
(including antibiotics, antifungals and antivirals) among bacteria, viruses and fungi. As existing
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antimicrobial medications are becoming less effective, strategies such as the UK Five Year Antimicrobial
Resistance Strategy23 have been introduced to help conserve the effectiveness of existing treatments.
One of the key priorities outlined in the UK Five Year Antimicrobial Resistance Strategy is the introduction
of antimicrobial stewardship programmes which aim to promote the rational prescribing of antimicrobial
medications, and the use of existing and new rapid diagnostic tests.
Recent surveillance data for England suggest that rates of meticillin-resistant S. aureus infection have
fallen, while there is an increase in the incidence of bloodstream infections caused by resistant
Enterobacteriaceae (Gram-negative bacteria) such as Klebsiella spp. and E. coli. Of particular concern in
some regions of England, such as the north-west and Greater London, is the increasing resistance to
carbapenem antibiotics which are often used as a last resort for treating severe infections.
Clinicians prescribing antimicrobial therapy should take into account the Department of Health’s guidance
on antimicrobial stewardship, which is based on the ‘start smart then focus’ strategy.32 The guidance
recommends that, when antimicrobials are administered empirically, the patient is reviewed after
48–72 hours to allow an ‘antimicrobial prescribing decision’ to be made. This decision should take into
account available microbiology results to determine whether therapy can be stopped or changed, that is,
the de-escalation, substitution or addition of antimicrobial agents to the treatment plan.32 Narrowing the
spectrum of antimicrobial coverage and reducing the duration of therapy is thought to be associated with
a reduction in the risk of a patient developing a superinfection, a reduction in the selection of resistant
organisms and a reduction in the treatment of related side effects. Adverse events associated with the use
of broad-spectrum antimicrobials may include diarrhoea, nausea, vomiting, hearing loss, damage to the
kidneys and an increased risk of developing a superinfection with Clostridium difficile.
Narrowing the spectrum of antimicrobial coverage may also be associated with an increase in treatment
efficacy, as certain broad-spectrum antibiotics may not be as effective as related narrow-spectrum
antibiotics against certain pathogens.32 In addition, a reduction in agents may result in cost savings.
The National Institute for Health and Care Excellence recently issued a draft clinical guideline on
antimicrobial stewardship which discussed the evidence for de-escalation of antimicrobials.33 A conclusion
of this draft guideline was that five RCTs had assessed the impacts of de-escalation (although only three
are explicitly referenced34–36), four of which were set in ICUs, the exception being hospital based, and only
one of which, by Leone et al.,35 was in patients with sepsis. The Guideline Development Group found no
evidence from these RCTs that de-escalation between 48 and 72 hours increased patient mortality. The
Guideline Development Group found little evidence of increased length of ICU or hospital stay but noted
the exception of Leone et al.,35 which was classified as a low-quality RCT, who recruited 116 patients with
severe sepsis who were randomised to de-escalation or continuation of empirical antimicrobial treatment.
Leone et al.35 reported statistically significantly greater rates of superinfection in the de-escalation group
(27% vs. 11%; p= 0.03) and in the mean number of antibiotic days (9 vs. 7.5 days; p= 0.03), although
the increase in median duration of ICU stay (9 vs. 8 days) was not statistically significant (p= 0.71).
The Guideline Development Group noted that it identified no health economic evidence regarding which
interventions, systems and processes are effective or cost-effective in reducing antimicrobial resistance
without causing harm to patients, nor did it identify any health economic evaluations that included
outcomes of antimicrobial resistance.
We have used the term ICU throughout the report as this is the term often used in the published
literature, although we recognise that care can also be provided in other critical care settings.
We have assumed that such settings are encompassed by the ICU categorisation.
The External Assessment Group note that clinical advice received during the scoping process stated that a
barrier to de-escalation in practice could be the resistance of family members to change the treatment in a
patient who was clearly improving and, thus, the extent to which de-escalation would occur in clinical
practice is unclear.
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The potential benefits and possible harms of a test that could
provide earlier information on pathogen
The individual characteristics of the three tests evaluated in this report [LightCycler SeptiFast Test
MGRADE® (Roche Diagnostics, Risch-Rotkreuz, Switzerland); SepsiTest™ (Molzym Molecular Diagnostics,
Bremen, Germany); and IRIDICA BAC BSI assay (Abbott Diagnostics, Lake Forest, IL, USA)] are detailed in
the following section. The aim of this section is to explain the benefits that could be provided by tests that
report information on the type of bacteria earlier than standard blood culture methods, with or without
MALDI-TOF MS, which can be used with or without Sepsityper. Were a rapid test to have a sensitivity of
100% and a specificity of 100% in identifying the pathogen(s), caused by bloodstream infection, that is,
the test was perfect, management strategies could be quickly altered dependent on whether or not there
was presence of a pathogen. Were a pathogen to be identified, then treatment could be tailored to
that pathogen alongside de-escalation of antimicrobial treatment by removing the components of
broad-spectrum treatment to which either the pathogen was not sensitive, or to which a targeted
treatment was more effective. Were a pathogen not identified, then treatment could be de-escalated or
removed entirely. Owing to the rapid identification by the test, these benefits would be achieved more
quickly than through standard techniques.
The advantages of earlier appropriate treatment have been reported in the published literature. A Spanish,
retrospective, matched, cohort study37 attempted to determine the attributable mortality and excess length
of stay associated with inadequate empirical antimicrobial therapy between 1997 and 2006. Therapy was
considered inadequate when no effective drug against the isolated pathogen(s) was included in the
empirical antibiotic treatment within the first 24 hours of admission to the ICU, or the doses and pattern
of administration were not in accordance with current medical standards. From 87 matched pairs, 59
(67.8%) died in the inadequate group compared with 25 (28.7%) in the control group. Removing pairs
with nosocomial infection still showed 31.4% excess in mortality (65.7% in the inadequate group vs.
34.3% in the control group). In those without a nosocomial infection there was a significant reduction in
the length of stay in ICU associated with adequate treatment (7 days in the inadequate group vs. 9 days
in the control group; p= 0.02).
Using a generalised linear model, adjusted for confounders, Zilberberg et al.38 estimated that the excess
length of hospitalisation was 7.7 days (95% CI 0.6 to 13.5 days) and excess costs were US$13,398
(95% CI US$1060 to US$26,736) when a patient had inadequate antifungal treatment. Inadequate
antifungal treatment was defined as a treatment delay of ≥ 24 hours from candidaemia onset or
inadequate dose of an antifungal agent active against the pathogen.
Arnold et al.39 attempted to estimate the costs of inappropriate treatment of candidaemia from 167
consecutive patients, which was defined as delayed antifungal therapy > 24 hours from culture collection.
Twenty-two patients had appropriate therapy; 145 did not. Length of stay was shorter in the appropriately
treated group than in the non-appropriately treated group (7 vs. 10.4 days, respectively; p= 0.037) and
the costs were lower (US$15,832 vs. US$33,021, respectively; p< 0.001).
Morrell et al.40 retrospectively analysed 157 consecutive patients who, over a 4-year period, developed a
Candida bloodstream infection, of whom 50 (32%) died during hospitalisation. The number of patients in
whom antifungal treatment was not delayed (> 12 hours) was nine, while treatment was delayed in 148
patients. The adjusted odds ratio associated with delay in antifungal treatment was 2.09 (95% CI 1.53 to
2.84). Delays in antifungal treatment were also associated with a longer stay in ICU (9.4 days, compared
with 0.4 days for those in whom treatment was not delayed; p= 0.019).
It is unlikely that the tests evaluated would be 100% sensitive and 100% specific, meaning that the
consequences of misdiagnoses would also need to be considered. These take the form of false positives
(a pathogen that is not present is identified) and false negatives (a pathogen that is present in the blood
culture is not identified). The consequences of these misdiagnoses are likely to differ. In the case of false
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positives, there is the risk of overtreatment, which would incur cost and could increase the risk of
antimicrobial resistance; in the case of false negatives, withdrawal of treatment could put the patient at
increased risk of morbidity and mortality.
However, it is known that diagnostic inaccuracy is not confined to the new tests and can occur in standard
techniques and, therefore, that standard techniques provide an inaccurate gold standard that may result in
biased evaluation of the interventions. This is believed most likely where the correct identification of a
pathogen could be classed as a false positive if it was not detected by blood culture. As detailed in this
report, some clinical experts believe that such results would provide valuable information in the patient
treatment decision, despite adversely affecting the specificity of the test against blood culture.
Description of the technologies under assessment
Our research aims to evaluate the clinical effectiveness and cost-effectiveness of three tests that potentially
allow the rapid detection and identification of bacterial and fungal deoxyribonucleic acid (DNA) in the
bloodstream of patients suspected of having sepsis. These tests are the SeptiFast, SepsiTest and IRIDICA
BAC BSI assays, which will be compared with blood culture, with or without, MALDI-TOF MS. Each test is
intended to be run directly on whole-blood samples without prior incubation or preculture steps, allowing
an earlier initial assessment of the patient. It is anticipated that blood cultures and clinical judgement
would be required in conjunction with each test to provide additional, potentially more definitive, data on
the most effective antimicrobial to use, as data on this provided by the interventions are very limited. This
section details the three technologies; the comparators have been described in Current practice for
detecting pathogens in those with suspected bloodstream infection or sepsis. For brevity, where the test
name alone is provided it should be assumed that this denotes its use in conjunction with blood cultures
and clinical judgement. Similarly, any reference to blood culture, with or without MALDI-TOF MS, also
denotes these being used in conjunction with clinical judgement.
LightCycler SeptiFast Test MGRADE
The LightCycler SeptiFast Test MGRADE – henceforth referred to as SeptiFast – is a Conformité Européenne
(CE)-marked in vitro diagnostic real-time polymerase chain reaction (PCR) test that simultaneously detects
and identifies bacterial and fungal DNA. The test requires 1.5 ml of ethylenediaminetetraacetic acid
(EDTA)-treated whole blood, which can be processed without prior incubation or culturing. SeptiFast
involves three distinct processes: specimen preparation by mechanical lysis and purification of DNA; real-
time PCR amplification of target DNA in three parallel reactions (Gram-positive bacteria, Gram-negative
bacteria and fungi); and detection using fluorescence-labelled probes specific to the target DNA. The test
takes around 6 hours in optimal conditions, but could take longer depending on laboratory workflow.
The SeptiFast Identification Software set v2.0 (Roche Diagnostics, Risch-Rotkreuz, Switzerland) analyses the
samples and generates a report including relevant laboratory data and details of the identified species.
The software also includes a crossing point cut-off rule that is intended to reduce the positive rate for
coagulase-negative staphylococci and Streptococcus spp. based on the assumption that they are
contaminants and not causal agents when the crossing point value is < 20.
Where S. aureus is identified in a sample, an aliquot of the SeptiFast Test MGRADE eluate can be further
tested for the presence of the mecA gene using the LightCycler SeptiFast MecA Test MGRADE. The test is
intended to determine the likely meticillin resistance of S. aureus through PCR using the LightCycler
2.0 instrument.
The bacterial and fungal species that can be detected by SeptiFast are shown in Table 2.
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The test has an analytical sensitivity of 100 cfu/ml for coagulase-negative staphylococci, Streptococcus
agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae and Streptococcus mitis. The minimum
analytical sensitivity for all other pathogens detected by SeptiFast is 30 cfu/ml.
SepsiTest
SepsiTest is a CE-marked PCR test for detecting bacterial and fungal DNA in 1ml of K-EDTA- (potassium-EDTA)
or citrate-treated whole blood. The test is able to identify species from more than 200 genera of bacteria and
65 genera of fungi. The manufacturer states that SepsiTest can identify Candida krusei, although this organism
has not been found in any study to date.
SepsiTest involves three distinct processes: extracting and purifying microbial DNA using centrifugation,
universal PCR and Sanger sequencing. The PCR result is available after 4 hours in optimal conditions,
although it could take longer depending on laboratory workflow, and indicates whether bacteria or fungi
are present in the sample. Amplicons from positive samples are then sequenced to confirm the PCR result
and to determine which bacterial or fungal species are present. Where readable sequences are available
from sequence analysis, bacteria and fungi can be identified using the SepsiTest-BLAST online tool
(www.sepsitest-blast.de/en/index.html). Sequencing results are typically available in 3–4 hours in optimal
conditions, depending on the analyser used, equating to a time of 8 hours from drawing blood, but could
take longer based on laboratory workflow.
The analytical sensitivity of SepsiTest ranges from 10 to 80 cfu/ml, depending on the target species.
Shortly before the submission of this report, Molzym Molecular Diagnostics, on 22 July 2015, informed NICE
that it had updated SepsiTest to version 4.0 (date of change 1 July 2015). The changes reported by the
company include the implementation of an internal extraction control to validate the extraction of DNA; the
removal of the internal control from the kits; and the fact that processing of duplicate samples is no longer
recommended. In consultation with NICE, a decision was taken to exclude the updated version of SepsiTest
from the analyses described in this report, primarily because no data on the diagnostic accuracy associated
with this version were provided. Given the potentially large change compared with the previous version
regarding the removal of the duplicate sample, it could not be assumed, without supportive evidence,
that the results from previous studies were applicable to the latest version of SepsiTest.
TABLE 2 Bacteria and fungi species detected by the LightCycler SeptiFast Test MGRADE
Bacteria
FungiGram negative Gram positive
E. coli S. aureus Candida albicans
Klebsiella (pneumoniae/oxytoca) Coagulase-negative staphylococci (including Staphylococcus
epidermidis and Staphylococcus haemolyticus)
Candida tropicalis
Serratia marcescens S. pneumoniae Candida parapsilosis
Enterobacter (cloacae/aerogenes) Streptococcus spp. (including Streptococcus pyogenes,
Streptococcus agalactiae, Streptococcus mitis)
Candida krusei
Proteus mirabilis Enterococcus faecium Candida glabrata
Pseudomonas aeruginosa Enterococcus faecalis Aspergillus fumigatus
Acinetobacter baumannii
Stenotrophomonas maltophilia
Species often referred to as Acinetobacter calcoaceticus–Acinetobacter baumannii (ACB complex) are not detected.
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IRIDICA BAC BSI
The IRIDICA BAC BSI assay – henceforth referred to as IRIDICA – is a CE-marked in vitro diagnostic test for
detecting and identifying bacterial and candidal DNA in 5ml of EDTA-treated whole blood. The test can
also detect the mecA (Staphylococcus-specific meticillin resistance), vanA and vanB (Enterococcus-specific
vancomycin resistance) and Klebsiella pneumoniae carbapenemase-producing (Gram-negative-associated
carbapenem resistance) genes, which are associated with antibiotic resistance. The test is designed for use
with the IRIDICA system, which combines broad-range PCR with electrospray ionisation time-of-flight mass
spectrometry to amplify and detect pathogens. The IRIDICA system includes a proprietary database and
software that identifies the organism present in the sample by comparing the sequence of the sample with
a library of known sequences. The IRIDICA system was developed incrementally from a previous test called
PLEX-ID (Abbott Diagnostics, Lake Forest, IL, USA), although the final IRIDICA system has key differences
from PLEX-ID as it uses a greater volume of whole blood (5 vs. 1.5ml, respectively) and has different
desalter and mass spectrometry modules. The company supplied confidential data regarding the
equivalency of IRIDICA and PLEX-ID, which the company declared demonstrated that the limits of
detection of four core organisms were comparable in IRIDICA and PLEX-ID. Based on these data, the
External Assessment Group was comfortable with including data from studies that used IRIDICA–PLEX-ID
hybrid systems.
The IRIDICA assay is able to detect over 780 bacterial and candidal species. The mean limit of detection for
the assay is 39 cfu/ml, with a range of 0.25–128 cfu/ml depending on the target species. The estimated
time to result is 5 hours and 55 minutes in optimal conditions, although it may take longer depending on
laboratory workflow.
The decision problem
This report aims to evaluate the clinical effectiveness and cost-effectiveness of the three interventions in
comparison with blood culture, with or without MALDI-TOF MS. As detailed in The potential benefits and
possible harms of a test that could provide earlier information on pathogen, there are reasons to believe
that a quicker identification of pathogens can produce health benefits. The quickest time at which clinically
important information would be available for each test is provided in An estimation of the time to clinically
important information associated with each intervention and comparator.
It is anticipated that good compliance with the guidelines described in Current standard of care for
patients with suspected bloodstream infections or suspected sepsis and Current practice for detecting
pathogens in those with suspected bloodstream infection or sepsis will be associated with better patient
outcomes. As such, the potential gains associated with the three tests have likely been reduced since the
introduction of the guidelines. Given the early use of broad-spectrum antibiotics, it is anticipated that there
will be much greater clinical utility in accurately determining the specific pathogen causing the infection
rather than in determining whether or not the patient has sepsis.
An estimation of the time to clinically important information associated
with each intervention and comparator
Table 3 denotes estimations of time to clinically relevant events in the detection of pathogens associated
with bloodstream infections. It is noted that for the interventions it has been assumed that workflow is
optimal; that is, that the test result will be reported back in a timely manner and not delayed because of
staff hours, waiting for additional blood to be gathered which will be tested simultaneously or transport
times. For the comparators, the time of day has been included in the estimates to produce a range of
possible time-to-event data. As such, the timings presented in Table 3 are favourable to the interventions.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
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TABLE 3 Estimated time to clinically relevant events associated with the interventions and the comparators
Test
Time to indication of
whether bacteria or
fungi are present
(hours) for SepsiTesta
or time to indication
of Gram stain positive
or Gram stain negative
in positive cultures
Time to
preliminary
identification
of type of
organism
Time to
preliminary
antimicrobial
sensitivity data
Time to earliest
possible identification
of precise bacteria
or fungia,b
Interventions
SeptiFast 6 hours
IRIDICA 6 hours
SepsiTest 4 hours (denoted as x) (x)+ 3–4 hours
(range 7–8 hours)
Comparators
Blood culture 15 hours (denoted as y)
(range 12–48 hours)c
(y)+ 12–24 hours
(denoted as z)d
(z) (z)+ 12–18 hourse
(range 36–90 hours)
Blood culture with
MALDI-TOF MS
(y) (z) (z) (z) (range 24–72 hours)
Blood culture with
MALDI-TOF MS
and Sepsityper
(y) (y)+ 1–13 hoursd (z) (z) (range 24–72 hours)
a Assuming optimal workflow conditions for the interventions. These times may be extended depending on work patterns
and location of the required equipment.
b Note that a subsequent identification based on blood culture methods will also become available.
c Based on the time at which a blood culture bottle flags positive.
d Positive blood cultures have been subcultured on agar plates. The time taken is dependent on the time of day at which
blood culture positivity is reported.
e The time taken is based on the speed of bacterial growth.
Note
Shading denotes that these components are not reported individually, but the combined information is provided by the
next non-shaded column.
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Chapter 2 Assessment of clinical effectiveness
A systematic review of the literature and meta-analysis (where appropriate) was undertaken to evaluatethe clinical effectiveness of the SeptiFast, SepsiTest and IRIDICA assays in conjunction with clinical
assessment for rapidly identifying bloodstream bacteria and fungi.
A review and meta-analysis was undertaken in accordance with the guidelines published by the Centre for
Reviews and Dissemination for undertaking systematic reviews41 and the Cochrane Diagnostic Test
Accuracy Working Group on the meta-analysis of diagnostic tests.42,43
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Methods for reviewing effectiveness
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases and research registers from
January 2006 to May 2015:
l MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE (via OvidSP)
l EMBASE (via OvidSP)
l Cochrane Database of Systematic Reviews (via Wiley Online Library)
l Cochrane Central Register of Controlled Trials (via Wiley Online Library)
l Health Technology Assessment Database (via Wiley Online Library)
l Database of Abstracts of Review of Effects (via Wiley Online Library)
l Science Citation Index Expanded (via the Web of Science)
l Conference Proceedings Index-Science (via the Web of Science)
l World Health Organization’s International Clinical Trials Registry Platform
l Current Controlled Trials
l National Institutes of Health ClinicalTrials.gov
l Manufacturer and User Facility Device.
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean operators
and database-specific syntax were developed to search the electronic databases. Synonyms relating to the
condition (e.g. sepsis) were combined with terms for the test (i.e. SeptiFast, SepsiTest and IRIDICA).
No language restrictions were used on any database; however, the clinical effectiveness searches were date
restricted. To date, all included rapid molecular tests (SeptiFast, SepsiTest and IRIDICA assay) have received a
CE mark for use on whole-blood samples. For the SeptiFast test, clinical studies on whole-blood samples
were first published in abstract form by Raglio et al.44 in 2006 with subsequent full-text peer-reviewed
publications by Mancini et al.45 and Louie et al.46 in 2008. The SeptiFast test gained its CE mark in 2006.
For the SepsiTest assay, studies evaluating the use of SepsiTest on whole-blood samples in the clinical setting
were first published in abstract form by Disqué et al.47 in 2008, with a subsequent full-text peer-reviewed
publication by Wellinghausen et al.48 in 2009. SepsiTest received a CE mark in 2008. For the IRIDICA assay,
studies evaluating the use of IRIDICA on whole-blood samples in the clinical setting were first published by
Bacconi et al.,49 in 2014, who used an IRIDICA–PLEX-ID hybrid system. The final version of the IRIDICA
platform received a CE mark in 2014 and has been available for purchase by the NHS since 16 November
2014. Based on these data, the clinical effectiveness searches were limited by date from 2006 to May 2015.
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The search strategy of the current review updated the search strategy of an existing review on SeptiFast50
and amended it within the scope of the current review (i.e. the search strategy was amended to include
generic, trademark or other product names of all the relevant index tests, other bacterial or fungal gene
terms were added and were combined with PCR and population terms, and a limit to exclude all animal-only
studies was introduced). An example of the MEDLINE search strategy is provided in Appendix 1.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies
were checked and a citation search of relevant articles (using the Web of Science Citation Index Expanded
and Conference Proceedings Citation Index – Science) was undertaken to identify articles that cite the
relevant articles. In addition, systematic keyword searches of the World Wide Web were undertaken using
the Google search engine (Google Inc., Mountain View, CA, USA), key experts in the field were contacted
and company submissions were screened for published or unpublished data additional to those identified
in studies retrieved from the literature search.
All identified citations from the electronic searches and other resources were imported into, and managed
using, the Reference Manager bibliographic software (version 12.0; Thomson ResearchSoft, San Francisco,
CA, USA).
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a three-step process. First, all titles were
examined for inclusion by one reviewer (LU). Any citations that clearly did not meet the inclusion criteria
(e.g. non-human, unrelated to sepsis) were excluded. Second, all abstracts were examined independently
by two reviewers (LU and AP) and the full manuscript of all potentially eligible articles that were considered
relevant was obtained, where possible. Third, two reviewers independently assessed the full-text articles
(n= 177) for inclusion (LU and AP). All potential studies for inclusion (n= 87) were then adjudicated by
three clinical experts independently (GDP, PD and RM). Any disagreements in the selection process were
resolved through discussion and included by consensus between the two reviewers and three clinicians.
The relevance of each article for the systematic review was assessed according to the criteria below.
Study design
All clinical diagnostic accuracy studies that evaluated the index test with standard culture results (with or
without MALDI-TOF MS) on patients’ whole-blood samples during the management of suspected sepsis
were included. In reviews of test accuracy the ‘index test’ (the test of which the performance is being
evaluated) can be viewed as the intervention.
Reviews of primary studies were not included in the analysis but were retained for discussion and
identification of additional studies. Moreover, the following publication types were excluded from the
review: animal models; biological studies; narrative reviews, editorials and opinions; case reports;
non-English-language papers; and reports published as meeting abstracts only when insufficient
methodological details are reported to allow critical appraisal of study quality.
Population
All studies of adults and children (of any age) with suspected bloodstream infections in secondary care
(i.e. departments and wards providing care for acutely unwell patients and/or critical care units) who
required blood cultures were included. Potential subgroups of interest included people with a suspected
health-care-associated infection, people with a suspected community-acquired infection, children and
neonates, people who are immunocompromised and people exposed to antibiotics prior to blood sample
collection. Following clinical advice, people with febrile neutropeniawere also considered as potential subgroup
of interest. This group of patients usually undergo blood culture testing as their ability to show the classical
signs of sepsis are impaired and failing to treat an underlying infection can result in mortality. This practice is
supported by a recent large, retrospective study by Kaukonen et al.,3 which found that a significant number of
poor outcomes from severe systemic infection occurs in the absence of SIRS criteria at inception.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Target conditions
Suspected sepsis, including severe sepsis and septic shock as defined by Levy et al.17
Interventions (index test)
The following tests (in conjunction with clinical assessment) performed on whole-blood samples for the
detection of bloodstream bacterial and fungal pathogens were included:
l SeptiFast
l SepsiTest
l IRIDICA assay (extended to include preceding versions of the test if the authors believed that the data
were likely to be generalisable to the IRIDICA assay).
Comparator test (reference standard)
The reference tests included current standard care to define the target condition, which included blood
culture (in conjunction with clinical assessment) for the identification of bloodstream bacterial and fungal
pathogens with or without MALDI-TOF MS. Where studies were identified that included more than one
intervention, these would also form comparators for each intervention.
Outcomes
The outcomes of the review included a range of intermediate measures (such as diagnostic accuracy,
discordant results with blood culture, time to result, time to treatment, test failure rates, duration of ICU
and/or hospital stay, duration of broad- and narrow-spectrum antimicrobial therapy, readmission rate and
change in antimicrobial treatment plan) and clinical outcome measures {such as side effects associated
with broad-spectrum antimicrobial use, morbidity and mortality, severity of disease [as measured by scoring
systems such as the Acute Physiology and Chronic Health Evaluation (APACHE) II, Simplified Acute
Physiology Score (SAPS) II and the Sequential Organ Failure Assessment (SOFA)], rates of superinfection
(including C. difficile), rates of resistant infections and health-related quality of life}, where available.
Data abstraction strategy
Data abstraction was performed by one of three reviewers into a standardised data extraction form and
independently checked for accuracy by a second reviewer (AP, LU or MMJ). Discrepancies were resolved by
discussion between the two reviewers and, if agreement could not be reached, a third reviewer was
consulted. When multiple publications of the same study were identified, data were extracted and
reported as a single study. Moreover, as this review of three rapid molecular tests incorporated an update
of the most recent review of SeptiFast by Dark et al.,50 all relevant data were extracted from the systematic
review in the first instance, but were cross-checked for accuracy with the original papers. When necessary,
additional data were extracted from the original papers. For the review of SepsiTest and IRIDICA, all data
were extracted from the original papers. Unpublished study data from the company (which were received
during the review process) that met the inclusion criteria were also extracted and quality assessed in
accordance with the procedures outlined in this chapter.
The following information was extracted for all studies when reported: study characteristics (e.g. author,
year of publication, country, study design, setting, funding), participant details (e.g. age, sex, inclusion and
exclusion criteria), test details, reference standard details and outcomes (including definitions).
Quality assessment strategy
The methodological quality of each included study was assessed by one of three reviewers and
independently checked by a second reviewer (AP, LU or MMJ). Disagreements were resolved by discussion
between the two reviewers and, if agreement could not be reached, a third reviewer was consulted.
The study quality characteristics were assessed according to (adapted) criteria based on those proposed by
Whiting et al.51 [Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)]. Further details are
provided in Appendix 2.
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Methods of data synthesis
The extracted data and quality assessment variables were presented for each study, both in structured
tables and as a narrative description. The analysis comprised a narrative synthesis and pairwise
meta-analysis.
Meta-analysis
Where sufficient data existed, a meta-analysis was undertaken to generate pooled estimates of diagnostic
parameters. The number of true positives, false negatives, false positives and true negatives from each
study was meta-analysed to estimate sensitivity and specificity under the assumption that blood culture
was 100% sensitive and specific. In brief, a bivariate normal model was used to model the population logit
sensitivities and specificities in each study to account for correlation between sensitivity and specificity
within studies.52 We assumed that the observed number of true positives in study i, TPi, was binomially
distributed, with parameter, πAi, representing the study-specific sensitivity given the total number of
positives on the reference test such that:
TPi∼ Binomial(πAi, (TPi + FNi)). (1)
Similarly, we assumed that the observed number of true negatives in study i, TNi, was binomially
distributed with parameter, πBi, representing the study-specific specificity given the total number of
negatives on the reference test such that:
TPi∼Binomial(πBi, (FPi + TNi)). (2)
We transform the parameters to the real line using the logit transformation such that:
µAi = logit(πAi) (3)
µBi = logit(πBi). (4)
Sensitivity and specificity are correlated within each study such that higher values for sensitivity tend to be
associated with lower values for specificity, and vice versa. We model this by assuming that the study-
specific logits for sensitivity and specificity arise from a bivariate normal distribution with population logits
for sensitivity and specificity, (µA,µB)T, respectively, and variance–covariance matrix, ΣAB, such that:
µAi
µBi
 
∼N µA
µB
 
,ΣAB
 
(5)
ΣAB =
σ2A σAB
σAB σ2B
 
. (6)
σ2A represents the variability in the logit sensitivities between studies, σ2B represents the variability in the logit
specificities between studies and σAB represents the covariance of the logit sensitivity and logit specificity.
The model was completed by giving the uncertain parameters the following prior distributions:
µA∼N(0, 10000) (7)
µB∼N(0, 10000) (8)
ΣAB∼IW
1 0
0 1
 
, υ ¼ 2
 
. (9)
IW represents the inverse Wishart distribution on υ degrees of freedom.
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This prior distribution has a between-study standard deviation (SD) of 1.5 [95% credible interval (CrI) 0.4
to 32.4].
Where there were relatively few studies to estimate the variance–covariance matrix, ΣAB, a weakly
informative prior distribution was used such that:
ΣAB∼IW
1 0
0 1
 
, υ ¼ 5
 
. (10)
This prior distribution has a between-study SD of 0.5 (95% CrI 0.3 to 1.4).
Reasons for the heterogeneity in sensitivity and specificity between studies were explored using
metaregression. Models with and without covariates were compared using the deviance information
criterion, which provides a relative measure of goodness of fit that penalises complexity and can be used
to compare different models for the same likelihood and data.53
All parameters were estimated using Markov chain Monte Carlo simulation implemented using the
WinBUGS software package (version 1.4.3; MRC Biostatistics Unit, Cambridge, UK).54 Analyses were
conducted in R using the R2WinBUGS interface package (version 3.1.2; R Foundation for Statistical
Computing, Vienna, Austria).55 Convergence was assessed using the Gelman–Rubin convergence statistic.
Convergence was achieved relatively quickly and generally within 5000 iterations; in practice, a burn-in of
10,000 iterations was used. There was no evidence of high autocorrelation between successive samples of
the Markov chains. Results were displayed as forest plots and summary receiver operating curve plots with
95% CrIs and 95% prediction intervals for sensitivity and specificity.
Narrative synthesis
A meta-analysis was not conducted on a range of intermediate measures (i.e. time to result, time to
treatment, test failure rates, duration of ICU and/or hospital stay, duration of broad- and narrow-spectrum
antimicrobial therapy, readmission rate and change in antimicrobial treatment plan) and clinical outcome
measures (e.g. side effects associated with broad-spectrum antimicrobial use, morbidity and mortality,
severity of disease, rates of superinfection, rates of resistant infections and health-related quality of life),
as the necessary data were not available or it was inappropriate to statistically pool studies because of their
variability in reporting outcome data. Therefore, as suggested by the guidance produced by the Cochrane
Collaboration56 and the Centre for Reviews and Dissemination for undertaking systematic reviews,41,57
a narrative synthesis of included studies (grouped by outcome) was undertaken.
Clinical effectiveness results
Quantity and quality of research available
Number of studies identified/included
The literature searches identified 2892 citations. Of these, 66 studies met the inclusion criteria. A flow
chart describing the process of identifying relevant literature can be found in Figure 2.
Number and type of studies excluded
A total of 111 full-text articles were excluded, as they did not meet all the prespecified inclusion criteria.
The majority of the articles were excluded primarily on the basis of having insufficient information to allow
calculation of a diagnostic 2 × 2 metrics table (which includes data for true positives, false negatives, false
positives and true negatives), incorrect population or interventions, or data reported in abstract form that
were replaced by published full-text papers. A full list of excluded studies with reasons for exclusion is
presented in Appendix 3.
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Full-text articles (references)
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Full-text articles included
(n = 66 studies)
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(n = 657)
Full-text articles excluded,
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(n = 111)
Inappropriate interventions
(n = 20), comparator (n = 2) 
or population (n = 19),
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diagnostics metric (n = 12) or
outcome data (n = 1) for
inclusion, foreign language
(n = 8), inappropriate
specimens (n = 7), cultured
samples (n = 7) or detection
of a single pathogen only
(n = 3), abstract reported 
(or data rereported) in a
full-text paper (n = 23),
inappropriate publication
type [letter, comment,
review (n = 2)], not available
(n = 1) or other [e.g. protocol,
trial record, pre-clinical or
ongoing study, etc. (n = 6)]
Diagnostic accuracy
studies included in
meta-analysis
(n = 62)
•
•
•
SeptiFast, n = 55 studiesa
SepsiTest, n = 5 studiesa
IRIDICA, n = 4 studies
Other intermediate
measures or clinical
outcomes
Studies included in narrative
synthesis (n = 41) (for one or
more outcomes)
FIGURE 2 Study flow chart (adapted from Moher et al.58): clinical effectiveness review. a, Two studies included both
SeptiFast and SepsiTest and are counted as individual studies in each test comparison (meta-analysis) with the
reference standard.
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Assessment of effectiveness
Description of included studies (design and patient characteristics)
Study design characteristics
The design characteristics of the 66 included studies that evaluated the effectiveness of the SeptiFast,
SepsiTest and IRIDICA in patients with suspected sepsis are summarised in Table 4 (further details are
provided in Appendix 4).
In total, 56 single index test studies compared SeptiFast with blood culture,44–46,59–111 and one study112
evaluated SeptiFast with blood culture and MALDI-TOF MS. All SeptiFast studies were single gate in design
(i.e. same patient characteristics for both reference standard and index test). With the exception of three
RCTs,100,110,112 all SeptiFast studies were diagnostic cohort studies. Two single index test studies48,113
compared SepsiTest with blood culture, and one study evaluated SepsiTest with blood culture and
MALDI-TOF MS.114 Two three-arm studies118,119 compared both SeptiFast and SepsiTest with blood culture.
Four single index test studies compared IRIDICA with blood culture,49,115–117 two of which employed
IRIDICA–PLEX-ID hybrid systems49,116 (confidential data suggest that the IRIDICA CE-certified systems is
equivalent to the hybrid systems). All SepsiTest and IRIDICA studies were single-gate diagnostic
cohort studies.
Two SeptiFast studies46,80 and one IRIDICA study49 were conducted in North America. One IRIDICA study
did not report the country.115 Two SeptiFast studies100,107 were conducted in Brazil, two were undertaken in
Japan82,87 and one was undertaken in Turkey.105 Two SeptiFast studies63,111 were undertaken in the UK.
(Confidential information has been removed.)
Twenty-four of the SeptiFast studies,46,65,67,71,74–77,81,82,84,85,90,95,99–101,104–107,110–112 one multitest SeptiFast and
SepsiTest study,119 (confidential information has been removed) had data collected prospectively.
Eight of the SeptiFast studies64,66,69,86,89,96,97,109 and one SepsiTest study114 had a retrospective design. One
SeptiFast study103 evaluated samples collected both retrospectively and prospectively. (Confidential
information has been removed.)
Where reported, the sampling period ranged from 2 months45 to 66 months.80
The clinical setting (e.g. community, emergency department, hospital, intensive/critical care, general/
specialist) was not reported for nine SeptiFast studies,44,65,69,72,88,98,100,105,110 or for one multitest SeptiFast and
SepsiTest study118 (confidential information has been removed). The setting across the remaining studies
varied (see Table 4). Explicit inclusion and exclusion criteria for patients were reported for seven SeptiFast
studies,74,80,83,106,110–112 (confidential information has been removed) and one IRIDICA study.116
With the exception of the SeptiFast study by Warhurst et al.,111 which reported on health-care-associated
bloodstream infections, and the SeptiFast study by Josefson et al.,85 which reported on community-acquired
bloodstream infections, reporting of whether infection was community or hospital acquired was unclear in
the remainder of the included studies.
Patient characteristics of included studies
The patient characteristics of the included studies are summarised in Table 5 (further details are provided in
Appendix 4). Twenty-four of the SeptiFast studies,44,59–63,65,68–70,72,73,79,81,82,84,86,88,93,98,99,101,102,108 one SepsiTest
study,48 and one multitest SeptiFast and SepsiTest study118 (confidential information has been removed) did
not report on the mean or median age of patients. Six of the SeptiFast studies70,85,93,96,99,111 included both
adults and children, two included children and neonates86,109 and one included children and infants.105
Three SeptiFast studies69,73,98 and one IRIDICA study115 included neonates and infants, and one SepsiTest
study included adults and children.48 (Confidential information has been removed.)
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Twenty-two SeptiFast studies,44,45,62,63,65,68,70–72,75,78,79,81,83,85,88,96,98–100,105,108 one multitest SeptiFast and
SepsiTest study,118 (confidential information has been removed) did not report details or a reference to a
guideline for defining sepsis. The remaining studies provided a description or a reference to a guideline for
defining sepsis for included patients; however, these definitions and descriptions varied across studies and
were sometimes not explicitly clear (see Appendix 4).
Ten SeptiFast studies45,46,64,70,93,94,102,105,106,112 and one IRIDICA study116 reported on the proportion of the
included patients who were immunocompromised. In addition, Paolucci et al.69 reported that one
patient was affected by primary congenital immunodeficiency; however, it was unclear if other
immunocompromised patients were included in this study.
Twenty-three SeptiFast studies62,64,65,68,70,71,77,80,83,90–94,97–100,102,104,106,110,111 reported on the proportion of
patients receiving antimicrobial therapy at the time of blood sampling. In addition, it was unclear in one
SeptiFast study74 if patients received antimicrobial therapy (98%) prior to blood sampling. Of the 23
SeptiFast studies, six71,83,91,98–100 reported that none of the included patients had received antimicrobial
therapy at the time of blood sampling. Similarly, in one IRIDICA study115 none of the included patients
received antimicrobial therapy at the time of blood sampling. In one multitest SeptiFast and SepsiTest
study,119 the majority of patients (72%) received antimicrobial therapy at recruitment. (Confidential
information has been removed.)
The SeptiFast studies by Alvarez et al.,89 Bloos et al.,74 Bingold et al.59 and Markota et al.104 reported that all
included participants had severe sepsis or septic shock. Bloos et al.74 also reported a mean SOFA score of
10 and SAPS II score of 49 for the entire cohort. Markota et al.104 reported a mean admission APACHE
score for the cohort of 25 (SD± 7.6). The SeptiFast studies by Herne et al.97 and Lehmann et al.76 reported
that all included patients had severe sepsis. Seven SeptiFast studies46,77,80,83,100,106,112 and the one multitest
SeptiFast and SepsiTest study119 reported mixed samples of patients with sepsis, severe sepsis and septic
shock in varying proportions. The SeptiFast RCT by Rodrigues et al.100 reported a mean APACHE II score of
17 for the SeptiFast group and 17 for the blood culture group, but was unclear whether or not this was at
study entry or following testing. The SeptiFast RCT by Tafelski et al.112 reported a median SAPS II on
admission for the SeptiFast group of 40 (interquartile range 32–50) and the blood culture group of 47
(interquartile range 34–65). Schreiber and Nierhaus119 also reported a median SAPS II score of 41
(interquartile range 33 to 49) for the entire cohort. The IRIDICA study by Vincent et al.116 reported a mean
SOFA score at baseline of 7.6 (SD 4.2) indicating a 15–20% risk in mortality in ICU, but did not report
proportions of the patients with sepsis, severe sepsis or septic shock. The remainder of the included studies
did not report on the proportion of patients with sepsis, severe sepsis or septic shock, or disease severity.
Across the included studies, the number of patients analysed ranged from 19 (45 paired blood samples)
(SeptiFast – Gimeno et al.65) to 1093 (1114 paired blood samples) (SeptiFast – Josefson et al.85).
Details of index and reference tests, blood sampling methods and Conformité
Européenne approval
A detailed summary of the index and reference tests, blood samples taken and interval between the index
and reference test, CE approval of the blood volume used for testing, definition of a true positive,
laboratory working times and the unit of analysis (pathogen/sample/patient/episode) is presented in
Appendix 4.
Thirty-four of the SeptiFast studies reported on the blood volume used for the SeptiFast
test.45,69,71–78,80–83,85–87,90–94,96–99,101–103,107,109–112,114 Of these, nine studies reported blood volumes that did not
comply with CE approval: Lehmann et al.,76 Lodes et al.92 and von Lilienfeld-Toal et al.71 all reported using
1ml in adults; Bloos et al.,74 Lamoth et al.,75 Paolucci et al.99 and Sitnik et al.107 all reported using 3ml in
adults; Berger et al.73 reported using 0.1 ml in neonates and infants; and Kasper and Altiok98 reported
using 0.1–0.7ml in neonates and infants. The remainder of the SeptiFast studies did not report the blood
volume used for the test.
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Thirty-eight SeptiFast studies reported that blood drawn for SeptiFast and for blood culture were drawn at
the same time.45,60,64,65,68,70–72,74–76,78,81–87,90–99,101,102,104–107,110–112 Of these, one SeptiFast study reported that
blood drawn for SeptiFast and for blood culture were drawn within 1 hour,102 and another study reported
that blood drawn for SeptiFast and for blood culture were drawn within 12 hours of each other.97
The remainder of the SeptiFast studies did not report on when blood samples were drawn.
Across the studies evaluating SeptiFast, the studies by Lehmann et al.,66 Westh et al.,72 Tsalik et al.,80
Wallet et al.81 and Yanagihara et al.82 all reported that either the BACTEC or BacT/ALERT blood systems
were used and was dependant on the testing site performing the assay. Across the remaining SeptiFast
studies, 19 reported using the BACTEC system.60,64,70,71,75,76,79,83,85–87,92–96,107,110,112 Of these, one used
the BACTEC system with MALDI-TOF MS.112 Seventeen studies reported using the BacT/ALERT
system.45,78,84,90,91,97–104,106,108,109,111 The remaining studies did not report the method used.
Details of the laboratory working times or when assays were carried out for the index test were reported
by 13 studies evaluating SeptiFast.45,64,76,90,96,97,99,101–104,110,112 Working times were 7 days per week for four
SeptiFast studies,45,64,97,101 6 days per week for one SeptiFast study104 and 5 days per week for six SeptiFast
studies.90,96,99,103,110,112 For the remainder of the studies reporting on working times, it was unclear how
many days of the week laboratories were working.
Definition of a true positive was reported by 12 SeptiFast studies.74,76,83,85,86,94,97,101,106,112,118,119 Definition of a
true positive varied across these studies (Table 6).
A range of metrics (units of analyses) was used to assess the diagnostic accuracy of SeptiFast. The unit of
analyses was ‘patients’ in 11 studies,46,60,69,73,77,80,84,85,88,98,106 pathogens in seven studies63,71,72,81,101,110,111 and
episodes in five studies.70,75,83,99,109 For the remainder of the studies evaluating SeptiFast against blood
culture (with or without MALDI-TOF MS) the unit of analysis was samples. Although the heterogeneity in
the metrics has the potential to introduce some bias, the impact on the results was believed to be modest.
Thirty studies evaluating SeptiFast against blood culture included contaminants in the diagnostic test
accuracy analysis in this assessment report.44,45,64,67–70,73,76,78,81–85,87,91–98,105–107,109,110,120 and eight studies
reported that contaminants were excluded.46,72,80,86,99,101,102,111 For the remainder of the SeptiFast studies it
was unclear if contaminants were included or excluded.
(Confidential information has been removed.) One study of SepsiTest did not report when bloods were
drawn.114 One study performed blood culture using a BACTEC system,48 (confidential information has been
removed) and one study reported using BacT/ALERT with MALDI-TOF MS.114 (Confidential information
has been removed.) Definition of a true positive was reported by one SepsiTest study.48 (Confidential
information has been removed.)
(Confidential information has been removed.) The study by Delco-Volante et al.115 reported using 0.5ml of
blood in neonates and infants. (Confidential information has been removed.)
Neither of the studies evaluating both SeptiFast and SepsiTest against blood culture reported the volume
of blood used for the index test assay.118,119 Leitner et al.118 reported that the reference standard and index
tests were performed on blood samples drawn at the same time. Schreiber and Nierhaus119 did not report
if blood samples for the index tests and blood culture assay were drawn at the same time. Both studies
reported that blood culture was undertaken using the BACTEC system. Both studies reported a definition
of a true positive. Neither study reported on laboratory working times. The unit of analysis for the study by
Leitner et al.118 was samples and the unit of analysis for Schreiber and Nierhaus119 was patients. Both
studies included contaminants in the diagnostic test accuracy analysis.
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Quality characteristics
The QUADAS-2 tool,51 designed to evaluate the methodological quality of diagnostic accuracy studies,
comprises four key domains: patient selection, index test, reference standard, and flow and timing. Using a
set of signalling questions, each domain is assessed in terms of risk of bias [low, high or unclear risk (in the
event of insufficient data in the publication to answer the corresponding question)] and the first three
domains are also assessed in terms of applicability (no, yes or unclear concerns).
The overall methodological quality of the 66 included studies is summarised in Figure 3 and Table 7.
The methodological quality of the included studies, as assessed using the QUADAS-2 tool, was variable.
With the exception of Warhurst et al.,111 all other studies were considered to be at risk of bias and to have
concerns regarding applicability.121
(Confidential information has been removed.)
(Confidential information has been removed.)
Effectiveness of the interventions
This section presents the results of the following separately:
l an assessment of diagnostic test accuracy (meta-analysis, where applicable) of each diagnostic tests
(i.e. SeptiFast, SepsiTest and IRIDICA in conjunction with clinical assessment) for rapidly identifying
bloodstream bacteria and fungi
l an assessment of each diagnostic test on a range of other intermediate and clinical outcome measures
(narrative synthesis).
Analyses were undertaken to assess the sensitivity of the results to alternative priors but these made little
difference and thus only the results using the priors detailed in Meta-analysis have been presented.
Diagnostic test accuracy
A total of 62 studies contributed to the meta-analysis of sensitivity and specificity, including two
studies118,119 that were three-arm (two index tests) studies. For simplicity, the correlation between tests was
ignored in the analyses.
In total, 54 studies44–46,59–65,67–88,90–99,101,102,104–111,118,119 evaluated SeptiFast compared with blood culture, four
studies48,113,118,119 evaluated SepsiTest compared with blood culture and four studies49,115–117 evaluated
IRIDICA compared with blood culture. Separate meta-analyses are presented for each of these three tests
in SeptiFast test, SepsiTest and IRIDICA assay compared with blood culture. In addition, one study112
evaluated SeptiFast compared with blood culture plus MALDI-TOF MS and one study114 evaluated SepsiTest
compared with blood culture plus MALDI-TOF MS. As there was only one study for each of these
comparisons, no meta-analysis was conducted and the data were summarised narratively.
SeptiFast test SeptiFast test compared with blood culture The pooled sensitivity and specificity of
SeptiFast compared with blood culture (54 studies) were 0.65 (95% CrI 0.60 to 0.71) and 0.86 (95% CrI
0.84 to 0.89), respectively (Figure 4). The 95% prediction intervals of 0.29 to 0.90 (sensitivity) and 0.62 to
0.96 (specificity) suggest considerable uncertainty in predicting the sensitivity and specificity of a new
study. The between-study SDs for logit sensitivity and specificity were estimated to be 0.76 (95% CrI 0.57
to 1.01) and 0.66 (95% CrI 0.53 to 0.85), respectively, with a correlation of –0.05 (95% CrI –0.38 to
0.28). Figure 5 presents the joint distribution for sensitivity and specificity. The proportion of discordant
results with blood culture (i.e. cases of disagreement between the reference standard and the index test)
varied across studies from 6% to 46%, with a median of 17%.
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TABLE 7 Summary of intermediate and clinical outcomes reported across studies
Author (year)
Time to
pathogen
identification:
index test
Time to
treatment
Test failure
rates Mortality
Duration
of ICU
and/or
hospital
stay
Duration of
antibiotic
therapy
Reported
changes in
antimicrobial
treatment
plan
Single index test studies: SeptiFast
Raglio et al.
(2006)44
✓
Bingold et al.
(2007)59
✓
Klemm et al.
(2007)60
✓
Louie et al.
(2008)46
✓
Mancini et al.
(2008)45
✓
Dierkes et al.
(2009)64
✓ ✓ ✓ ✓ ✓
Lehmann et al.
(2009)66
✓ ✓ ✓
Palomares et al.
(2009)68
✓
Paolucci et al.
(2009)69
✓
Westh et al.
(2009)72
✓
Bloos et al.
(2010)74
✓ ✓
Lehmann et al.
(2010)76
✓
Maubon et al.
(2010)77
✓ ✓
Regueiro et al.
(2010)78
✓
Tsalik et al.
(2010)80
✓ ✓ ✓
Wallet et al.
(2010)81
✓ ✓
Hettwer et al.
(2011)84
✓
Josefson et al.
(2011)85
✓ ✓
Vrioni et al.
(2011)88
✓ ✓
Alvarez et al.
(2012)89
✓ ✓
Grif et al. (2012)90 ✓ ✓
Lodes et al.
(2012)92
✓ ✓
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TABLE 7 Summary of intermediate and clinical outcomes reported across studies (continued )
Author (year)
Time to
pathogen
identification:
index test
Time to
treatment
Test failure
rates Mortality
Duration
of ICU
and/or
hospital
stay
Duration of
antibiotic
therapy
Reported
changes in
antimicrobial
treatment
plan
Mauro et al.
(2012)93
✓
Pasqualini et al.
(2012)94
✓
Tschiedel et al.
(2012)96
✓ ✓
Herne et al.
(2013)97
✓ ✓
Paolucci et al.
(2013)99
✓
Rodrigues et al.
(2013)100
✓ ✓ ✓ ✓
Avolio et al.
(2014)101
✓
Mancini et al.
(2014)103
✓ ✓ ✓
Markota et al.
(2014)104
✓ ✓ ✓
Ozkaya-Parlakay
et al. (2014)105
✓ ✓
Schaub et al.
(2014)106
✓ ✓ ✓
Sitnik et al.
(2014)107
✓
Idelevich et al.
(2015)110
✓ ✓ ✓ ✓ ✓
Tafelski et al.
(2015)112
✓ ✓ ✓ ✓ ✓ ✓ ✓
Warhurst et al.
(2015)111
✓ ✓ ✓
Single index test studies: SepsiTest
Loonen et al.
(2014)114
✓
Single index test studies: IRIDICA
Confidential
information has
been removed
Confidential
information
has been
removed
Vincent et al.
(2015)116
✓ ✓
Two index test studies: SeptiFast and SepsiTest
Schreiber and
Nierhaus (2013)119
✓
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FIGURE 4 Sensitivity and specificity of SeptiFast compared with blood culture. FN, false negative; FP, false positive;
PrI, prediction interval; TN, true negative; TP, true positive.
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Additional analyses were undertaken for the following subgroups only: neonates and children, antibiotic
use prior to blood sample collection, suspected community- or health-acquired infection, patients with
febrile neutropenia and studies that included/excluded contaminants in the data analysis. There was
insufficient information on studies at low risk of bias (see Quality characteristics) and people who were
immunocompromised to allow a meaningful estimate of test accuracy. None of the subgroups analysed
was shown to significantly affect the results.
l Neonates and children Six studies provided data on children and neonates. Of these, three studies
included neonates only,69,73,98 one included children only aged 1 month to 17 years105 and two included
both neonates and children.86,109 Of the remaining studies, six were conducted in adults and
children,70,85,93,96,99,111 28 were conducted in adults45,46,63,64,67,68,71,74–76,78,80,81,83,84,87,90–92,94,95,97,101,102,104,106,110,119
and 14 did not report the age of participants.44,59–62,65,72,77,79,82,88,107,108,118 Based on comparison of models
with and without covariates for an age category, there was no evidence that sensitivity and specificity
was affected by the age of the subjects (see Appendix 5).
l People exposed to antibiotics prior to blood sample collection The proportion of patients receiving
antibiotics prior to blood draw was recorded in 24 studies24,62,64,65,68,70,71,74,77,80,83,90–94,97–99,104,106,110,111,119
and ranged from 0% to 100% with a median of 72%. The remaining studies either did not report
prior exposure to antibiotics or provided only limited information and were, therefore, excluded from
the analysis. There was no evidence that exposure to antibiotics prior to blood sample collection
affected the estimates of sensitivity and specificity (see Appendix 5).
l People with suspected community- or health-acquired infection Clinical setting was used as a proxy for
suspected community- or health-acquired infection. Studies were grouped according to whether
infection was diagnosed in hospital (38 studies45,59–64,67,68,70,71,73–79,81,83,85,86,90–97,99,102,104,107–109,111,119),
emergency department (three studies80,84,106), mixed setting of emergency or other hospital department
(four studies46,82,87,101) or not recorded (nine studies44,65,69,72,88,98,105,110,118). Based on comparison of models
with and without covariates for the clinical setting, there was no evidence that this affected sensitivity
and specificity (see Appendix 5).
l People with febrile neutropenia In total, eight studies provided data on patients with febrile
neutropenia.45,65,71,75,91,99,108,110 Of these, six studies included patients (100%) with febrile neutropenia
only.65,71,75,91,99,108 Studies by Mancini et al.45 and Idelevich et al.110 reported that 92% and 98% of
patients had febrile neutropenia, respectively. Based on a comparison of models with and without
covariates for the presence of patients with febrile neutropenia, there was no evidence that this
affected sensitivity and specificity (see Appendix 5).
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FIGURE 5 Summary receiver operating curve plot of SeptiFast compared with blood culture (all studies). The 95%
prediction interval indicates the extent of heterogeneity between studies. The green circles represent the
sensitivity and specificity estimates from each study, with the circle size reflecting the study sample size.
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l Studies with inclusion/exclusion of contaminants In total, 32 studies44,45,64,67–70,73,76,78,81–85,87,91–98,105–110,118,119
included contaminants in the reported results, eight studies46,72,80,86,99,101,102,111 excluded contaminants and
14 did not report on handling of contaminants.59–63,65,71,74,75,77,79,88,90,104 Based on a comparison of models
with and without covariates for the inclusion/exclusion of contaminants, there was no evidence that this
affected sensitivity and specificity (see Appendix 5).
SeptiFast test compared with blood culture plus MALDI-TOF MS Only one study,112 which compared
the SeptiFast test with MALDI-TOF MS, provided data on diagnostic test accuracy. This study reported a
sensitivity and specificity of 0.58 (95% CI 0.30 to 0.86) and 0.74 (95% CI 0.64 to 0.85), respectively.
SepsiTest SepsiTest compared with blood culture The pooled sensitivity and specificity of SepsiTest
compared with blood culture was 0.48 (95% CrI 0.21 to 0.74) and 0.86 (95% CrI 0.78 to 0.92),
respectively (Figure 6). The 95% prediction intervals of 0.07 to 0.90 (sensitivity) and 0.66 to 0.95
(specificity) suggest considerable uncertainty in predicting the sensitivity and specificity of a new study. The
between-study SDs for logit sensitivity and specificity were estimated to be 0.90 (95% CrI 0.50 to 1.92)
and 0.45 (95% CrI 0.27 to 0.90), with a correlation of –0.03 (95% CrI –0.73 to 0.68). Figure 7 presents
the joint distribution for sensitivity and specificity, and highlights the extent of the heterogeneity between
studies (as indicated by the 95% prediction interval). Owing to insufficient information provided in the
included studies, planned subgroup analyses were not conducted and there were insufficient studies to
conduct meaningful analyses.
SepsiTest compared with blood culture plus MALDI-TOF MS Only one study114 that compared the
SepsiTest assay with MALDI-TOF MS provided data on diagnostic test accuracy. This study reported a
sensitivity and specificity of 0.11 (95% CI 0.00 to 0.23) and 0.96 (95% CI 0.92 to 1.00), respectively.
IRIDICA assay compared with blood culture The pooled sensitivity and specificity of IRIDICA compared
with blood culture was 0.81 (95% CrI 0.69 to 0.90) and 0.84 (95% CrI 0.71 to 0.92), respectively
(Figure 8). The 95% prediction intervals of 0.55 to 0.94 (sensitivity) and 0.50 to 0.96 (specificity) suggest
considerable uncertainty in predicting the sensitivity and specificity of a new study. The between-study SDs
for logit sensitivity and specificity were estimated to be 0.46 (95% CrI 0.28 to 0.93) and 0.65 (95% CrI
0.39 to 1.27), with a correlation of 0.06 (95% CrI –0.71 to 0.75). Figure 9 presents the joint distribution
for sensitivity and specificity and highlights the extent of the heterogeneity between studies (as indicated
by the 95% prediction interval). Owing to insufficient information provided in the included studies,
planned subgroup analyses were not conducted and there were insufficient studies to conduct
meaningful analyses.
FIGURE 9 Confidential information has been removed.
FIGURE 8 Confidential information has been removed.
FIGURE 7 Confidential information has been removed.
FIGURE 6 Confidential information has been removed.
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Other intermediate measures and clinical outcomes
A total of 41 studies provided data on one or more intermediate and/or clinical outcome measures: 37
SeptiFast studies,44–46,59,60,64,66,68,69,72,74,76–78,80,81,84,85,88–90,92–94,96,97,99–101,103–107,110–112 one SepsiTest study,114 two
IRIDICA studies116,117 and one study evaluating both SeptiFast and SepsiTest.119 A brief summary of the
studies reporting data on each of the intermediate and clinical outcomes measure is presented in Table 7.
Across the studies reporting intermediate and/or clinical outcomes, the majority of studies reported data
for the whole patient cohort, as opposed to comparative data for the index and reference test.
Furthermore, for some outcomes, for example mortality, it was often unclear at what point the outcome
was assessed. These limitations in reporting prohibited any statistical analysis to pool any intermediate
and/or clinical outcome across included studies. None of the included studies provided data on readmission
rates, adverse events associated with broad-spectrum antimicrobial use, morbidity, changes in disease
severity over time, rates of superinfection, rates of resistant infection or health-related quality of life.
Time to result (pathogen identification) A summary of the studies reporting the times to pathogen
identification of the index and reference test is presented in Table 8. Twenty-one SeptiFast studies reported
data on the time to availability of results/pathogen identification.44–46,59,60,64,68,69,77,80,81,85,88,93,96,97,101,106,107,110,112
However, for the majority of these studies, it was unclear if the value was the mean or median, and
variance estimates or ranges were not reported. Across these studies, the reported time to pathogen
identification with SeptiFast ranged from 4 hours68 to a median of 26.25 hours [range 6.75–79 hours
(for samples collected at beginning of a weekend)].64 In contrast, the time to pathogen identification using
blood cultures (with or without MALDI-TOF MS) ranged from 24 hours (minimum) to a median of
80 hours. Although the majority of studies that reported data on time to pathogen identification suggest
that results are obtained sooner using SeptiFast than using blood culture, laboratory working times
(e.g. laboratories operating on weekdays only) might delay the time to pathogen identification in real
clinical practice. Time to pathogen identification was not reported by any of the studies evaluating
SepsiTest or IRIDICA.
Time to treatment Time to treatment was reported by three SeptiFast studies, one of which was the RCT
by Tafelski et al.112 comparing SeptiFast with blood culture and MALDI-TOF MS, and two of which were
the RCTs by Rodrigues et al.100 and Idelevich et al.110 comparing SeptiFast with blood culture. The time to
treatment modification reported by all three RCTs was shorter in the SeptiFast group than in the blood
culture group. Tafelski et al.112 reported that the mean (SD) time from initially drawing blood to adaptation
of empirical antimicrobial treatment was 18.8 (SD 5.6) hours in the intervention group (SeptiFast, n= 4),
compared with 38.3 (SD 14.5) hours in the control group (n= 5) (p-value for difference not reported). The
number of patients with therapy modification based on a positive diagnostic test was 4 out of 41 (9.8%)
in the SeptiFast group and 5 out of 37 (13.5%) in the blood culture group. Rodrigues et al.100 reported a
mean time to change in therapy of 580 minutes (9.7 hours) with SeptiFast, compared with 3007 minutes
(50.1 hours) (p-value for the between-group difference= 0.004) for blood culture. The number of patients
in whom an adjustment of treatment was performed was 6 out of 17 (35%) in the SeptiFast group and
7 out of 29 (24%) in the blood culture group. Idelevich et al.110 reported that the median time to the
first change to a targeted antimicrobial therapy was significantly shorter with SeptiFast (21.4 hours,
range 16.2–46.3 hours) than with blood culture (47.5 hours, range 7.3–59.2 hours) (p-value for the
between-group difference= 0.018). There were 14 and 12 changes in antimicrobial therapy as a result of
microbiological findings in the study group and the control group, respectively.
DOI: 10.3310/hta20460 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 46
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
TABLE 8 Time to test results for index and reference test
Author (year)
Time to pathogen identification: index
test
Time to pathogen identification:
reference test
SeptiFast studies (non-comparative)
Raglio et al. (2006)44 16–30 hours 5–7 days
Bingold et al. (2007)59 6 hours 24–48 hours
Klemm et al. (2007)60 6.5 hours (minimum) 2 days
Louie et al. (2008)46 6.54 hours (mean) 65 hours (median) (range 24–214 hours)
Mancini et al. (2008)45 NR Detection with blood culture (lowest to
highest range of mean number of hours):
10 hours for E.coli to 22.2 hours for
coagulase-negative staphylococci.
Definitive identification (lowest to highest
range of mean number of hours):
44.2 hours for coagulase-negative
staphylococci to 56.6 hours for E. faecalis
Dierkes et al. (2009)64 18 hours (median): twice daily analysis
(range 6.75–74 hours for samples
collected at beginning of weekend).
26.25 hours (median): once-daily analysis
(range 6.75–79 hours for samples
collected at beginning of weekend)
NR
Palomares et al. (2009)68 4 hours 6.5 hours
Paolucci et al. (2009)69 Information on antimicrobial susceptibility
or microorganism viability ≈ 8 hours
48–72 hours
Maubon et al. (2010)77 6.5 hours NR
Tsalik et al. (2010)80 6.5 hours (approximately) NR
Wallet et al. (2010)81 7–15 hours 24–72 hours
Josefson et al. (2011)85 6 hours NR
Vrioni et al. (2011)88 7–15 hours 24–72 hours
Mauro et al. (2012)93 6 hours (approximately) NR
Tschiedel et al. (2012)96 17 hours (range 6–17 hours) 48 hours (range 48–120 hours, median
120 hours)
Herne et al. (2013)97 NR (range 5–22 hours) NR
Avolio et al. (2014)101 Mean 16.6 hours (95% CI 14.9 to
18.2 hours) or median 15 hours (range
13–17 hours) (excludes SeptiFast and
blood culture negative results)
Mean 84.2 hours (95% CI 82 to
86.4 hours) or median 80 hours (range
79–84 hours) (excludes SeptiFast and
blood culture-negative results)
Schaub et al. (2014)106 6 hours Median 16 hours (range 6–44 hours)
Sitnik et al. (2014)107 < 8 hours (mean) 3.5 days (mean) for blood culture-positive
results. 5 days for blood culture-negative
results
SeptiFast studies (comparative: RCTs)
Idelevich et al. (2015)110 20.3 hours (mean) 58.3 hours (mean)
Tafelski et al. (2015)112 Mean 15.9 hours (SD± 5.9 hours) (95%
CI 14.1 to 17.7 hours, assuming n= 41)a
Mean 38.1 hours (SD± 11.6 hours) (95%
CI 34.4 to 41.8 hours, assuming n= 37)a
NR, not reported.
a Estimated by authors.
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Test failure rates (internal control, reagents, other) Seven SeptiFast studies64,72,84,99,106,111,112 reported
information relating to failure rates. In the SeptiFast studies, test failure rates ranged from 1.5%106 to
24.2%.84 A summary of the failure rates reported by the SeptiFast studies is presented in Table 9. No data
on failure rates associated with SepsiTest were available.
(Confidential information has been removed.)
The clinical significance of failure rates is that no additional information will be provided by the tests. As
such, it is expected that the patient will be treated as would be the case without the test being available.
Duration of ICU and/or hospital stay Thirteen of the included studies,64,74,76,80,89,100,103–106,110–112 all of
which evaluated SeptiFast compared with blood culture, reported details of ICU and/or hospital stay.
Details of these studies and the length of stay are reported in Table 10. Across the RCTs, Idelevich et al.110
reported no statistically significant between-group difference in either ICU or hospital length of stay
(p= 0.815 and p= 0.235, respectively); Tafelski et al.112 also reported no significant between-group
differences in either ICU or hospital length of stay (p≥ 0.05 for both comparisons); and Rodrigues et al.100
reported no statistically significant between-group difference in hospital stay (p= 0.632). Across the other
studies reporting this outcome, data were often reported as characteristics of the included participants and
it was often unclear if the length of stay was up to, including and/or after blood sampling.
Change in antimicrobial treatment plan Details of change in antimicrobial treatment plan were
reported by 14 SeptiFast studies64,66,77,81,88,90,92,96,97,100,103,104,110,112 and one IRIDICA study.116 Details of these
studies and the reported changes are presented in Table 11.
Nine of the SeptiFast studies reported on changes in antimicrobial therapy based on the SeptiFast
results.64,77,81,88,90,92,96,97,104 These studies did not report on changes based on blood culture results. One
SeptiFast study reported on changes based on the blood results only.66 The SeptiFast RCT by Rodrigues
et al.100 reported that 6 out of 17 (35%) patients in the SeptiFast group and 7 out of 29 (21%) patients in
the blood culture group had an adjustment of antimicrobial therapy. The corresponding numbers for the
RCT by Idelevich et al.110 were 7 out of 74 (9.5%) patients in the SeptiFast group and 8 out of 76 (10.5%)
patients in the blood culture group. The RCT by Tafelski et al.112 reported that 4 out of 41 (9.8%) patients
in the SeptiFast and blood culture with MALDI-TOF MS group and 5 out of 37 (13.5%) patients in the
blood culture with MALDI-TOF MS group had an adjustment of antimicrobial therapy. A p-value for the
between-group difference was not reported by any of these RCTs.
TABLE 9 Test failure rates (internal control, reagents, other)
Author (year) Reported test failure rate details
SeptiFast studies
Dierkes et al. (2009)64 One failure was attributed to technical problems during the analysis; however, no further
details were provided
Westh et al. (2009)72 70/558 (12.5% of episodes)
Hettwer et al. (2011)84 38/157 (24.2%)
Paolucci et al. (2013)99 100/437 (22.9% of samples corresponding to 75 febrile episodes)
Schaub et al. (2014)106 3/205 (1.5% of samples had technical failure where the internal control was not
detected)
Tafelski et al. (2015)112 4/37 (10.8%)
Warhurst et al. (2015)111 69/1006 (6.9% of episodes) [SeptiFast assay failure: reagent control (n= 6), internal
control (n= 56) and other reasons (n= 7)]
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TABLE 10 Details of studies (all SeptiFast) reporting duration of ICU and/or hospital stay
Study author (year) Duration of ICU and/or hospital stay
SeptiFast studies (non-comparative)
Dierkes et al. (2009)64 Hospital stay: 35 days (median)
Bloos et al. (2010)74 ICU stay: 13 days (median)
Hospital stay: 34 days (median)
Lehmann et al. (2010)76 ICU stay true negatives: 17 days (range 1–89 days)
ICU stay true positives: 36 days (range 8–87 days)
Hospital stay true negatives: 23 days (range 1–93 days)
Hospital stay true negatives: 38 days (range 8–90 days)
Tsalik et al. (2010)80 Hospital stay: 6.3 days (mean)
Alvarez et al. (2012)89 ICU stay, SeptiFast: 22.9 days (mean) (SD± 29.9 days)
ICU stay, blood culture: 31.0 days (mean) (SD ± 19.4 days)
Hospital stay, SeptiFast: 18.3 days (mean) (SD± 21.4 days)
Hospital stay, blood culture: 21.3 days (mean) (SD± 23.4 days)
Between-group difference ICU and hospital: p< 0.05
Mancini et al. (2014)103 Hospital stay: no between-group differences were observed (no data reported)
Markota et al. (2014)104 Hospital stay: 27 days (mean) (SD± 28.9 days)
Ozkaya-Parlakay et al. (2014)105 ICU stay: 15.3 days (mean) (SD± 23.8 days)
Schaub et al. (2014)106 Hospital stay: 11 days (median)
Warhurst et al. (2015)111 ICU stay: 16 days (IQR 9–30 days)
SeptiFast studies (comparative: RCTs)
Rodrigues et al. (2013)100 Hospital stay, SeptiFast: 32 days (mean)
Hospital stay, blood culture: 31 days (mean)
Between-group difference: p= 0.632
Idelevich et al. (2015)110 ICU stay, SeptiFast: 0.8 days (mean) (SD± 4.0 days)
ICU stay, blood culture: 0.9 days (mean) (SD± 3.4 days)
Hospital stay, SeptiFast: 40.4 days (mean) (SD± 25.3 days)
Hospital stay, blood culture: 42.9 days (mean) (SD± 22.0 days)
Between-group difference: hospital, p= 0.235; ICU, p= 0.815
Tafelski et al. (2015)112 ICU stay, SeptiFast: 34 days (range 13–65 days)
ICU stay, blood culture: 32 days (range 16–57 days)
Hospital stay, SeptiFast: 53 days (range 33–79 days)
Hospital stay, blood culture: 37 days (range 20–76 days)
IQR, interquartile range.
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TABLE 11 Details of studies reporting changes in antimicrobial treatment plan
Author (year) Reported changes in antimicrobial treatment plan
SeptiFast studies (non-comparative)
Dierkes et al. (2009)64 SeptiFast: from pathogens identified by SeptiFast only, five (7.7%) patients had an adjustment of
antimicrobial therapy
Lehmann et al. (2009)66 Blood culture: in 49 out of 467 (9.5%) episodes, antimicrobial treatment was changed
Maubon et al. (2010)77 SeptiFast: results would have significantly improved treatment in 11 (10%) patients, and
prompted immediate antimicrobial therapy not given initially in three patients
Wallet et al. (2010)81 SeptiFast: on the basis of results, 8 out of 72 (11.1%) patients had an adjustment of antimicrobial
therapy
Vrioni et al. (2011)88 SeptiFast: on the basis of results, 5 out of 33 (15.2%) patients had an adjustment of antimicrobial
therapy
Grif et al. (2012)90 SeptiFast and concordant results from blood culture: 3 out of 33 (9.1%) patients had an
adjustment of antimicrobial therapy
SeptiFast and concordant results from samples from body sites: 5 out of 33 (15.2%) patients had
an adjustment of antimicrobial therapy
Lodes et al. (2012)92 SeptiFast: on the basis of results, 25 out of 148 (16.9%) samples had an adjustment of
antimicrobial therapy
Tschiedel et al. (2012)96 Patients with positive SeptiFast: 35 out of 75 (46%) had an adjustment of antimicrobial therapy
Patients with negative SeptiFast: 5 out of 75 (6%) had an adjustment of antimicrobial therapy
Herne et al. (2013)97 SeptiFast: on the basis of results, 21 out of 54 (39%) positive cases had an adjustment of
antimicrobial therapy
Mancini et al. (2014)103 Reports no between-group differences were observed in changes in management (propensity matching)
Markota et al. (2014)104 SeptiFast: on the basis of results, four (6.3%) samples had an adjustment of antimicrobial therapy
SeptiFast studies (comparative: RCTs)
Rodrigues et al.
(2013)100
SeptiFast: on the basis of results, 6 out of 17 (35%) patients had an adjustment of antimicrobial
therapy
Blood culture: on the basis of results, 7 out of 29 (21%) patients had an adjustment of
antimicrobial therapy
Between-group difference not reported
Idelevich et al. (2015)110 SeptiFast: on the basis of results, 7 out of 74 (9.5%) patients had an adjustment of antimicrobial
therapy
Blood culture: on the basis of results, 8 out of 76 (10.5%) patients had an adjustment of
antimicrobial therapy
Between-group difference not reported
Tafelski et al. (2015)112 SeptiFast and blood culture with MALDI-TOF MS: on the basis of results, 4 out of 41 (9.8%)
patients had an adjustment of antimicrobial therapy
Blood culture with MALDI-TOF MS: on the basis of results, 5 out of 37 (13.5%) patients had an
adjustment of antimicrobial therapy
Between-group difference not statistically significant: p≥ 0.05
IRIDICA studies
Vincent et al. (2015)116 A panel of three independent experts (randomly selected from a pool of seven) would have
recommended a change in management, including initiation of therapy, altered antimicrobial
spectrum and/or change in duration of therapy, based on the IRIDICA results. The panel
recommended a change in management in 41% of patients. Where IRIDICA tests were positive
and blood culture results were negative, a change in management was recommended in 57% of
patients; no values were provided for other scenarios
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Mortality Seventeen of the SeptiFast studies,64,66,74,78,80,85,89,90,92,94,100,103–105,110–112 one SepsiTest study,114 one
IRIDICA study116 and one study evaluating both SeptiFast and SepsiTest119 reported data on mortality. The
majority of studies reported data for the whole patient cohort, as opposed to comparative data for the index
and reference test. A summary of the mortality rates across all included studies is presented in Table 12.
Across the RCTs, the SeptiFast RCT by Tafelski et al.112 reported ICU mortality of 7 out of 41 (17%)
participants in the SeptiFast group and 8 out of 37 (22%) participants in the blood culture group. The
between-group difference was not statistically different (p≥ 0.05); the SeptiFast RCT by Idelevich et al.110
reported that five (6.6%) participants in the blood culture group and three (4.1%) participants in the
SeptiFast group died, but did not report when this occurred. The SeptiFast RCT by Rodrigues et al.100
reported that the between-group difference in 28-day mortality was not statistically significant.
In summary, the current evidence for the impact any of the index tests evaluated against blood culture on
intermediary and clinical outcomes, such as mortality and reduced length of stay in critical care units, is
limited. A small number of RCTs of low methodological quality have not shown SeptiFast to produce a
statistically significant improvement compared with blood culture and there are presently no RCTs
comparing the other index tests (SepsiTest or IRIDICA) of interest with blood culture, or any RCTs
comparing any of the index tests of interest in a head-to-head manner.
Additional information on matrix-absorbed laser desorption time-of-flight
mass spectrometry
Although not an intervention, and therefore omitted from the systematic review of clinical effectiveness,
information on the diagnostic accuracy and in the potential benefits associated with MALDI-TOF MS was
required. Two recent systematic reviews have been published:30,122 one focusing on the time taken to
identify microbial organisms from positive blood cultures122 and one reviewing the performance of
Sepsityper kit in conjunction with MALDI-TOF MS.30
Dixon et al.122 identified 10 studies which provided evidence that MALDI-TOF MS is associated with faster
identification of pathogens, usually 24 hours sooner than blood culture alone. Where data were reported,
MALDI-TOF MS was associated with a reduction in hospital costs and length of stay. However, the authors
state that ‘all the included studies were observational and their findings have a relatively high risk of bias’
and that ‘MALDI-TOF MS has the potential to reduce length of stay and costs while improving patient
outcomes, but more and better evidence, including that on cost-effectiveness, is required’.
Morgenthaler and Kostrzewa30 summarise data from 21 reports to assess the reliability of the Sepsityper kit
in the rapid identification of bloodstream infection. It was reported that ‘no relevant misidentification on
the genus level was reported at a log (score) cut-off of 1.6’, whereas time to a result was reduced by
several hours or days.
In addition to these reviews, papers known to the authors, submitted by the company or identified in the
sifting related to the review of economic evaluations of the interventions were read to provide additional
information regarding MALDI-TOF MS. Citation searching was performed to identify further information.
TABLE 12 Details of studies reporting data on mortality
Author (year) Reported mortality details
Single index test studies: SeptiFast (non-comparative)
Dierkes et al. (2009)64 In-hospital mortality: 33%
Lehmann et al. (2009)66 30-day mortality: 33.8% of 467 episodes
Bloos et al. (2010)74 29.9% – location/time period NR
Regueiro et al. (2010)78 37.5% – location/time period NRa
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TABLE 12 Details of studies reporting data on mortality (continued )
Author (year) Reported mortality details
Tsalik et al. (2010)80 2.6% – location/time period NR
Josefson et al. (2011)85 30-day mortality: 4%
Alvarez et al. (2012)89 28-day mortality SeptiFast: 29%
28-day mortality blood culture: 24%
6-month mortality SeptiFast: 41.6%
6-month mortality blood culture: 37%
Between-group difference: p=NS
Grif et al. (2012)90 24-hour mortality: 61%
Lodes et al. (2012)92 43.2% – location/time period NR
Pasqualini et al. (2012)94 In-hospital: 12%
Mancini et al. (2014)103 The mortality difference in the original propensity score matching was not significant:
8.24% (prospective cohort) vs. 13.48% (retrospective cohort) (p= 0.39). However, in
a more stringently matched group, SeptiFast was reported to be associated with
lower mortality rates [3.13% (n= 2 deaths) in the prospective cohort and 14.71%
(n= 10 deaths) in the retrospective cohort (p= 0.04)]
Markota et al. (2014)104 In-hospital mortality: 52.6%
Ozkaya-Parlakay et al. (2014)105 25.3% – location/time period NR
Idelevich et al. (2015)110 SeptiFast: 4.1% – location/time period NR
Blood culture: 6.6% – location/time period NR
Between-group difference: p= 0.719
Single index test studies: SeptiFast (comparative: RCTs)
Rodrigues et al. (2013)100 28-day mortality SeptiFast: 53%
28-day mortality blood culture: 59%
Between-group difference: p= 0.765
Tafelski et al. (2015)112 ICU mortality, SeptiFast and blood culture with MALDI-TOF MS: 17%
ICU mortality, blood culture with MALDI-TOF MS: 22%
Between-group difference: not statistically significant (p≥ 0.05)
Warhurst et al. (2015)111 28-day mortality: 14%
Single index test studies: SepsiTest
Loonen et al. (2014)114 3.2% – location/time period NR
Single index test studies: IRIDICA
Vincent et al. (2015)116 29% – location/time period NR
Two index test studies: SeptiFast and SepsiTest
Schreiber and Nierhaus (2013)119 ICU mortality: 16%
28-day mortality: 24%
NR, not reported; NS, not significant.
a Reporting discrepancy in article, text says 32.8% whereas tables say 37.5%.
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It is noted that often MALDI-TOF MS was introduced in conjunction with another change, such as the
establishment of an antimicrobial stewardship team, and, therefore, the exact gain attributable to
MALDI-TOF MS was unknown.
Perez et al.123 report the implementation of an evidence-based intervention that integrated MALDI-TOF MS,
rapid antimicrobial susceptibility testing and near-real-time antimicrobial stewardship practices.
A comparison of the results before and after testing was made. The mean hospital length of stay for
survivors (n= 100) after bloodstream infection onset was 9.9 days in the pre-intervention group, compared
with 8.1 days in the intervention group (n= 101; p= 0.01). Within a multivariate model, receiving active
antibiotic therapy at 48 hours was associated with a hazard ratio for discharge of 2.90 (95% CI 1.15 to
7.33; p= 0.02) and the intervention was associated with a hazard ratio for discharge of 1.38 (95% CI
1.01 to 1.88; p= 0.04). Total hospitalisation costs were US$45,709 in the pre-intervention cohort and
US$26,162 in the intervention cohort.
A further paper124 reported a pre–post quasi-experimental study that analysed the impact of MALDI-TOF MS
with an antimicrobial stewardship team. The intervention (n= 256) decreased time to organism identification
compared with previous treatment prior to MALDI-TOF with an antimicrobial stewardship team (n= 245) (55.9
vs. 84.0 hours; p< 0.001) and improved time to effective antibiotic therapy (20.4 vs. 30.1 hours; p= 0.021),
optimal antibiotic therapy (47.3 vs. 90.3 hours; p< 0.001) and length of ICU stay (8.3 vs. 14.9 days; p= 0.014).
The 30-day all-cause mortality was lower in the intervention arm than in the pre-intervention arm (12.7% vs.
20.3%; p= 0.021), as was length of hospitalisation (14.2 vs. 11.4 days; p= 0.066).
A study in Texas (USA) compared the outcomes of antibiotic-resistant Gram-negative bacteraemia in
112 patients admitted during January 2009 to November 2011 and 157 patients admitted during February 2012
to June 2013 following the introduction of an intervention (MALDI-TOF MS and antimicrobial stewardship).125
Time to initiation of active treatment was 90 hours in the first group and 32 hours in the second group
(p< 0.001). There were 33 (21%) deaths from any cause in the pre-intervention cohort and 10 (9%) in the
intervention cohort. In multivariate logistic regression, the intervention was a significant predictor of survival
(odds ratio 0.28, 95% CI 0.12 to 0.71; p= 0.008). A significant reduction in average total hospital costs was
observed, from US$78,991 to US$52,693.
A quasi-experimental study126 was conducted to evaluate the effect of introducing MALDI-TOF MS plus
antimicrobial stewardship team review on the treatment of hospitalised patients in whom blood samples
tested positive for coagulase-negative staphylococci (n= 324). Before the introduction of the intervention,
117 positive cultures (72%) were deemed to be contaminated and 46 (28%) were from patients with
bacteraemia. The corresponding figures after the introduction of the intervention were 129 (80%) and
32 (20%), respectively. Following the introduction of MALDI-TOF MS plus antimicrobial stewardship team
review, patients with bacteraemia received optimal therapy sooner (34.4 vs. 58.7 hours; p= 0.032) and
exhibited a lower mortality rate than patients treated before the introduction of the intervention (3.1% vs.
21.7%; p= 0.023). In addition, following introduction of the intervention, patients whose blood samples
were contaminated experienced a shorter duration of unnecessary antibiotic therapy (1.31 vs. 3.89 days;
p= 0.032) and underwent fewer vancomycin trough assays (0.88 vs. 1.95; p< 0.001). However, rates of
mortality, duration of hospitalisation stay, recurrent bloodstream infections and 30-day hospital
readmissions were not significantly different.
A paper by Martiny and Debaugnies127 reports that the use of MALDI-TOF MS resulted in the modification
of treatment in 21 out of 157 adults and 1 out of 40 children.
The potential benefits associated with MALDI-TOF MS, albeit not from RCTs, is believed to be the
motivation for the RAPIDO study,31 which will report the required data for assessing the clinical
effectiveness of MALDI-TOF MS, typically in conjunction with Sepsityper and blood culture compared with
blood culture alone within clinical practice. It is envisaged that the results from this study will make the
preceding data in this section largely redundant.
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Chapter 3 Assessment of cost-effectiveness
Systematic review of existing economic evidence
This section of the report describes a review of the existing published evidence on the economic impact of
the SeptiFast, SepsiTest and IRIDICA tests to rapidly detect and identify bacterial and fungal DNA, which
may be present in the bloodstream of people who are suspected of having sepsis. As previously stated,
earlier versions of the IRIDICA BAC BSI assay were assumed by the authors to provide generalisable data,
and these have been included in the review, with explicit reference made to the version of IRIDICA.
Methods
Electronic resources
A systematic search was undertaken of the existing published literature evaluating the economic impact of
the SeptiFast, SepsiTest and IRIDICA tests to rapidly detect and identify bacterial and fungal DNA that may
be present in the bloodstream in people who are suspected of having sepsis.
Studies were identified by searching the following electronic databases and research registers:
l MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE (via OvidSP), searched from 1948 to
May 2015
l EMBASE (via OvidSP), searched from 1980 to May 2015
l Cochrane Database of Systematic Reviews (via Wiley Online Library), searched from 1996 to May 2015
l Cochrane Central Register of Controlled Trials (via Wiley Online Library), searched from 1898 to
May 2015
l Health Technology Assessment Database (via Wiley Online Library), searched from 1995 to May 2015
l Database of Abstracts of Review of Effects (via Wiley Online Library), searched from 1995 to May 2015
l NHS Economic Evaluation Database (via Wiley Online Library), searched from 1995 to May 2015
l Science Citation Index Expanded (via the Web of Science), searched from 1899 to May 2015
l Conference Proceedings Index-Science (via the Web of Science), searched from 1990 to May 2015
l World Health Organization’s International Clinical Trials Registry Platform, searched from 2007 to
May 2015
l Current Controlled Trials, searched from 2000 to May 2015
l NIH ClinicalTrials.gov, searched from 2000 to May 2015
l Manufacturer and User Facility Device, searched from 1991 to May 2015
l MEDION database.
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean operators
and database-specific syntaxes were developed to search the electronic databases. Synonyms relating to
the condition (e.g. sepsis) and the test (i.e. SeptiFast, SepsiTest and IRIDICA) were combined with a search
filter aimed at restricting results to economic and cost-related studies (used in the searches of MEDLINE
and EMBASE). No language restrictions were used on any database; however, the searches were restricted
by date (see Chapter 2, Methods for reviewing effectiveness, for further details). In brief, CE approval for
the oldest rapid molecular test (i.e. SeptiFast) was obtained in 2006. As a result, no relevant economic
evaluations were expected to be published prior to this date. An example of the MEDLINE search strategy
is provided in Appendix 6.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies
were checked and a citation search of relevant articles (using the Web of Science Citation Index Expanded
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and Conference Proceedings Citation Index – Science) was undertaken to identify articles that cited the
relevant articles. In addition, systematic keyword searches of the World Wide Web were undertaken using
the Google search engine, key experts in the field were contacted and company submissions were
screened for published or unpublished data additional to those identified in studies retrieved from the
literature search.
All identified citations from the electronic searches and other resources were imported into, and managed
using, the Reference Manager bibliographic software.
Studies were selected for inclusion according to predetermined inclusion and exclusion criteria. A summary
of these criteria is provided in Table 13.
Studies were selected for inclusion through a two-stage process:
l Level 1 screening: titles and abstracts were independently examined for inclusion by two reviewers
(RR and MS). Any disagreements in the selection process were resolved through discussion.
l Level 2 screening: full manuscripts of selected citations were then retrieved and assessed by one
reviewer (RR). A second reviewer (MS) performed an independent quality check to ensure that the
inclusion criteria were applied correctly. Any disagreements in the selection process were resolved
through discussion.
No formal quality assessment was conducted. When assessing the methodological quality of the economic
literature, a number of checklists are available; however, quality assessment checklists for assessing
economic evaluations of diagnostic tests are limited. Similarly, the majority of checklists focus on the
quality of reporting rather than the methodological quality of a study. Owing to these limitations the
relevance of each study to the decision problem is discussed within Descriptive summary of the study
included in the review, Critique of the studies included in the review and Relevance of existing economic
evaluations for National Institute for Health and Care Excellence decision-making.
TABLE 13 Inclusion and exclusion criteria for the review of economic evaluation
Criteria Included Excluded
Countries All No restriction
Settings All No restriction
Study design Economic evaluations (model or study based)
comparing one of the interventions listed
below with an appropriate comparator,
including other interventions if applicable
Non-economic evaluation
Cost study of one test only (comparison of
costs of different reagents or techniques)
Population Adults and children (of any age) with
suspected bloodstream infections in secondary
care (i.e. departments and wards providing
care for acutely unwell patients and/or critical
care units) who required blood cultures
Those people not meeting the inclusion
criteria
Target condition People with suspected sepsis People who do not have suspected sepsis
Comparator test Blood culture with or without MALDI-TOF MS Other tests done in house
Interventions (index test) SeptiFast, SepsiTest and IRIDICA Economic evaluations that do not
investigate one of the interventions of
interest in at least one of the arms
Outcomes Cost minimisation, cost-effectiveness,
cost–utility analysis
Other forms of economic evaluations
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Results
Identified studies
A total of 89 citations were retrieved. Of these, 77 citations were identified via database searching and an
additional 12 citations were retrieved through other sources (Figure 10).
Eighty references were excluded at title and abstract stage. Nine references related to eight studies were
examined at full-text level and four studies (corresponding to four references) were identified as meeting
the inclusion criteria of the systematic review of economic evaluations.89,103,128,129 These included an
economic evaluation of the IRIDICA–PLEX-ID hybrid assay reported in a poster presentation (submitted by
the company).128 It was highlighted that the system evaluated in the poster presentation was not the final
IRIDICA BAC BSI assay but was an earlier version that used components of PLEX-ID and is assumed to be
equivalent (see Chapter 1, IRIDICA BAC BSI).
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References included
(n = 4)
IRIDICA-PLEX-ID hybrid
assay
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(not reported in a
full-text paper)
Excluded by title and/or
abstract
(n = 80)
References excluded, with
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(n = 5)
• Inappropriate interventions,
   n = 3
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   evaluation and inappropriate 
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SeptiFast
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FIGURE 10 Study flow chart (adapted from Moher et al.58): economic review.
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Five papers were excluded after retrieval of the full papers,130–134 the rationale being that the results were
published in full elsewhere,130 they were other interventions131–133 and there was an absence of an
economic evaluation and inappropriate intervention.134
Descriptive summary of the study included in the review
A tabulated summary of the key characteristics of the studies included in the economic review, as
determined by the authors of this report, is presented in Table 14. It was not possible for the External
Assessment Group to check the economic models, as only the publications were available in the
public domain.
Of the four identified economic studies (corresponding to three full texts89,103,129 and one poster
presentation128), three economic evaluations (full text) compared the addition of SeptiFast to blood culture
with blood culture alone89,103,129 and one compared the addition of the IRIDICA–PLEX-ID hybrid assay to
blood culture with blood culture alone (poster presentation).128 No economic evaluations of SepsiTest were
identified. None of the four published economic evaluations was conducted in a UK setting. However, the
RADICAL study,116 used for the impact of the IRIDICA–PLEX-ID hybrid assay on treatment modification,
included two UK (out of nine) sites.116
Two103,129 out of the three SeptiFast studies were funded by Roche Diagnostics; it was unclear whether or
not the third study89 was funded by the company. The IRIDICA–PLEX-ID hybrid cost minimisation study was
funded by Abbott Diagnostics.
The target population, condition and setting varied between the four identified economic studies. Mancini
et al.103 included haematological patients with signs of systemic inflammatory response syndrome with
suspected sepsis (SIRS-SS). Alvarez et al.89 included patients diagnosed with severe sepsis and septic shock.
Lehmann et al.129 included all post-surgical and ICU patients with a sepsis episode (predominantly
hospital-acquired infection), while Bilkovski et al.128 included critically ill patients with suspected
bloodstream infection.
Three studies were cost-minimisation studies.89,103,128 Two were conducted within studies: a non-matched
retrospective study evaluating SeptiFast89 and a propensity score-matched study evaluating SeptiFast
against blood culture.103 The Alvarez et al. study89 justified the use of cost minimisation given the absence
of mortality data associated with the use of SeptiFast. The third cost minimisation study was undertaken
using a decision tree model128 and evaluated the IRIDICA–PLEX-ID hybrid assay by combining evidence
from the RADICAL study116 on the impact of the test in terms of treatment decision, and evidence from
MALDI-TOF MS studies123,124 on the impact of rapid identification on the reduction in hospital and ICU
length of stay. The main assumptions within the model were that (a) all patients start on empiric
antimicrobial therapy and (b) only patients testing positive using the IRIDICA–PLEX-ID hybrid assay
experience a reduction in length of stay.
Only one study was a cost-effectiveness (cost–utility) analysis and estimated the ‘cost per incremental
survivor’ and the cost per quality-adjusted life-year (QALY) gained of introducing SeptiFast.129 An algebraic
model was constructed, which independently estimated the potential cost impacts and clinical outcomes
associated with a change in treatment plan as a result of the earlier identification of inadequate treatment
through the use of SeptiFast. Only positive SeptiFast results were considered to provide sufficient evidence
to allow a treatment change, with the authors concluding that ‘withdrawal of antimicrobial treatment
upon a PCR negative result is not recommended’.129 Cost savings and increased health associated with
quicker adequate treatment were estimated assuming a relationship between a reduction of 1 day in
inadequate treatment and changes in both length of stay and mortality. This study used evidence collected
prospectively from five hospitals to inform the change in treatment decision: two based in Germany, one in
Spain, one in Italy and one in the USA.66 In addition, the modelling uses pooled data on the impact of
inadequate treatment on outcomes from two previously published studies135,136 conducted in the USA.
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Although not clearly stated by the authors, it is believed by the authors of this report that Mancini et al.103
and Alvarez et al.89 report results from an Italian and Spanish setting, respectively. In the case of the
studies by Lehmann et al.129 and Bilkovski et al.,128 the country on which the analysis was based is unclear,
as the data came from multicentre studies.
The economic evaluation was conducted in patients in the ICU in three studies.89,128,129 All studies appear to
use a hospital (health-care payer) perspective, although this was not explicitly stated in two studies.103,128
Uncertainty was examined in two studies.89,129 Only one study used QALYs as a measure of benefit.129
The cost of performing SeptiFast varied between studies and ranged from €178.75103 (£128.70 assuming
an exchange rate of €1 to £0.72137) to €300129 (£216). One study evaluated the IRIDICA–PLEX-ID hybrid
assay and assumed a cost of US$250 per test128 (£160.67 assuming an exchange rate of US$1 to £0.64).137
Two studies89,103 considered antibiotics costs, and both reported a reduction in antibiotics costs associated
with the use of SeptiFast. One study included the savings in classical diagnostic assays103 with the use of
SeptiFast. Three of the four studies considered the costs associated with ICU/hospital stay, and all reported
a reduction in hospital/ICU stay with the use of the test.76,89,128 None of the studies identified considered
the impact on costs associated with the potential reduction in antibiotic resistance.
Overall, all three cost-minimisation studies reported a reduction in total costs, with the additional cost of
SeptiFast and the IRIDICA–PLEX-ID hybrid assay being outweighed by the savings in antibiotics and/or
hospital costs.89,103,128 Mancini et al.103 reported an overall saving of €430.73 per patient receiving a SeptiFast
test and blood culture compared with those diagnosed using only blood culture (€1579.80 vs. €2010.53),
considering savings in diagnostic and instrumental assays, and medications (including antibiotics,
antimycotics, antiviral agents and other drugs). Alvarez et al.89 reported a saving of €9970 per SeptiFast test,
with the majority of savings achieved based on a reduction in ICU length of stay. Bilkovski et al.128 reported
a total saving of US$1,123,372 over 422 patients tested (equating to a saving of £2662 per patient tested),
with the IRIDICA–PLEX-ID hybrid assay associated with a reduction in hospital or ICU length of stay. Finally,
Lehmann et al.129 reported that the cost of the SeptiFast test could be recovered if the daily medical costs
were above €717 and suggested that this was likely to be the case.129 The authors reported the cost per
incremental survivor and cost per QALY gained to be €11,477 (95% CI €9321 to €14,977) and €3107
(95% CI €2523 to €4055), respectively.
Critique of the studies included in the review
The Lehmann et al.129 economic evaluation, which compared the use of SeptiFast and conventional blood
culture, appears to be a reasonably well-conducted cost-effectiveness analysis based on the description
provided by the authors. However, this study has a number of limitations that may restrict the
generalisability to UK practice, not only because none of the hospitals contributing to the study was
located in the UK. The data used in the Lehmann et al.129 cost-effectiveness model on the potential impact
of the test in terms of treatment modification are relatively out of date and were collected prior to recent
guidelines on the diagnosis and treatment of sepsis.16,18–20 Therefore, the extent to which the inadequate
treatment observed in Lehmann et al.66 is generalisable to current practice in the UK is not known.
Furthermore, the studies on how earlier adequate treatment translates into reduced morbidity and
mortality were dated and cohort based and, as acknowledged by Lehmann et al.,129 could be potentially
confounded. Lehmann et al.129 used a relative risk of non-survival between immediate and delayed
adequate antimicrobial treatment of 2.32, but report in their discussion section that a value of 1.8
estimated in a clinical trial of immunomodulating therapy for severe sepsis138 would have been a better
estimate of the relative risk of non-survival associated with inadequate treatment. Using this value led
to an increase in the cost per incremental survivor from €11,477 to €14,670 (an alternative cost per QALY
gained value was not reported). It should be noted that the relative risk is still relatively dated as it was
published in 2003.138 The relative risk of mortality was pooled from three studies, rather than the more
appropriate method of meta-analysing. The same limitations of the relationship between inadequate
treatment and mortality also apply to the relationship between inadequate treatment and length of
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hospitalisation, which uses data from the two old studies. It is noted that, in the original Lehmann et al.66
paper, data were collected from two separate sites of attendance: ICU or surgical ward, and emergency
room or other. The estimated gainable days of adequate treatment per 100 SeptiFast tests were 36.4 days
for the ICU or surgical ward group and 10.6 days for the remaining attendance method. It is unclear if the
evaluation by site was preplanned or if the analysis on ICU patients alone could be viewed as data
dredging; ideally a replication of the study within the ICU would provide more conclusive data. The failure
rate of the SeptiFast test was also not considered. In the model, patients receiving SeptiFast are assumed
to experience a mortality benefit associated with rapid identification. Although this may be plausible, so
far, evidence on the impact of SeptiFast on clinical outcomes of mortality and hospital length of stay is
inconclusive from five comparative studies.89,103,110,112,139
The cost-minimisation study conducted by Alvarez et al.89 is based on a retrospective non-matched
comparison of the costs in a cohort prior to the introduction of SeptiFast and a cohort following the use of
SeptiFast. Alvarez et al.89 reported a non-significant increase in mortality in the cohort receiving the
intervention at 28 days (29% vs. 24%, non-significant; p-value not reported), and at 6 months (41.6% vs.
37%, non-significant; p-value not reported). In contrast, the authors reported a significant reduction in ICU
length of stay for survivors (31.0± 19.4 vs. 22.9± 29.9 days; p< 0.05), hospital length of stay (21.3± 23.4
vs. 18.3± 21.4 days; p< 0.05) and ICU length of stay (24.1± 21.9 vs. 18.3± 11.4 days; p< 0.05). The
authors calculated the total cost to be €42,198 for the control group and €32,228 for the intervention
group, corresponding to a saving of €9970 (with more than 85% of savings attributable to a reduction in
ICU length of stay). This study has serious limitations that need further consideration. The results need to
be interpreted with caution because of the retrospective nature of this study, the small sample size of each
arm (48 patients in the intervention group and 54 patients in the control group) and the imbalances
between patient characteristics, as shown in Table 15. It is also unclear whether patients were randomly
selected to receive SeptiFast or whether these patients were selected based on their characteristics.
Although the authors reported no differences in terms of patients’ ages, sex distribution or risk indices, it is
unclear from the paper how these risk indices were calculated. There appear to be large imbalances in the
initial diagnoses that could impact on ICU length of stay (main source of savings). It should be noted that
TABLE 15 Comparison of baseline characteristics between the control and intervention group (adaptation of table 2
in Alvarez et al.89)
Baseline characteristics
Group
Control (n= 54) Intervention (n= 48)
Age (years), mean ±SD 65± 14.7 54± 12.9
Sex, % male 83.30% 72.90%
Initial diagnoses, %
Emergency abdominal surgery 20.37 18.75
Elective abdominal surgery 3.70 4.17
Pneumonia 7.41 –
Pancreatitis 1.85 14.58
CNS lesions 16.67 10.42
Polytrauma/head injuries 7.41 41.67
Heart surgery 37.04 4.17
Major vascular surgery 5.56 2.08
Pneumonectomy – 2.08
CNS, central nervous system.
Paper only reported the initial diagnosis for 47/48 people who received the intervention.
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no difference in ICU or hospital length of stay was observed in other comparative studies (RCT or
propensity-matched score studies).103,110,112,139 The authors report a saving in antibiotics (excluding cost of
the test) of €764 per patient [as a result of a reduction in the number of antibiotics used per patient of 0.9
(from 5.1 to 4.2)]. The authors do not say which antibiotics were used in the study, or for how long. It
should be noted that, in England, antibiotics are typically given as a 5- to 7-day course, with a daily cost
around £50. The failure rate of the SeptiFast test was not considered.
The second cost-minimisation study, by Mancini et al.103 evaluated the use of SeptiFast with blood culture
and is based on a propensity score-matched approach with 101 matched SIRS-SS episodes. The authors
reported a trend (although not significant) towards a reduction in SIRS-SS-related mortality associated with
SeptiFast. The authors reported that the differences in mortality reached statistical significance when the
tolerance (calliper) used for the propensity matching was reduced to only 5%, corresponding to 77
matched episodes (64 patients in the intervention group and 68 in the control group). Although the use of
a lower calliper improved the quality of matching, it reduced the precision by decreasing the sample size
and could also introduce bias, as the estimate is no longer the effect of treatment in the treated subjects,
but the effect of treatment in those treated subjects for whom a control was found.140 Using the tight
calliper of 0.05, the authors found a mortality rate of 3.13% in the intervention group and 14.71% in the
control group (i.e. a difference in the mortality rate of 11.58%). Based on a pilot study, the authors
reported that 278 pairs of SIRS events were needed to demonstrate a 10.6% difference in mortality (9.7%
in the intervention group vs. 20.3% in the control group), which is greater than the numbers analysed in
Mancini et al.103 The results from this study therefore need to be interpreted with caution. It should also be
noted that the PCR test was implemented under optimal conditions. The authors found no reduction in
SIRS-SS episode length, even under a tight strict matching criterion. In this study, the SeptiFast test was
estimated to lead to a reduction in medication. Based on information provided in a supplementary
appendix associated with the paper, the cost of antibiotics was higher in patients receiving SeptiFast
(€11.78). In contrast, the costs of antimycotics (commonly called antifungals in England) (€376.62), antiviral
agents (€1.65) and other drugs (€91.39) were reduced. Although the two cohorts were propensity
matched, it is unclear whether or not the suspected organisms in the two cohorts were matched, which
may affect the antibiotics prescribed. In the control arm, antimycotics represented approximately 53% of
total medication costs. This figure appears relatively high compared with that expected in England based
on Warhurst et al.10 It is also unclear how the cost of antibiotics and antifungals differ between England
and Italy. The failure rate of the SeptiFast test was not considered, nor was it clear whether patients were
randomly selected to receive SeptiFast or were selected based on their characteristics.
Finally, the Bilkovski et al. study128 is a decision tree using evidence from the RADICAL study116 on the
impact of the IRIDICA–PLEX-ID hybrid assay (referred to by the authors as the PCR/ESI-MS) in terms of
treatment decision and studies on MALDI-TOF MS123,124 for the impact of the test on clinical outcomes. This
study was available only as a poster presentation and, therefore, it is difficult to judge its quality. However,
the External Assessment Group notes some inconsistencies. In the RADICAL study, Vincent et al.116
reported that, among the 529 patients included, the overall mortality rate was 29%, suggesting that about
375 patients survived hospital discharge. However, the economic evaluation conducted by Bilkovski et al.128
is based on 422 patients and includes only 290 patients surviving to hospital discharge. Patients who
tested positive using the IRIDICA–PLEX-ID hybrid were assumed to experience a reduction in hospital and
ICU length of stay because of the earlier availability of results and potential therapy changes based on
data from two previous studies of MALDI-TOF MS.123,124 The validity of this assumption is uncertain as
MALDI-TOF MS and the IRIDICA–PLEX-ID hybrid assay are used differently and provide different
information. Notably, studies of MALDI-TOF MS are conducted in patients with a positive blood culture
only. Therefore, the impact of treatment changes when blood culture is negative is unknown and there
may be unintended consequences. Importantly, studies on MALDI-TOF MS123,124 used in the economic
evaluation evaluated the impact of MALDI-TOF MS in combination with an antimicrobial stewardship
programme compared with blood culture prior to the programme. Hence, the impacts of MALDI-TOF MS
in these studies are highly likely to be confounded by the simultaneous introduction of an antimicrobial
stewardship programme. These studies were also non-randomised in nature and, therefore, subject to
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potential biases. Bilkovski et al.128 predicted that the use of the IRIDICA–PLEX-ID hybrid system would lead
to a reduction in hospital and ICU length of stay of 1.6 days and 0.7 days, respectively, in all patients and
of 4.2 days and 1.8 days, respectively, in patients with positive IRIDICA-PLEX-ID results. It is unclear how
the model estimate relates to the impact of the test in practice and whether or not such savings would be
observed. As previously stated, evidence from five comparative studies of SeptiFast on the impact of a
similar test in terms of mortality or ICU and hospital length of stay is inconclusive.89,100,103,110,112 Test failure
was not considered in the analysis.
Relevance of existing economic evaluations for National
Institute for Health and Care Excellence decision-making
Overall, the existing economic evidence has limited relevance to the current UK setting. To date, only two
of the three tests (SeptiFast and IRIDICA–PLEX-ID hybrid) have supporting published economic evidence.
However, a number of limitations are noted.
There were a number of issues in the evaluations that require further consideration:
l It is unclear if results are generalisable to the UK. Notably, the current standard of care, the type of
antibiotics used and costs may differ between countries.
l All economic evaluations compared the use of either SeptiFast or the IRIDICA–PLEX-ID hybrid test with
blood culture. No comparison is provided against MALDI-TOF MS, which is an increasing part of current
practice in some units in the UK.
l Two studies included economic evaluations.89,103 However, there are limitations because of the
retrospective nature of these studies and potential biases associated with patient selection. Notably, the
study by Alvarez et al.89 is believed to be highly confounded, with large imbalances between groups in
terms of initial diagnosis: in the control group (n= 54), 20 patients had had heart surgery and four
patients had polytrauma/head injuries whereas, in the SeptiFast group (n= 48), only two patients had
had heart surgery but 20 suffered from polytrauma/head injuries.
l Two studies used modelling approaches to assess the impact of SeptiFast129 or the IRIDICA–PLEX-ID
hybrid assay,128 compared with blood culture, on treatment modification and the resulting effect in terms
of inadequate therapy or rapid identification. The results produced contradict the evidence of the impact
of the tests on clinical outcomes. The evidence so far is inconclusive, despite five comparative studies
comparing the impact of SeptiFast with that of blood culture, with or without MALDI-TOF MS, on
mortality and hospital/ICU length of stay.89,100,103,110,112 In the SeptiFast modelling study129 the impact of
the test on treatment change and on clinical outcomes was based on relatively old evidence that was
collected prior to recent guidelines on the diagnosis and treatment of sepsis.16,18–20 Bilkovski et al.128 based
their model of the IRIDICA-PLEX-ID hybrid assay on the results of two earlier MALDI-TOF MS studies.123,124
Both of these studies128,129 suffer from limitations: not only were they non-randomised, and therefore
subject to biases, but they evaluated the use of MALDI-TOF MS in combination with an antimicrobial
stewardship programme only in patients with positive blood cultures. Furthermore, the potential impact
of the test on treatment modification was estimated retrospectively, which may have introduced a further
source of bias.
l The cost of SeptiFast differed among the three studies89,103,129 and does not necessarily reflect the most
likely cost estimated by the External Assessment Group. Similarly, the cost of the IRIDICA–PLEX-ID
hybrid assay128 does not necessarily reflect the most likely cost estimated by the External
Assessment Group.
l The range of costs included varied between studies. With the exception of Mancini et al.,103 most
savings are attributable to a reduction in length of hospital stay. However, as previously mentioned,
there is no robust evidence on the impact of any of the interventions on hospital or ICU length
of stay.89,100,103,110,112
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l Mancini et al.103 reported a reduction in the costs associated with ‘classical diagnostic assays and
instrumental procedures’ following the introduction of SeptiFast and a large reduction in the costs of
empirical therapy predominantly associated with antifungals. It is unclear whether or not these
reductions are generalisable to the NHS in England.
l The identified economic evaluations focused on the positive impact of the test, for example a potential
reduction in antibiotics and/or length of stay. It is noted that tests may be associated with unintended
detrimental effects, such as a greater incidence of superinfection, as reported by Leone et al.,35 who
evaluated the effects of de-escalation in patients with sepsis. Furthermore, any detrimental effects that
may occur as a result of the wrong decision being made have been ignored.
l The results are also likely to be optimistic as the interventions appear to be implemented under optimal
conditions in the majority of identified economic evaluations103,129 rather than considering delays that
may occur under current practice conditions.
l The benefits associated with better antibiotic stewardship are not included in the economic evaluations;
however, the External Assessment Group acknowledges the difficulty of robustly quantifying
such benefits.
l It is also unclear whether or not patients were preselected in the studies.
l Finally, the failure rates within interventions were not considered. A recent UK study conducted by
Warhurst et al.10 suggests a test failure rate of 7% for SeptiFast. An alternative study reported failure
rates of 22.9%.99
Independent economic assessment: conceptual model
and methods
The conceptual model developed by the External Assessment Group was relatively simplistic because of the
lack of appropriate data. A decision tree approach was adopted with a lifetime horizon and discounting
undertaken at 3.5% per annum.
The NICE diagnostic reference case141 requests that cost-effectiveness is presented in terms of cost per
QALY gained. This has been adhered to although the authors highlight the considerable uncertainty in any
estimate because of the lack of robust data on key components of the calculation.
The cost per QALY can be divided into the incremental costs incurred and the incremental QALYs gained.
The incremental costs should consider:
l the cost of each test/comparator
l the net effect on hospital length of stay for both ICU and non-ICU patients, noting that rapid tests
could be detrimental to the patient as well as beneficial
l the net effect on the costs of antimicrobial treatment
l any net cost impact associated with the potential impact on antimicrobial resistance.
The incremental QALYs would ideally consider:
l the impact on sepsis-related mortality
l the impact of net effect on hospital length of stay for both ICU and non-ICU patients, noting that rapid
tests could be detrimental to the patient as well as beneficial
l any net QALY impact associated with the potential impact on antimicrobial resistance.
Although the costs of the tests and comparators can be estimated relatively well from current data, there
are no conclusive data on any other parameter listed in the bullet points above that were identified in the
External Assessment Group’s review. Therefore, a scenario analysis was undertaken in which these values
were estimated by clinical experts.
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Within the model it was assumed that the rapid identification of a pathogen could result in changes in
four key outcomes: 30-day mortality rates; the length of stay in an ICU; the length of stay in the hospital;
and the costs associated with antimicrobial treatment. Of these, changes in the mortality rate were
assumed to affect QALYs only, with the remaining categories assumed to affect costs only. This is a
simplification in that, for example, additional time in an ICU may be associated with slightly lower QALYs,
but the impact of such omissions was assumed not to affect the overall conclusions. In all scenarios the
potential impact of better antimicrobial stewardship in terms of drug resistance was not evaluated because
of both the complexity of such a task and the absence of information on how the tests would reduce
antimicrobial use.
It was assumed that negative tests would not impact on any of the four key outcomes. This assumption
was supported by the clinical experts to the External Assessment Group. The decision to ignore negative
tests was because of the potential fatal consequences if treatment was withdrawn from a patient with
sepsis. Acknowledged reasons for a false-negative result include the test being unable to detect the
pathogen or the quantity of the pathogen being below the test’s limit of detection. Similarly, tests that
would be denoted as failures were assumed to have no impact on the four key outcomes. Both negative
tests and failures would, however, be associated with the cost of the test.
A pictorial representation of the conceptual model is provided in Figure 11. The net cost impact and the
net QALY impact of rapid identification were used to estimate a cost per QALY gained ratio.
Rapid
identification
of a pathogen
(costs)
30-day
mortality
(QALYs)
ICU length of
stay (costs)
Hospital
length of stay
(costs)
Antimicrobial
treatment
(costs)
Aggregated result
Change in costs
Change in QALYs
From these values, the cost
per QALY gained could be
estimated
It was assumed that negative
results from rapid identification
would not impact on patient
management
It was assumed that failures
would not impact on patient
management
Both would, however, be
associated with costs
FIGURE 11 The components within the conceptual model.
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The evaluations presented by the External Assessment Group have been divided into five categories.
1. Base case 1: an analysis based on currently published evidence.
2. Base case 2: an analysis in which parameter values were populated by estimates from clinical experts in
order to estimate the cost-effectiveness of each test. This has a benefit in that if, in base case 1, the
rapid tests offered little or no benefit compared with the comparators, based on the absence, or lack of
statistical significance, of the required data, then clinical beliefs could be incorporated.
3. Threshold analyses were undertaken to guide decision-makers on the likelihood of the interventions
having cost per QALY gained values of £20,000 or lower and of £30,000 or lower, as it was assumed
that experts in the field would be more confident in providing an indication of whether the value of a
parameter was greater than, or less than, a threshold value than in estimating a value in the absence of
data (as was requested in base case 2). The variables assessed within the threshold analysis in the
threshold base case were the number of mortalities within 30 days that were prevented and the
reduction in days in ICU. For simplicity, and to allow thresholds to be presented purely in terms of net
30-day mortality or net cost, it was assumed that no additional QALY gain was associated with a
reduction in ICU duration of stay. The results are presented allowing for a mixture of both net
mortalities and of net reduced ICU stay. In an alternative analysis, the thresholds of both the reduction
in the net number of ICU days and the net reduced costs of antimicrobial treatment are also presented.
4. Analyses comparing the interventions with MALDI-TOF MS based on published literature.
5. Analyses of data taken from studies in which more than one intervention were compared directly.
Given the large divergence in results produced by base cases 1 and 2, the External Assessment Group
decided that probabilistic sensitivity analyses would provide spurious accuracy with respect to the decision
being undertaken. As such, only deterministic answers have been provided. If robust data are produced in
relation to the efficacy of the interventions on key patient outcomes, then probabilistic sensitivity analyses
should be conducted.
The lack of evidence for heterogeneous diagnostic accuracy among subgroups resulted in the External
Assessment Group providing only an overall measurement of cost-effectiveness rather than by subgroup.
Although the cost-effectiveness may differ among subgroups – for example, a neonate would be expected
to accrue more QALYs than an adult – these do not affect the fundamental uncertainty of whether or not
the interventions would be associated with any key patient outcome.
For all but the threshold analyses, the incremental cost per test has been calculated accounting for the net
effect on ICU and hospital length of stay, and changes in the costs of antimicrobial treatment. The rate of
positivity for each test must also be known, as it has been assumed that only positive intervention tests
would result in a change in management.
As an illustrative example, assuming that the cost of a test was £400, that each positive test was
associated with a 0.1-day reduction in ICU length of stay, a 0.3-day reduction in hospital stay and a £50
reduction in antimicrobial treatment, and a 20% rate of positivity, the incremental costs would be
estimated to be:
£400 + (f(−0:1 × £1057) + ½(−0.3− −0.1) × £275 + −£50g × 20%) = £357.86. (11)
Note that these values are for illustrative purposes and are not necessarily those used in the modelling
exercises that are detailed in later sections.
The incremental QALYs have been calculated assuming 11.32 discounted QALYs per 30-day mortality
avoided (see The quality-adjusted life-year gains associated with preventing a 30-day mortality). Thus, if an
intervention was assumed to reduce 0.01 deaths per test, then the discounted QALYs gained would be
0.1132. To calculate the numbers of deaths avoided, data are required on the assumed underlying
mortality rate at 30 days, the estimated reduction in the rate of 30-day mortality associated with each test
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and the rate of positivity. As an example, if it was assumed that the underlying mortality rate was 13%,
the reduction following a positive test was 5% and the rate of positivity was 20%, then the estimated
number of deaths prevented would be 13%× 5%× 20% per test, which equals 0.0013.
The principles outlined above in calculating incremental costs and QALYs have been maintained
throughout the analyses undertaken in this report. For simplicity, the example provided above did not
distinguish between the assumed impacts of the interventions when a subsequent blood culture was either
negative or positive although, as detailed in Model parameters assumed for base case 1, separate values
for these were provided by the clinical experts.
Independent economic assessment: populating the model
General model parameters
The number of blood samples that need analysing per day
Three broad scenarios were undertaken regarding the number of blood samples that need to be
analysed each day: based on the number observed in a recent clinical study10 assuming an increase for
community-acquired infection (2.4 blood samples); assuming 17 blood samples; and assuming 68 blood
samples. These values were thought to provide a wide range of plausible values that could be undertaken
within units of different sizes.
Assuming the numbers of samples that need analysing based on the number
observed in a recent clinical study
These data were calculated from data reported in Warhurst et al.,10 as summarised in Table 16. This source
was chosen as it was a recent, large, high-quality study set in England. In this study there was a central
hub, in Salford, with a SeptiFast machine that supplied results to four sites. A monthly rate per site was
calculated and then these were added to estimate a monthly throughput. This was assumed to be plausibly
representative of the use of a centrally located machine relevant to an intervention serving a number of
satellite hospitals. Note that the daily value does not equal the average across the Warhurst et al.10 study
because of the different lengths of enrolment in the study by site. It is not reported why the monthly rate in
site 4 was considerably lower than in the remaining sites.
The sites’ requirements sum to 36.48 tests per month, although results were provided for only 922 out of
1006 samples: the SeptiFast had a failure rate of 69 out of 1006 (7%) and a further 15 samples were lost for
clinical reasons. The Warhurst et al. study10 included only health-care-acquired sepsis. Based on clinical
opinion, it was assumed that 50% of sepsis cases are health care acquired and 50% are community acquired,
and thus, to include both types of sepsis, the number of tests required was doubled to 72.96 each month, or
2.40 tests each day. It was assumed that two tests would be analysed on 60% of days and three tests would
be analysed on 40% of days. However, on clinical advice, it was further assumed that testing would be
carried out on only 5 days a week; therefore, the numbers of tests were divided so that there were three
TABLE 16 Calculation of the estimate of the daily number of tests undertaken
Site number
Number of months in
study by Warhurst et al.10
Number of tests sent
from the site for analysis Estimated tests per month
1 30 481 16.03
2 30 343 11.43
3 21 170 8.10
4 13 12 0.92
Total 1006 36.48
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times the expected number of tests on Monday compared with Tuesday to Friday. It was assumed that all
tests sent for processing would be tested and that no allowance would be made for the possibility of rejecting
requests for tests on blood that was sampled on a Friday evening but which would not be processed until
Monday morning. This assumption was supported by our clinical advisors, who deemed that this would be
how the system would work in practice, although clearly the gain in speed of identification is reduced for
those samples collected on Friday evening and over the weekend. It was assumed that there would be two
runs on a Monday, with an initial run analysing those samples collected after staff had finished working on a
Friday evening and a second run analysing those samples collected on the Monday itself.
Assuming that the number of samples that need to be analysed each day is 17
In this example, the value was set to approximately seven times that estimated from the Warhurst et al.
study.10 This value is also the maximum number of blood samples that one IRIDICA system can process in
1 day, assuming three runs per day, although it is noted that SeptiFast could process 21 tests over three
runs and, thus, the selected number may favour IRIDICA. In this scenario it is assumed that practice has
been changed to accommodate the interventions being used 7 days a week, and that each intervention
could be run three times daily. The costs of these changes in standard practice have not been incorporated,
although a statement of the magnitude of this compared with any potential savings has been made.
Assuming that the number of samples that need to be analysed each day is 68
In this example, the value was set to approximately 28 times that estimated from the Warhurst et al.
study.10 This scenario assumes that four SeptiFast machines and four IRIDICA machines would be required
to process the requested blood samples. In this scenario it is assumed that practice has been changed to
accommodate the interventions being used 7 days a week and that each intervention could be run three
times daily. The costs of these changes in standard practice have not been incorporated, although a
statement of the magnitude of this compared with any potential savings has been made.
The estimated costs of the interventions and matrix-absorbed laser
desorption/ionisation time-of-flight mass spectrometry
For all tests there is a fixed cost and a variable cost that is determined by the numbers of tests undertaken.
Following advice obtained from our clinical advisors, we assumed that the purchase cost of a machine
could be equally divided over an assumed 7-year period of use. Annual costs associated with the
maintenance of the machines were incorporated.
For each intervention, the cost will be dependent on whether or not the equipment required for the
specific test (SeptiFast, SepsiTest, IRIDICA and MALDI-TOF MS) is already available within the microbiology
laboratory. SeptiFast and IRIDICA have their own bespoke PCR machines, whereas SepsiTest can be run on
generic PCR machines. This led to two scenarios being evaluated for each intervention. These, in order of
cost, are (1) purchasing of the required machine for the specific test or a generic PCR machine; and (2) no
additional machinery needing to be purchased. In both cases consumable costs would be incurred.
The estimation of the cost of an average test is far from robust, relying on uncertain assumptions in the
number of tests per day and machinery costs, and therefore adds additional uncertainty.
Note that, in accordance with the NICE reference case for diagnostic evaluations, value-added tax (VAT) is
not included in economic evaluations.141 Based on advice from our clinical experts, it was assumed that no
additional staff costs or room costs would be incurred if any of the interventions were purchased, although
this is less likely to be the case should it be assumed that 17 or 68 samples need to be analysed per day. For
simplicity, neither transport costs associated with sample testing nor additional staff training was included.
No discounts associated with bulk purchasing of equipment has been assumed for any intervention. It is
possible that these exist in reality; if the costs of the test are lower than those assumed in the analyses,
then the incremental cost-effectiveness ratio (ICER) would be lower than those presented with all other
variables held constant.
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The costs associated with SeptiFast
Data provided by Roche Diagnostics on the list prices of the required Roche instruments to run a SeptiFast
test are shown in Table 17. The sum of these individual items is £26,397, excluding VAT.
Additionally, Roche Diagnostics reports an annual service charge of £3000, excluding VAT, that covers any
repairs required (including a replacement system if necessary) and an annual calibration check.
The key consumables required to run a test, along with their list price, are shown in Table 18.
Roche Diagnostics estimated the cost per test based on the number of tests per run, assuming one daily
run and a 5-day working week. Running more tests per run reduces the average reagent cost per sample
because of the requirement of having two control samples for each run. The costs estimated by Roche
Diagnostics, excluding VAT, for reagent costs are replicated in Table 19. From Table 19 it can be calculated
that the marginal cost of one additional sample in a run is £122.00.
TABLE 19 Reagent cost per SeptiFast test estimated by Roche Diagnostics
Tests per run Reagent cost per reportable result (£)
1 333.99
2 228.00
3 192.68
4 175.01
5 164.41
6 157.35
7 152.30
TABLE 18 The key consumables required to run a SeptiFast test, along with their list price
Product name Category number List price (£) Number per item
LightCycler M Grade Capillaries 3612066001 883.93 768
LightCycler SeptiFast Kit, CE 4469046001 1422.62 54
LightCycler SeptiFast mecA Kit, CE 4488814001 624.44 10
SeptiFast Lys Kit, CE 4404432001 745.95 200
SeptiFast Prep Kit, CE 4404459001 320.73 10
TABLE 17 The instruments required to run SeptiFast and their list prices
Instrument Category number List price (£)
LightCycler 2.0 Instrument with Software 4.1 03 531 414 001 18,000.00
LC Carousel Centrifuge 2.0 03 709 582 001 3060.00
MagNA Lyser Instrument (230 V) 03 358 976 001 4500.00
Multi-Colour Compensation Set 4484355001 536.76
SeptiFast Cooling Block 4555864001 300.45
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The estimated average costs per SeptiFast test are provided in Table 20 for the three scenarios related to
the number of blood samples to be analysed (2.39, 17 and 68) and for the two purchasing scenarios
(where the SeptiFast platform does or does not need to be purchased). In both purchasing scenarios,
consumable costs will be incurred.
The costs associated with SepsiTest
As previously detailed (see Chapter 1, SepsiTest), an updated version of SepsiTest was recently released.
This version does not require duplicate samples and thus the cost of the reaction per sample is halved.
Owing to the lack of diagnostic accuracy data on the updated version of the test, the analysis conducted
in this report is based on the previous version of SepsiTest.
The company (Molzym Molecular Diagnostics) that manufactures SepsiTest reports that the list price for
48 reactions for use in SepsiTest is £3000, including VAT, which equates to £2500, excluding VAT, and a cost
per reaction of £52.08, excluding VAT. Each test is assumed to require two slots of a 96-well PCR machine, and
that two controls (one negative and one positive) are required for each run. Thus, a maximum of 47 SepsiTest
analyses can be performed in one run. The costs of the controls were not provided by Molzym Molecular
Diagnostics.; these were estimated to be £104.17 for the pair, which is the cost of two reactions. This is likely to
underestimate the cost as additional costs associated with spiking blood to produce the positive control have not
been included, although this omission is unlikely to affect the conclusions of the report.
The cost of additional sequencing following a positive SepsiTest was assumed to be €11 for bacteria and
€5.50 for fungi based on information supplied by Molzym Molecular Diagnostics. These costs include VAT
at 19% and are equivalent to €9.24 and €4.62, respectively, once VAT is deducted. Assuming an exchange
rate of €1 to £0.72,137 these values were calculated as £6.66 and £3.33, respectively.
The costs of the machinery required to undertake PCR testing and Sanger sequencing were estimated from
data provided by Molzym Molecular Diagnostics. These costs are reproduced in Table 21. The data were
assessed by a clinical expert advising the External Assessment Group and were deemed appropriate.
Therefore, it was considered not unreasonable to assume a cost of €60,000 (a high estimate based on the
values in Table 21) to purchase the equipment needed to undertake PCR and to cover any maintenance
required. This is equivalent to £43,200, assuming an exchange rate of €1 to £0.72.137
In order that the profile of bacteria and fungi was representative of that observed in England, an assumption
was made that the proportion of positive results for bacteria and fungi identified by SeptiFast would be
applicable to SepsiTest. This proportion, calculated from table 14 of Warhurst et al.,10 was 18 fungi from
167 positive SeptiFast tests (10.8%), which was used to estimate a weighted cost of additional sequencing of
£6.30. Based on the data synthesis conducted (see Figure 6), it was assumed that SepsiTest had a sensitivity
of 0.48 and a specificity of 0.86, which, when combined with an assumed blood culture-positive rate of
8.7% calculated from Warhurst et al.,10 equated to a positivity rate of 17% for SepsiTest. The company
manufacturing SepsiTest confirmed that the cost per SepsiTest assay is not dependent on throughput.
TABLE 20 Estimated average costs per SeptiFast test
Scenario
Average cost per test assuming
samples per day calculated
from Warhurst et al.10 (£)
Average cost per test
assuming 17 samples
per day (£)
Average cost per test
assuming 68 samples
per day (£)
Assuming that SeptiFast
machinery needs to be
purchaseda
205.54 160.52 154.28
Assuming no additional
machinery is needed
201.23 159.91 153.67
a Assuming that the intervention costs were spread over a 7-year period.
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TABLE 21 The costs assumed for undertaking the PCR required by SepsiTest as submitted by Molzym
Molecular Diagnostics
Price (€)
Apparatus
Thermomixer (24 × 2.0-ml tubes, adjust at 37 °C, 56 °C and 70 °C) ≈2000
Cooling racks for 1.5-ml tubes (adjust at 4 °C and –20 °C) ≈50
Vortexer (e.g. VWR, Germany) ≈170
Bench-top microcentrifuge (≥ 13.000 rpm, ≥ 12.000 × g) ≈1100
Clear work places
l UV workstation or ≈3000
l UV laminar flow [e.g. BDK UVF, Germany (optional)] ≈8000
One set of precision pipettes: up to 10 µl, up to 20 µl, up to 200 µl and up to 1000 µl
(e.g. Eppendorf, Germany)
≈400
Thermocycler
l PCR cycler with ≈3000
l Gels analysis system or ≈4000
l Real-time PCR cycler (ramp 2 °C per second) ≈15,000
Sequencing analysis as service (GATC, Germany) ≈5 per sequencing
ABI 310 (Applied Biosystems, CA, USA) refurbished ≈30,000
Plastic ware
Pipette tips with aerosol filter (e.g. Biosphere®, Sarstedt AG & Co., Germany)
PCR tubes
Chemicals
DNA decontamination: DNA Exitus®, Applichem, Germany
Agarose gel (2%) for standard PCR
A container for plastic waste (pipette tips, vials, tubes) and another for liquid waste, autoclavable
Others
Sterile disposables
Gloves (e.g. Kimberly-Clark, Germany)
Sleeves (e.g. Cardinal Health, Ireland)
Bouffant covers (e.g. VWR, Germany)
Overshoes (e.g. hygi, Germany)
rpm, revolutions per minute; UV ultraviolet.
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The estimated average costs per SepsiTest assay are provided in Table 22. These costs assume the
sensitivity and specificity of SepsiTest reported in the data synthesis. In alternative analyses, when specific
trial data are used, these costs will change slightly as the number of sequencing tests needed will differ
owing to assumed alternative diagnostic accuracy data.
The costs associated with an IRIDICA test
Abbott Diagnostics reports that the cost of the IRIDICA analyser is £268,000, excluding VAT, and that the
cost of annual maintenance is £30,150, excluding VAT. The cost of an IRIDICA test is reported to be £174,
excluding VAT. Following clarification, the manufacturer provided costs in relation to the number of tests
per day, as the control test needs to be changed every 24 hours. These costs are summarised in Table 23.
According to Abbott Diagnostics, it is possible to analyse 23 samples per day, assuming that one control is
used at the start of the day along with five samples and that subsequent runs do not need a control and
therefore six samples can be analysed simultaneously. The External Assessment Group comments that,
although it is technically possible to conduct four runs, each taking slightly < 6 hours, in a 24-hour period,
this is unlikely to be possible in practice. Therefore, the External Assessment Group assumed that 17 tests
per day represents the limit of an IRIDICA machine. The estimated average costsper IRIDICA test are
provided in Table 24.
The costs associated with a matrix-absorbed laser desorption time-of-flight mass
spectrometry system
The costs associated with MALDI-TOF MS were provided by Bruker UK Limited (Coventry, UK) (Erika
Tranfield, Bruker UK, 2015, personal communication). It was assumed that these costs would be
generalisable to other MALDI-TOF MS systems such as bioMérieux’s VITEK® MS system (Marcy-l'Étoile,
France). The cost of the MALDI-TOF MS machine was assumed to be £125,000. A further technology, the
Sepsityper kit, is available at a cost of approximately £3 per test. The Sepsityper kit is a sample preparation
method that involves the lysis of blood cells, followed by centrifugation and washing steps to produce a
pellet of bacteria or fungi, which is further processed by standard MALDI-TOF MS methods. Given that
Sepsityper was in widespread use in the RAPIDO trial,31 a large UK study comparing MALDI-TOF MS and
standard practice with standard practice alone, this will be used for the purposes of this economic
evaluation. On clinical advice, no further costs for MALDI-TOF MS were assumed in addition to that
for the Sepsityper kit (assumed to be £3), as these are relatively inexpensive. The costs for preventative
maintenance are dependent on the number of maintenances performed per year: for two maintenances
per year the cost is £13,985, whereas the cost for 3–5 maintenances per year is £17,000. It was assumed
that the higher number of preventative maintenances applies.
It is noted that MALDI-TOF MS can be used for many investigations other than just the use of pathogen
identification in those with suspected sepsis. Based on clinical advice it was assumed that only 50% of the
purchase and maintenance cost would be attributable to sepsis investigations. Our clinical advisors did not
advocate attributing the costs of any of the interventions to non-sepsis-related disease areas.
TABLE 22 Estimated average costs per SepsiTest
Scenario
Average cost per test assuming
samples per day calculated
from Warhurst et al.10 (£)
Average cost per test
assuming 17 samples
per day (£)
Average cost per test
assuming 68 samples
per day (£)
Assuming a generic PCR
machine and sequencer needs
to be purchaseda
149.53 112.29 108.55
Assuming no additional
machinery is needed
142.48 111.36 108.30
a Assuming that the intervention costs were spread over a 7-year period.
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TABLE 24 Estimated average costs per IRIDICA test
Scenario
Average cost per test assuming
samples per day calculated
from Warhurst et al.10 (£)
Average cost per test
assuming 17 samples
per day (£)
Average cost per test
assuming 68 samples
per day (£)
Assuming the IRIDICA analyser
needs to be purchaseda
314.61 203.52 203.52
Assuming no additional
machinery is needed
270.89 197.35 197.35
a Assuming that the intervention costs were spread over a 7-year period.
TABLE 23 The assumed cost per IRIDICA test based on different numbers of blood samples to be analysed
Number of samples to be analysed Total cost per sample (£)
1 362.04
2 273.29
3 242.53
4 226.28
5 215.82
6 211.78
7 208.38
8 205.40
9 202.69
10 200.18
11 197.80
12 197.28
13 196.56
14 195.71
15 194.73
16 193.65
17 192.49
18 192.44
19 192.21
20 191.93
21 191.31
22 190.68
23 189.96
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Data on the number of blood culture bottles that are flagged as positive were taken from Warhurst et al.10
and assumed generalisable to England. Data from table 6 of Warhurst et al.10 show that, of 922 episodes,
80 were blood culture positive (8.7%), and it was assumed that these samples would undergo further
analysis via MALDI-TOF MS. As such, it was estimated that the MALDI-TOF MS machine would process
8.7% of the daily throughput of 2.40 tests (see Assuming the numbers of samples that need analysing
based on the number observed in a recent clinical study), which is 0.21 tests per day. When the assumed
number of blood samples that need to be analysed was increased to 17 and 68 per day, the number of
samples analysed using MALDI-TOF MS was increased to 1.48 and 5.92 per day, respectively. The
estimated costs of MALDI-TOF MS are provided in Table 25.
Care should be taken not to directly compare the costs per test between the interventions and MALDI-TOF
MS as all samples would be processed by the interventions, while only those where the blood culture had
tested positive would be analysed by MALDI-TOF MS.
The costs associated with blood culture
Given that blood culture would be used alongside all interventions and alongside MALDI-TOF MS,
the costs would have no bearing on the incremental costs associated with the intervention tests and
MALDI-TOF MS. For this reason no resources were spent in trying to ascertain the costs per blood sample
and the cost was assumed to be £0 in all analyses.
The assumed failure rates of the interventions
Both SeptiFast and IRIDICA use internal controls that could be subject to failure, as could the controls on a
PCR machine used by SepsiTest. For SeptiFast, a 6.9% failure rate was reported in Warhurst et al.,10
although a greater value of 22.9% was reported in Paolucci et al.99 Data on the failure rate of IRIDICA
have been reported in Metzgar et al,117 and indicate a rate of (confidential information has been removed).
No data on the failure rate of SepsiTest were identified.
In the base case it has been assumed that SeptiFast has a failure rate of 6.9%. In sensitivity analyses a
failure rate of 11.7% was assumed for SeptiFast based on a naive pooling of failure results from Warhurst
et al.10 (69 failures) and from Paolucci et al.99 (100 failures) divided by the numbers of samples analysed in
all of the SeptiFast versus blood culture trials combined (11,659 samples), assuming no failures in any
SeptiFast study. This results in an estimated failure rate for SeptiFast of 1.4%. For the base case for
IRIDICA, a failure rate of (confidential information has been removed) was assumed based on a naive
pooling of data from all of the studies assuming no failures in any study but Metzgar et al.117
Although Warhurst et al.,10 Paolucci et al.99 and Metzgar et al.117 explicitly stated that any failures were
excluded from analyses of diagnostic accuracy, it is not clear if failures occurred in the remaining identified
studies but were not reported as such and were treated as a negative result. If failures had been excluded
from the analysis of diagnostic accuracy but not reported, then this would be beneficial to the
relevant intervention.
TABLE 25 Estimated average costs per MALDI-TOF MS
Scenario
Average cost per test assuming
samples per day calculated
from Warhurst et al.10 (£)
Average cost per test
assuming 17 samples
per day (£)
Average cost per test
assuming 68 samples
per day (£)
Assuming a MALDI-TOF MS
machine needs to be
purchaseda
232.39 35.35 11.09
Assuming no additional
machinery is needed
114.88 18.78 6.94
a Assuming that the intervention costs were spread over a 7-year period.
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No data were identified on the failure rate of SepsiTest. Rather than assign an arbitrary value to this parameter,
the value was set to zero with the acknowledgement that this was likely to be favourable to SepsiTest.
The quality-adjusted life-year gains associated with preventing
30-day mortality
It was assumed that each 30-day mortality avoided is associated with a gain of 11.32 discounted QALYs.
This value was calculated based on (a) the estimated number of discounted life-years for a typical patient and
(b) the estimated quality of life after a sepsis episode to account for the possible reduced quality of life in
sepsis survivors. It should be noted that the discounted QALY gains for neonates and children would be
greater than those for adults because of their longer life expectancy, although the exact increase is uncertain.
Although there is evidence that the survival after a sepsis episode may be lower than in the general
population,142–144 for simplicity we assumed that survival of patients with sepsis was comparable with that
of the general population. National life tables for England and Wales for the period 2011–13145 were
used to estimate the life expectancy of a typical patient, assuming an age of 58 years and a sex split of
60%/40% (male/female) as reported in Warhurst et al.10
Patients were assumed to have a utility value of 0.68 based on the European Quality of Life-5 Dimensions
score reported by Cuthbertson et al.142 at 5 years after a severe sepsis episode, which is similar to the value
reported by Drabinski et al.146 If the utility predicted for the general population for an age and sex profile147
was lower than 0.68, this value was used instead. A discount rate of 3.5% per annum was used, as
recommended in the NICE reference case.141
The assumed cost of 1 day’s treatment in an intensive care unit
This value was calculated from NHS reference costs.148 Service code CCU03 [medical adult patients
(unspecified specialty)] was assumed to be representative of treatment for sepsis patients. This service code
is subdivided by the number of organs supported, ranging from 0 to ≥ 6, and an average of the reported
average unit costs weighted by activity levels was calculated. This resulted in a cost of ICU care of £1057
per day. This is slightly more than the weighted average for service code CCU002 [surgical adult patients
(unspecified specialty)] selected, which was £987 per day.
The assumed cost of 1 day’s treatment in a standard hospital ward
This value was calculated from NHS reference costs,148 assuming that the average excess bed-day cost per
non-elective impatient of £275 was appropriate.
The assumed cost of typical empirical antimicrobial treatment for sepsis
Based on the advice of our clinical advisors, it was assumed that 7 days’ treatment with either 18 g of
piperacillin/tazobactam per day or 3 g of meropenem per day was an appropriate empirical treatment for
typical sepsis patients. Using British National Formulary costs,149 these prices were estimated to be £51.60
per day (assuming 4.5 g every 6 hours) for piperacillin/tazobactam and £48.00 (assuming 1 g every 8 hours)
for meropenem. Given the uncertain proportion of the drugs used in England, it was assumed that a cost
per day of £50, equating to a cost for a course of treatment of £350, was not unreasonable. However, an
expert clinician on the Diagnostic Appraisal Committee commented that these costs may be high for adults
admitted to regular hospital wards or for children. If this was the case, then the value used for a course of
treatment would be favourable to the interventions.
The assumed 30-day mortality rate for those with suspected sepsis
It was assumed that the 28-day mortality rate reported in a recent health technology assessment,111 set in
England, could be generalised to a 30-day mortality rate. This value was 13% (95% CI 11% to 16%),10
with the rate of hospital mortality being 21% (95% CI 17% to 23%). This value has some support from
data provided by Kaukonen et al.,3 which analysed hospital mortality rates in patients with severe sepsis in
Australia and New Zealand and showed a decrease across time, with values of approximately 10% for
SIRS-positive sepsis and 20% for SIRS-negative sepsis.
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An alternative value of 29%, as reported in Mouncey et al.9 (albeit for 90-day mortality), in patients with
early septic shock was tested in sensitivity analyses. This value was supported by data from Levy et al.,6
who reported hospital mortality rates of 29% when there was high compliance with a resuscitation
bundle, although the patients included in this study were those with severe sepsis and septic shock and
would be likely to have a worse prognosis.
Model parameters assumed for base case 1
In base case 1, only data from the published literature related to patient outcomes were included in an
economic evaluation to estimate the cost-effectiveness of each test.
Based on the literature identified by the External Assessment Group, no data were found that provided a
conclusive and non-confounded indication that any of the interventions provided benefits in terms of
30-day mortality (see Chapter 2, Mortality), length of stay in ICU or length of stay in hospital (see Chapter 2,
Duration of intensive care unit and/or hospital stay). One study of a propensity score-matched design was
identified103 and indicated a significant reduction in the costs of empirical therapy, but this study had a
number of limitations. First, the study population was of haematological patients who were prescribed
empirical antifungal drugs, which is not typical for a suspected sepsis patient. Second, the cost savings
predominantly came from the reduction in relatively expensive empiric antifungals; however, according to
our clinical experts the most widely used antifungal treatment in England is fluconazole, which is now
relatively cheap, with a cost of £1.83 per day for a dose of 400mg.149
Data were found showing that the time to therapy modification was much shorter following the
introduction of SeptiFast (18.8 hours compared with 38.3 hours),112 but no data were provided on the
change in costs of modified therapy. Changes in costs were also not provided for the studies identified in
Table 9. Therefore, it was assumed that the costs of antimicrobials were unchanged in the base case.
Thus, in base case 1, it was assumed that the results did not differ depending on whether an intervention
was used or was not used. An analysis was undertaken to estimate the reduction in antimicrobial costs
needed in order for an intervention to be cost neutral.
Model parameters assumed for base case 2
In base case 2, parameter values were populated using estimates from clinical experts in order to estimate
the cost-effectiveness of each test if the benefits anticipated were realised. A document (reproduced in
Appendix 7) was sent to the clinicians on the Diagnostic Assessment Committee and to the clinical experts
who are authors of this report with a request to estimate key parameters – supporting information
identified by the External Assessment Group was also supplied. Seven clinical experts responded, with a
wide variation in the answers provided. Although the clinicians were asked for ranges in their answers,
six of the seven clinicians provided point estimates only. Typically the clinicians reported that the task was
difficult to complete, and the majority assumed the same values for SeptiFast, IRIDICA and SepsiTest.
The values for MALDI-TOF MS were typically less favourable than for the three interventions as information
on the pathogen would be provided at a later time point than for the interventions. The average values
from the clinical experts shown in Table 26 relate to the situation that an intervention is positive and the
subsequent blood culture is positive; those in Table 27 relate to the situation that an intervention is
positive and the subsequent blood culture is negative. Note that monetary savings in antimicrobial costs
were transformed into a percentage reduction, assuming a typical course of treatment cost of £350.
The clinicians predicted comparable gains when the blood culture was negative with when the blood
culture was positive. This is believed to be because the clinical experts trusted the intervention result rather
than the blood culture result in this scenario. This contrasts with the majority of diagnostic accuracy studies,
in which blood culture is assumed to be the gold standard, and casts uncertainty over meta-analyses in
which this assumption is made.
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Consideration was given to attempting to construct a distribution to represent the values provided by the
clinicians. However, we decided against this as it was not clear that it would provide significantly better
data than an aggregate value. In addition, it would necessitate analysis at the individual clinician level as
well as further assumption regarding the distribution type and the range surrounding the mid-point
answers provided.
Data from individual clinicians were used in sensitivity analyses. These values are shown in Tables 28–31
for the three interventions and MALDI-TOF MS when the blood cultures were subsequently positive, and in
Tables 32–34 for the three tests when the subsequent blood cultures were negative.
TABLE 26 The parameter values assumed in base case 2 when the intervention was positive and the subsequent
blood culture was positive
Parameter SeptiFast SepsiTest IRIDICA MALDI-TOF MS
Average net effect on ICU length of stay (days) –0.607 –0.671 –0.736 –0.175
Average net effect on hospital length of stay (days) –1.050 –1.214 –1.329 –0.758
Average net effect on the cost of antimicrobials –17.78% –21.63% –25.92% –14.26%
Net effect on 30-day mortality –3.16% –3.87% –4.59% –3.00%
TABLE 27 The parameters values assumed in base case 2 when the intervention was positive and the subsequent
blood culture was negative
Parameter SeptiFast SepsiTest IRIDICA
Average net effect on ICU length of stay (days) –0.571 –0.629 –0.700
Average net effect on hospital length of stay (days) –1.307 –1.471 –1.586
Average net effect on the cost of antimicrobials –28.98% –31.84% –37.12%
Net effect on 30-day mortality –3.93% –4.64% –5.36%
TABLE 28 Individual clinician responses for SeptiFast when the subsequent blood culture was positive
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobials
Net effect on
30-day mortality
1 –0.2 –0.5 –5% –3%
2 0 –1 –15% –1%
3 –0.1 –0.2 –£40 (–11%) –0.1%
4 –2.5 (range –4 to –1) –1.5 (range –3 to –0) Not known
(assumed to be £0)
–1.0%
(range –2% to 0%)
5 –1 –3 –£175 (–50%) –2%
6 –0.001 0 –18% 0%
7 –0.45 –1.15 –25% –15%
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TABLE 29 Individual clinician responses for SepsiTest when the subsequent blood culture was positive
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobial
drugs
Net effect on
30-day mortality
1 –0.2 –0.5 –5% –3%
2 0 –1 –15% –1%
3 –0.1 –0.2 –£40 (–11%) –0.1%
4 –2.5 (range –4 to –1) –1.5 (range –3 to –0) Not known
(assumed to be £0)
–1.0%
(range –2% to –0%)
5 –1 –3 –£175 (–50%) –2%
6 0 0 0% 0%
7 –0.9 –2.3 –70% –20%
TABLE 30 Individual clinician responses for IRIDICA when the subsequent blood culture was positive
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobials
Net effect on
30-day mortality
1 –0.2 –0.5 –5% –3%
2 0 –1 –15% –1%
3 –0.1 –0.2 –£40 (–11%) –0.1%
4 –2.5 (range –4 to –1) –1.5 (range –3 to –0) Not known
(assumed to be £0)
–1.0 (range –2 to –0)
5 –1 –3 –£175 (–50%) –2%
6 –0.001 0 –20% 0%
7 –1.35 –3.1 –80% –25%
TABLE 31 Individual clinician responses for MALDI-TOF MS when the subsequent blood culture was positive
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobials
Net effect on
30-day mortality
1 –0.1 –0.2 –2% –1%
2 0 –1 –15% –1%
3 No answers provided
4 0 0 0 0
5 –0.5 –1.5 –£100 (–29%) –1%
6 0 0 –10% 0
7 –0.45 –1.85 –30% –15%
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TABLE 32 Individual clinician responses for the SeptiFast when the subsequent blood culture was negative
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobials
Net effect on
30-day mortality
1 –1 –1 –15% –8%
2 0 –1 –15% –1%
3 0 –1.5 –£80 (–23%) 0%
4 –2.5 (range –4 to –1) –3.5 (range –5 to –2) Not known
(assumed to be £0)
–3.5%
(range –5% to –2%)
5 0 –1 –£700 (–100%a) –0%
6 –0.05 0.0 –25% 0%
7 –0.45 –1.15 –25% –15%
a The percentage reduction was capped at 100%.
TABLE 34 Individual clinician responses for IRIDICA when the subsequent blood culture was negative
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobials
Net effect on
30-day mortality
1 –1 –1 –15% –8%
2 0 –1 –15% –1%
3 0 –1.5 –£80 (–23%) 0%
4 –2.5 (range –4 to –1) –3.5 (range –5 to –2) Not known
(assumed to be £0)
–3.5 (range –5 to –2)
5 0 –1 –£700 (–100%a) –0%
6 0.05 0 –27% 0%
7 –1.35 –3.1 –80% –25%
a The percentage reduction was capped at 100%.
TABLE 33 Individual clinician responses for SepsiTest when the subsequent blood culture was negative
Clinician
Average net effect
on ICU length of
stay (days)
Average net effect
on hospital length
of stay (days)
Average net effect
on the cost of
antimicrobials
Net effect on
30-day mortality
1 –1 –1 –15% –8%
2 0 –1 –15% –1%
3 0 –1.5 –£80 (–23%) 0%
4 –2.5 (range –4 to –1) –3.5 (range –5 to –2) Not known
(assumed to be £0)
–3.5%
(range –5 to –2)
5 0 –1 –£700 (–100%a) –0%
6 0 0 0% 0%
7 –0.9 –2.3 –70% –20%
a The percentage reduction was capped at 100%.
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Independent economic model: results
As previously stated, the results will be presented in three broad categories: (1) base case 1, in which only
data from the published literature considered appropriate are included in an economic evaluation to
estimate the cost-effectiveness of each test; (2) base case 2, in which parameters were populated from
estimates by clinical experts in order to estimate the cost-effectiveness of each test; and (3) a series of
threshold analyses. For clarity, threshold analyses indicate the value of a parameter at which the decision is
likely to change. In the results presented in this report, these values indicate the level above which the cost
per QALY reduces to an assumed value (either £20,000 or £30,000 per QALY). In addition, supplementary
analyses using studies deemed to provide additional information on head-to-head comparisons between
interventions, or of an intervention with MALDI-TOF MS, have been undertaken. Given the results of the
data synthesis, which did not show a difference in diagnostic accuracy by subgroup, only one set of
analyses is presented. It is acknowledged that this is likely to underestimate the gains in mortality
prevented associated with neonates, but it was deemed that this would not affect the conclusion,
which would remain uncertain.
Results from base case 1
The estimated costs and estimated QALYs when the machinery required for the intervention needs to be
purchased are shown in Table 35 and when no additional machinery needs to be purchased are provided
in Table 36. For brevity, these results are presented only for the cost per test estimated using the number
of blood samples per day from the Warhurst et al.10 study; the conclusions remain the same at lower cost
of tests owing to the assumed lack of QALY gain. The conclusion is that all the tests are dominated, in
that they are associated with an additional cost but are assumed to provide no additional QALYs.
TABLE 36 Estimated cost per QALY when it is assumed that no additional machinery needs to be purchased
Test
Incremental cost per test
compared with blood culture (£)
Incremental QALYs
gained per test compared
with blood culture
Cost per QALY gained
compared with blood culture
SeptiFast 201.23 0.00 Dominated
SepsiTest 142.48 0.00 Dominated
IRIDICA 270.89 0.00 Dominated
Dominated denotes that an intervention is more expensive and does not provide additional QALYs.
TABLE 35 Estimated cost per QALY when it is assumed that the machinery required for the intervention needs to
be purchased
Test
Incremental cost per test
compared with blood culture (£)
Incremental QALYs
gained per test compared
with blood culture
Cost per QALY gained
compared with blood culture
SeptiFast 205.54 0.00 Dominated
SepsiTest 149.53 0.00 Dominated
IRIDICA 314.61 0.00 Dominated
Dominated denotes that an intervention is more expensive and does not provide additional QALYs.
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An analysis was undertaken to estimate the reduction in antimicrobial costs needed per test in order that the
introduction of the intervention would be cost neutral. These results are shown in Table 37 when machinery
needs to be purchased and in Table 38 when no additional machinery is required.
If it is assumed that a reduction in antibiotic costs will be achieved only in the event of a positive test, then,
assuming the positivity rates calculated for each test based on their estimated sensitivity and specificity
values, the costs of the tests cannot be recouped from reduced antimicrobial treatment costs alone.
Results from base case 2
Results are presented separately using the average value from all clinician responses and by individual
clinician. The results are also differentiated based on the assumed mortality rate associated with suspected
sepsis. As clinicians provided estimates for the potential benefit of MALDI-TOF MS in addition to the
interventions, this technique has also been included in the tables. These results are divided into those
assuming a mortality rate of 13% (from Warhurst et al.10) and those assuming a mortality rate of 29%
(from Mouncey et al.9). For SeptiFast, the results from Warhurst et al.10 have been given primacy as this is
an English study10 and was assessed as high quality; however, sensitivity analyses have been undertaken
using the evidence from the data synthesis undertaken in this report. For SepsiTest and IRIDICA, the results
presented use the evidence from the data synthesis.
TABLE 37 The reduction in antimicrobial costs due to an intervention that would be required per test for each
intervention in order to be cost neutral when machinery needs to be purchased
Test
Required reduction in antimicrobial
treatment costs assuming samples
per day, calculated from
Warhurst et al.10 (%)
Required reduction in
antimicrobial treatment
costs, assuming 17
samples per day (%)
Required reduction in
antimicrobial treatment
costs, assuming 68
samples per day (%)
SeptiFast 59 46 44
SepsiTest 43 32 31
IRIDICA 90 58 58
TABLE 38 The reduction in antimicrobial costs due to an intervention that would be required per test for each
intervention in order to be cost neutral when machinery does not need to be purchased
Test
Required reduction in antimicrobial
treatment costs assuming samples
per day, calculated from
Warhurst et al.10 (%)
Required reduction in
antimicrobial treatment
costs, assuming 17
samples per day (%)
Required reduction in
antimicrobial treatment
costs, assuming 68
samples per day (%)
SeptiFast 57 46 44
SepsiTest 41 32 31
IRIDICA 77 56 56
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The machinery-purchasing requirements vary according to the machinery already available to process the
blood samples. In order to facilitate an estimation of the relative cost-effectiveness of each intervention
and MALDI-TOF MS across these combinations, the results have been summarised in terms of net
monetary benefit (NMB)150 compared with blood culture. Comparison of NMB is simple, and the strategy
with the highest NMB is estimated to be the most cost-effective. Figures 12–23 present findings that are
combinations of the assumed mortality rate (either 13% or 29%), the maximum acceptable incremental
cost-effectiveness ratio (MAICER) (either £20,000 or £30,000 per QALY gained) and the number of blood
samples that need to be analysed per day (2.4, 17 or 68). It is likely that the mortality rate is inversely
correlated with the number of tests per day, in that high throughput may be associated with a greater
proportion of relatively minor investigations. This is noted as a limitation, but has not been formally
investigated. Following this summary, the results for each intervention in each scenario are presented
reporting incremental QALYs, incremental costs and ICERs compared with blood culture. All results are
presented assuming a timescale of testing of 1 year, although discounted QALYs accrued in future years
are included.
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FIGURE 12 Net monetary benefit assuming a MAICER of £20,000, a mortality rate of 13% and 2.4 blood samples to
be analysed per day.
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FIGURE 13 Net monetary benefit assuming a MAICER of £30,000, a mortality rate of 13% and 2.4 blood samples to
be analysed per day.
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FIGURE 15 Net monetary benefit assuming a MAICER of £30,000, a mortality rate of 29% and 2.4 blood samples to
be analysed per day.
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FIGURE 16 Net monetary benefit assuming a MAICER of £20,000, a mortality rate of 13% and 17 blood samples to
be analysed per day.
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FIGURE 14 Net monetary benefit assuming a MAICER of £20,000, a mortality rate of 29% and 2.4 blood samples to
be analysed per day.
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FIGURE 18 Net monetary benefit assuming a MAICER of £20,000, a mortality rate of 29% and 17 blood samples to
be analysed per day.
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FIGURE 19 Net monetary benefit assuming a MAICER of £30,000, a mortality rate of 29% and 17 blood samples to
be analysed per day.
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FIGURE 17 Net monetary benefit assuming a MAICER of £30,000, a mortality rate of 13% and 17 blood samples to
be analysed per day.
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FIGURE 21 Net monetary benefit assuming a MAICER of £30,000, a mortality rate of 13% and 68 blood samples to
be analysed per day.
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FIGURE 22 Net monetary benefit assuming a MAICER of £20,000, a mortality rate of 29% and 68 blood samples to
be analysed per day.
SeptiFast
N
M
B
 c
o
m
p
ar
ed
 w
it
h
 b
lo
o
d
 c
u
lt
u
re
 (
£)
0
50
100
150
200
300
250
350
400
SepsiTest IRIDICA MALDI-TOF
MS
Test machine to be
purchased
No purchase
required
FIGURE 20 Net monetary benefit assuming a MAICER of £20,000, a mortality rate of 13% and 68 blood samples to
be analysed per day.
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It is seen that, regardless of the scenario, all three interventions and MALDI-TOF MS produced a positive
net benefit compared with blood culture. This conclusion was not affected regardless of whether or not
the acquisition cost of the machine was incorporated in the calculation.
In the scenario in which the mortality rate is assumed to be 13%, the MAICER £20,000 per QALY and the
number of blood samples per day 2.4, SepsiTest or IRIDICA has the highest estimated NMB depending on
the assumption regarding machine purchase. For all other scenarios, IRIDICA is estimated to have the
highest NMB. However, these results are highly uncertain and it remains plausible that each (or none) of
the interventions is most cost-effective.
However, as will be detailed later, these results are highly dependent on the individual clinician questioned
and thus there is large uncertainty in these estimates.
Results from base case 2 using the average clinician values and assuming a
30-day mortality rate of 13%
The estimated costs and estimated QALYs for each intervention and MALDI-TOF MS compared with blood
culture when it is assumed that the machinery required for the intervention needs to be purchased are
shown in Table 39. The results when no additional machinery needs to be purchased are provided in
Table 40.
It is seen that the cost per QALY values are relatively low for all interventions. It is assumed that any costs
associated with allowing machines to be run on a 7 days per week, 24 hours per day basis could be
subsumed into the intervention costs while still producing ICERs that are below £20,000 per QALY gained.
To illustrate this, if it was assumed that there were additional costs of £100,000 to operate SeptiFast
continuously, then the ICER, assuming 17 samples to be analysed per day and machine purchase, would
be calculated as:
Incremental cost (see Table 39): £201,782+ £100,000= £301,782.
Incremental QALYs (see Table 39): 48.81.
ICER: £301,782/£48.81= £6183.
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FIGURE 23 Net monetary benefit assuming a MAICER of £30,000, a mortality rate of 29% and 68 blood samples to
be analysed per day.
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TABLE 39 Estimated cost per QALY when it is assumed that only the machinery required for the intervention needs
to be purchased. Mortality rate assumed to be 13%
Scenario and test
Incremental cost per
annum compared
with blood culture (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with blood culturea
Cost per QALY gained
compared with blood
culture (£)b
Assuming 2.4 blood samples per day
SeptiFast 67,878 6.88 9862
SepsiTest –15,963 9.72 Dominating
IRIDICA 73,501 13.96 5264
MALDI-TOF MS –548 0.23 Dominating
Assuming 17 blood samples per day
SeptiFast 201,782 48.81 4134
SepsiTest –343,990 68.96 Dominating
IRIDICA –168,633 99.01 Dominating
MALDI-TOF MS –13,094 1.65 Dominating
Assuming 68 blood samples per day
SeptiFast 652,257 195.22 3341
SepsiTest –1,470,568 275.82 Dominating
IRIDICA –674,533 396.06 Dominating
MALDI-TOF MS –56,914 6.59 Dominating
a These values include QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
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Results from base case 2 using the average values from the clinician survey
and assuming a 30-day mortality rate of 29%
The estimated costs and estimated QALYs for each intervention test compared with blood culture, when it
is assumed that the machinery required for the intervention needs to be purchased, are shown in Table 41.
The results when no additional machinery needs to be purchased are provided in Table 42.
Results from base case 2 using the average values from the clinical survey,
using the results from the data synthesis for SeptiFast
In the base case, for SeptiFast, it is assumed that data from Warhurst et al.10 are the most appropriate, as
these data were taken from a large study (853 patients) in an English population that was believed to be
the study with the highest quality (see Table 6). The only study with a similar level of quality was that by
Tafelski et al.112 but, as that was a small study (88 patients) set in Germany, the results are believed to be
not as generalisable as those from Warhurst et al.10
In an alternative scenario, the impact of using the estimated results from the synthesis of diagnostic
accuracy data (see Figure 3) was explored. The mid-point values of 65% sensitivity and 86% specificity were
used, with the prevalence of sepsis identified by blood culture by episode assumed to be that reported in
table 6 of Warhurst et al.,10 of 80 out of 922 (8.7%). These data result in an estimated positivity rate of
18.4% for SeptiFast with 30.6% of subsequent blood cultures also being positive and 67% being negative.
In this analysis, a failure rate of 1.4% was assumed for SeptiFast, based on a naive pooling of failure results
from Warhurst et al.10 (69 failed samples) and from Paolucci et al.99 (100 failed samples) divided by the
number of samples analysed in the SeptiFast versus blood culture trials (11,659 samples).
TABLE 40 Estimated cost per QALY when it is assumed that no additional machinery needs to be purchased.
Mortality rate assumed to be 13%
Scenario and test
Incremental cost per
annum compared
with blood culture (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with blood culturea
Cost per QALY gained
compared with blood
culture (£)b
Assuming 2.4 blood samples per day
SeptiFast 64,107 6.88 9314
SepsiTest –22,134 9.72 Dominating
IRIDICA 35,215 13.96 2522
MALDI-TOF MS –1322 0.23 Dominating
Assuming 17 blood samples per day
SeptiFast 198,011 48.81 4057
SepsiTest –350,161 68.96 Dominating
IRIDICA –206,919 99.01 Dominating
MALDI-TOF MS –13,869 1.65 Dominating
Assuming 68 blood samples per day
SeptiFast 637,173 195.22 3264
SepsiTest –1,476,739 275.82 Dominating
IRIDICA –827,676 396.06 Dominating
MALDI-TOF MS –57,688 6.59 Dominating
a These values include QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
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TABLE 41 Estimated cost per QALY when it is assumed that only the machinery required for the intervention needs
to be purchased. Mortality rate assumed to be 29%
Scenario and test
Incremental cost per
annum compared
with blood culture (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with blood culturea
Cost per QALY gained
compared with blood
culture (£)b
Assuming 2.4 blood samples per day
SeptiFast 67,878 15.35 4421
SepsiTest –15,963 21.69 Dominating
IRIDICA 73,501 31.15 2360
MALDI-TOF MS –548 0.52 Dominating
Assuming 17 blood samples per day
SeptiFast 201,782 108.88 1853
SepsiTest –343,990 153.82 Dominating
IRIDICA –168,427 220.88 Dominating
MALDI-TOF MS –13,094 3.67 Dominating
Assuming 68 blood samples per day
SeptiFast 652,257 435.50 1498
SepsiTest –1,470,568 615.30 Dominating
IRIDICA –674,533 883.51 Dominating
MALDI-TOF MS –56,914 14.69 Dominating
a These values include QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
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The estimated cost per QALY values for SeptiFast, obtained using the results of the synthesis of diagnostic
accuracy, are shown in Table 43 (assuming a 13% mortality rate) and Table 44 (assuming a 29%
mortality rate).
It is seen that, using the pooled results for SeptiFast, rather than the results of Warhurst et al.10 study,
would be more favourable to SeptiFast, with estimated ICERs below £10,000 in all scenarios analysed
regardless of the diagnostic accuracy data used.
Results from base case 2 using the individual clinician values
Cost-effectiveness results produced by individual clinicians are provided in Table 45 for SeptiFast, Table 46
for SepsiTest, Table 47 for IRIDICA and Table 48 for MALDI-TOF MS. For concision, only the cost per QALY
values are presented, with incremental costs and incremental QALY values omitted. Only the results
assuming 2.4 tests a day have been documented, as the purpose was to show the concordance between
individual clinicians, which is largely unaffected by the numbers of blood samples assumed to be analysed
per day.
For all tests the answers were highly discordant between clinicians, with answers ranging from dominated
(higher cost and the same or fewer QALYs) to dominating (lower cost the same or more QALYs), indicating
high levels of uncertainty in the assumed effectiveness of the interventions and MALDI-TOF MS.
TABLE 42 Estimated cost per QALY when it is assumed that no additional machinery needs to be purchased.
Mortality rate assumed to be 29%
Scenario and test
Incremental cost per
annum compared
with blood culture (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with blood culturea
Cost per QALY gained
compared with blood
culture (£)b
Assuming 2.4 blood samples per day
SeptiFast 64,107 15.35 4175
SepsiTest –22,134 21.69 Dominating
IRIDICA 35,215 31.15 1131
MALDI-TOF MS –15,240 0.52 Dominating
Assuming 17 blood samples per day
SeptiFast 198,011 108.88 1819
SepsiTest –350,161 153.82 Dominating
IRIDICA –206,919 220.88 Dominating
MALDI-TOF MS –159,840 3.67 Dominating
Assuming 68 blood samples per day
SeptiFast 637,173 435.50 1463
SepsiTest –1,476,739 615.30 Dominating
IRIDICA –827,676 883.51 Dominating
MALDI-TOF MS –664,860 14.69 Dominating
a These values include QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
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TABLE 43 The estimated cost per QALY values of SeptiFast using the results from the synthesis of diagnostic
accuracy data and assuming a mortality rate of 13%
Scenario and test
Incremental cost per
annum compared
with blood culture (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with blood culturea
Cost per QALY gained
compared with blood
culture (£)b
Assuming 2.4 blood samples per day
Assuming SeptiFast
machine purchase required
39,631 8.64 4588
Assuming no purchase
required
35,860 8.64 4152
Assuming 17 blood samples per day
Assuming SeptiFast
machine purchase required
1477 61.25 24
Assuming no purchase
required
–2294 61.25 Dominating
Assuming 68 blood samples per day
Assuming SeptiFast
machine purchase required
–148,963 245.00 Dominating
Assuming no purchase
required
–164,047 245.00 Dominating
a These values include discounted QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
TABLE 44 The estimated cost per QALY values of SeptiFast using the results from the synthesis of diagnostic
accuracy data and assuming a mortality rate of 29%
Scenario and test
Incremental cost per
annum compared
with blood culture (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with blood culturea
Cost per QALY gained
compared with blood
culture (£)b
Assuming 2.4 blood samples per day
Assuming SeptiFast
machine purchase required
39,631 19.27 2057
Assuming no purchase
required
35,860 19.27 1861
Assuming 17 blood samples per day
Assuming SeptiFast
machine purchase required
1477 136.63 11
Assuming no purchase
required
–2294 136.63 Dominating
Assuming 68 blood samples per day
Assuming SeptiFast
machine purchase required
–148,963 546.53 Dominating
Assuming no purchase
required
–164,047 546.53 Dominating
a These values include discounted QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
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TABLE 45 The estimated cost per QALY values for SeptiFast by individual clinicians using data from Warhurst et al.10
Clinician
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
13% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
13% (£)
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
29% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
29% (£)
1 6036 5720 2706 2564
2 73,884 71,870 33,120 32,217
3 2,137,101 2,075,380 958,011 930,343
4 Dominating Dominating Dominating Dominating
5 42,886 39,800 19,225 17,841
6 Dominated Dominated Dominated Dominated
7 2985 2851 1338 1278
Dominating means providing more or the same QALYs at a reduced cost.
Dominated means providing fewer or the same QALYs at an increased cost.
TABLE 46 The estimated cost per QALY values for SepsiTest by individual clinicians
Clinician
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
13% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
13% (£)
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
29% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
29% (£)
1 Dominating Dominating Dominating Dominating
2 37,700 34,874 16,900 15,633
3 1,294,903 1,179,881 580,474 528,912
4 Dominating Dominating Dominating Dominating
5 Dominating Dominating Dominating Dominating
6 Dominated Dominated Dominated Dominated
7 Dominating Dominating Dominating Dominating
Dominating means providing more or the same QALYs at a reduced cost.
Dominated means providing fewer or the same QALYs at an increased cost.
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TABLE 47 The estimated cost per QALY values for IRIDICA by individual clinicians
Clinician
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
13% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
13% (£)
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
29% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
29% (£)
1 6737 4541 3020 2036
2 78,491 64,489 35,186 28,909
3 2,288,469 1,857,349 1,025,865 832,605
4 Dominating Dominating Dominating Dominating
5 50,386 28,830 22,587 12,924
6 Dominated Dominated Dominated Dominated
7 Dominating Dominating Dominating Dominating
Dominating means providing more or the same QALYs at a reduced cost.
Dominated means providing fewer or the same QALYs at an increased cost.
TABLE 48 The estimated cost per QALY values for MALDI-TOF MS by individual clinicians
Clinician
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
13% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
13% (£)
Only the machinery
required for the
intervention needs to
be purchased. Mortality
rate assumed to be
29% (£)
No additional
machinery needs
to be purchased.
Mortality rate
assumed to be
29% (£)
1 10,265 255 4601 114
2 Dominating Dominating Dominating Dominating
3 Did not answer this question
4 Dominated Dominated Dominated Dominated
5 Dominating Dominating Dominating Dominating
6 Dominated Dominated Dominated Dominated
7 Dominating Dominating Dominating Dominating
Dominating means providing more or the same QALYs at a reduced cost.
Dominated means providing fewer or the same QALYs at an increased cost.
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Results from the threshold analyses
Threshold analyses are presented for each intervention in comparison with blood culture and with MALDI-
TOF MS. It is assumed that, where a comparison with MALDI-TOF MS is made, the unit already had a
MALDI-TOF MS machine in place. The analyses have been undertaken assuming that an intervention needs
to be purchased – it is assumed that if a laboratory already had one of the interventions in place then this
would be routinely used.
Thresholds are reported for net reduction in mortality and net reduction in ICU length of stay combined,
and for net reduction in antimicrobial costs and net reduction in ICU length of stay combined. All
threshold results are presented per 100 positive tests and for 100 tests, irrespective of the test result. For
the net reduction in antimicrobial costs and net reduction in ICU length of stay combined, there is no
separate curve based on the MAICER as it is assumed that both factors affect cost only and the decision
regarding cost-effectiveness reduces to one of cost minimisation.
Owing to the number of figures presented, the threshold analyses are contained in Appendix 8. Note that,
in all analyses, the diagnostic accuracy for SeptiFast has been taken from Warhurst et al.,10 as this was
assumed to be a more representative study of English practice and was graded as a higher-quality study
than the remaining studies (see Table 6).
In summary, relatively small mortality gains would be required for the interventions to achieve a cost per
QALY gained of £20,000. The threshold levels compared with blood culture, assuming that 2.4 samples
per day need to be analysed, are shown in Table 49. The values assuming that the comparator is
MALDI-TOF MS are shown in Table 50.
These values assume no change in either of the two remaining parameters. All other scenarios require
lower threshold values to attain a cost per QALY gained of £20,000.
TABLE 50 Threshold levels require to achieve a cost per QALY gained of £20,000, assuming that the number of
samples that need to be analysed per day is 2.4 and a comparator of MALDI-TOF MS
Test
Per 100 tests Per 100 positive tests
Reduction in
30-day
mortality
(lives)
Reduction in
ICU length of
stay (days)
Reduction in
antimicrobial
treatment
costs (£)
Reduction in
30-day
mortality
(lives)
Reduction in
ICU length of
stay (days)
Reduction in
antimicrobial
treatment
costs (£)
SeptiFast 0.09 18.50 195.57 0.59 127.33 1345.90
SepsiTest 0.06 13.20 139.56 0.36 77.89 823.34
IRIDICA 0.13 28.82 304.65 0.63 135.79 1435.32
TABLE 49 Threshold levels require to achieve a cost per QALY gained of £20,000, assuming that the number of
samples that need to be analysed per day is 2.4 and a comparator of blood culture
Test
Per 100 tests Per 100 positive tests
Reduction in
30-day
mortality
(lives)
Reduction in
ICU length of
stay (days)
Reduction in
antimicrobial
treatment
costs (£)
Reduction in
30-day
mortality
(lives)
Reduction in
ICU length of
stay (days)
Reduction in
antimicrobial
treatment
costs (£)
SeptiFast 0.09 19.45 205.54 0.62 133.82 1414.50
SepsiTest 0.07 14.15 149.53 0.39 83.46 882.15
IRIDICA 0.14 29.76 314.61 0.65 140.23 1482.28
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Results from the studies comparing SeptiFast with matrix-absorbed laser
desorption/ionisation time-of-flight mass spectrometry and comparing
SepsiTest with matrix-absorbed laser desorption/ionisation time-of-flight
mass spectrometry
Two studies had a comparator of MALDI-TOF MS in addition to blood culture. These were the studies by
Tafelski et al.,112 in which the index test was SeptiFast, and by Loonen et al.,114 in which the index text was
SepsiTest. The cost-effectiveness of SeptiFast and SepsiTest was estimated using the data from the trials
with MALDI-TOF MS as a comparator and assuming the average benefits estimated by the clinicians. These
results were then compared with the results produced by the indirect comparisons of SeptiFast and
MALDI-TOF MS, and of SepsiTest and MALDI-TOF MS, generated through the evidence provided by the
clinical experts relative to blood culture to see if they were concordant.
The benefits associated with the interventions were amended to account for any benefit associated with a
positive MALDI-TOF MS. Thus, for example, if (as an illustrative example) SeptiFast was associated with an
estimated reduction in ICU stay of 0.607 per positive test and MALDI-TOF MS with a reduction of 0.175
day per positive test, then, assuming that MALDI-TOF MS had a sensitivity of 0.798 compared with blood
culture, which was the reliable identification value at species level from Morgenthaler and Kostrzewa,30 the
benefit of a positive SeptiFast test when the accompanying blood culture was positive in terms of ICU
length of stay reduction would be calculated as (0.607 – 0.175) × 0.798, which equals 0.468 days.
The costs of MALDI-TOF MS were subtracted from the costs of the tests based on the estimated number
of tests performed. The results are provided in Table 51 (assuming a mortality rate of 13%) and Table 52
(assuming a mortality rate of 29%). Given the relatively low ICERs, for concision, evaluations in which
machinery was not required to be purchased to use SeptiFast or SepsiTest are not reported. As no failures
were mentioned by Tafelski et al.112 or Loonen et al.,114 it was assumed that there were none for the
analyses presented.
TABLE 51 The estimated ICERs based on trials directly comparing interventions with MALDI-TOF MS, assuming a
mortality rate of 13% and that machinery needs to be purchased
Scenario and test
Incremental cost per
annum compared with
MALDI-TOF MS (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with MALDI-TOF MSa
Cost per QALY gained
compared with
MALDI-TOF MS (£)b
Assuming 2.4 blood samples per day
SeptiFast –38,345 12.40 Dominating
SepsiTest 84,087 2.41 34,848
Assuming 17 blood samples per day
SeptiFast –499,681 87.95 Dominating
SepsiTest 417,246 17.11 24,385
Assuming 68 blood samples per day
SeptiFast –2,128,094 351.79 Dominating
SepsiTest 1,599,875 68.44 23,375
a These values include discounted QALYs gained in subsequent years.
b Dominating means providing more QALYs for the same or lower cost.
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The results indicate that SeptiFast appears to be more cost-effective than MALDI-TOF MS when aggregated
clinicians values are used. The results for SepsiTest are less conclusive, with estimated values of > £20,000
per QALY gained when a mortality rate of 13% is assumed, and with values below this when a mortality
rate of 29% is assumed.
These results differ from those of the main analyses, in which SepsiTest appeared considerably more
cost-effective than both MALDI-TOF MS and SeptiFast (see Figures 12–23).
Results from studies comparing SeptiFast and SepsiTest simultaneously with
blood culture
Two studies evaluated both SeptiFast and SepsiTest against blood culture: those by Schreiber and
Nierhaus119 and Leitner et al.118 The cost-effectiveness of these studies was estimated to see if it was
concordant with the results produced by the indirect comparisons of SeptiFast and SepsiTest generated
through the evidence provided by the clinical experts relative to blood culture. Neither study mentioned
the SeptiFast failure rate and, thus, it was assumed to be zero. It was further assumed that machinery
would need to be purchased for both tests. The ICERs for SeptiFast compared with SepsiTest are provided
in Table 53 (mortality rate assumed to be 13%) and in Table 54 (mortality rate assumed to be 29%). It is
seen that in all of the scenarios the ICER for SeptiFast compared with SepsiTest is > £30,000 per QALY
gained. This conclusion is concordant with those of the main analyses as shown in Figures 12–23.
TABLE 52 The estimated ICERs based on trials directly comparing interventions with MALDI-TOF MS, assuming a
mortality rate of 29% and that machinery needs to be purchased
Scenario and test
Incremental cost per
annum compared with
MALDI-TOF MS (£)
Incremental QALYs gained
through number of avoided
30-day mortalities within 1 year
compared with MALDI-TOF MSa
Cost per QALY gained
compared with
MALDI-TOF MS (£)b
Assuming 2.4 blood samples per day
SeptiFast –38,345 37.67 Dominating
SepsiTest 84,087 5.38 15,621
Assuming 17 blood samples per day
SeptiFast –499,681 196.19 Dominating
SepsiTest 417,246 38.17 10,931
Assuming 68 blood samples per day
SeptiFast –2,128,094 784.76 Dominating
SepsiTest 1,599,875 152.68 10,479
a These values include discounted QALYs gained in subsequent years.
b Dominating means providing more QALYS at the same or lower cost.
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TABLE 53 The estimated ICERs based on trials directly comparing both SeptiFast and SepsiTest with blood culture,
assuming a mortality rate of 13% and that machinery needs to be purchased
Study Test
Incremental
cost per
annum (£)
Incremental QALYs
gained through
number of avoided
30-day mortalities
within 1 yeara
Cost per
QALY
gained (£)b
Cost per QALY of
SeptiFast compared
with SepsiTest (£)c
Assuming 2.4 blood samples per day
Schreiber and Nierhaus119 SeptiFast 87,022 5.81 14,975 90,855
SepsiTest 49,147 5.39 9111
Leitner et al.118 SeptiFast 67,686 6.95 9739 Dominated
SepsiTest –7910 9.27 Dominating
Assuming 17 blood samples per day
Schreiber and Nierhaus119 SeptiFast 337,533 41.21 8191 74,363
SepsiTest 117,708 38.25 3077
Leitner et al.118 SeptiFast 200,421 49.28 4067 Dominated
SepsiTest –286,890 65.73 Dominating
Assuming 68 blood samples per day
Schreiber and Nierhaus119 SeptiFast 1,195,262 164.83 7252 69,267
SepsiTest 376,224 153.00 2459
Leitner et al.118 SeptiFast 646,815 197.13 3281 Dominated
SepsiTest –1,242,168 262.91 Dominating
a These values include QALYs gained in subsequent years.
b Dominating means providing more or the same QALYs at a reduced cost.
c Dominated means providing fewer or the same QALYs at an increased cost.
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Interpretation of the independent economic model results
Forming conclusions based on the economic modelling is very difficult because of the lack of high-quality
evidence regarding the impact of the interventions on hard patient outcomes, such as sepsis-related
mortality, length of stay in the ICU and on changes in the costs of antimicrobial therapy.
In base case 1, which includes only data from the published literature on patient-related outcomes, all
interventions were estimated to be dominated as there was no evidence that any knowledge gained
translated into a benefit for the patient and all interventions were associated with additional cost.
In base case 2, parameter values were populated from estimates provided by clinical experts. The results
contrasted with those in base case 1. Using the average values provided by the clinical experts, the
estimated cost per QALY for all interventions was below a threshold of £20,000 per QALY in all scenarios.
However, when the results were broken down by individual clinician estimates, there was a wide variation
in the cost per QALY. In the scenario of a 13% mortality rate and 2.4 samples analysed per day, costs per
QALY estimates were > £20,000 for four out of seven clinicians for SeptiFast, for two out of seven
clinicians for SepsiTest, for four out of seven clinicians for IRIDICA and for two out of six clinicians for
MALDI-TOF MS. The clinical experts commented on the difficulty of the task of populating the model
parameters and thus all results should be treated with caution.
TABLE 54 The estimated ICERs based on trials directly comparing both SeptiFast and SepsiTest with blood culture,
assuming a mortality rate of 29% and that machinery needs to be purchased
Study Test
Incremental
cost per
annum (£)
Incremental QALYs
gained through
number of avoided
30-day mortalities
within 1 yeara
Cost per
QALY
gained (£)b
Cost per QALY of
SeptiFast compared
with SepsiTest (£)c
Assuming 2.4 blood samples per day
Schreiber and Nierhaus119 SeptiFast 87,022 12.96 6713 40,728
SepsiTest 49,147 12.03 4084
Leitner et al.118 SeptiFast 67,686 15.50 4366 Dominated
SepsiTest –7910 20.68 Dominating
Assuming 17 blood samples per day
Schreiber and Nierhaus119 SeptiFast 337,533 91.92 3672 33,335
SepsiTest 117,708 85.33 1379
Leitner et al.118 SeptiFast 200,421 109.94 1823 Dominated
SepsiTest –286,890 146.62 Dominating
Assuming 68 blood samples per day
Schreiber and Nierhaus119 SeptiFast 1,195,262 367.69 3251 31,051
SepsiTest 376,224 341.31 1102
Leitner et al.118 SeptiFast 646,815 439.75 1471 Dominated
SepsiTest –1,242,168 586.50 Dominating
a These values include QALYs gained in subsequent years.
b Dominating means providing more or the same QALYs at a reduced cost.
c Dominated means providing fewer or the same QALYs at an increased cost.
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The External Assessment Group also caution against forming conclusions from a direct comparison of the
interventions, although, for completeness, these results have been presented along with a description of
the key assumptions and data driving these comparative results. IRIDICA is estimated to have much better
sensitivity than either SeptiFast or SepsiTest, and this results in an increase in QALYs and reduced costs
resulting from reductions in ICU and hospital lengths of stay and changes in antimicrobial costs. The
specificity of the interventions is similar, although the specificity of IRIDICA is marginally lower than that of
SeptiFast or SepsiTest; this will result in QALY gains and cost savings as the clinical experts believed false
positives to be associated with an imperfect reference standard rather than an inaccurate test. Additionally,
the data provided by the expert clinicians indicated that a positive IRIDICA test would be more beneficial
than the other tests. The QALY gains and cost savings associated with IRIDICA were sufficient to offset its
higher costs and to confer on IRIDICA the highest NMB. The second highest NMB was typically for
SepsiTest, not because of its inherent accuracy, as it has lower sensitivity than SeptiFast, but because the
assumed cost per test is lower and the benefit per test estimated by the clinicians is higher. MALDI-TOF MS
was presumed to be better than blood culture, but as the number of samples tested using MALDI-TOF MS
was much smaller, with only those that were blood culture positive being tested, the NMB was lower than
for any of the interventions.
Additional analyses undertaken using the results from multitest studies of SeptiFast, SepsiTest and blood
culture and the data provided by clinicians, were concordant with base case 2, in that SeptiFast has an
estimated cost per QALY gained value of > £20,000 compared with SepsiTest. However, the indirect
results produced when using studies directly comparing MALDI-TOF MS were contradictory, with SeptiFast
estimated to dominate SepsiTest.
Given the discordant results between base case 1 and base case 2, the External Assessment Group cannot
confidently suggest any cost per QALY gained value for the interventions. It is clear that the majority of
clinicians questioned believe that the interventions are likely to be cost-effective, yet there are no
conclusive data to show that the tests provide a benefit to patients.
Threshold analyses were carried out, as these may be helpful to decision-makers in formulating guidance.
It was seen that relatively small mortality gains would be required for the interventions to achieve a cost
per QALY gained of £20,000 compared with standard practice.
The External Assessment Group comments that studies comparing the use of an intervention with standard
practice, with the results of the tests fed into a treatment management plan, are urgently needed to
produce more definitive estimates of the cost per QALY gained. The RAPIDO study31 is undertaking this for
MALDI-TOF MS in addition to blood culture and clinical judgement. Although this study was recently
completed, data analysis had not been fully conducted at the time of writing. When the results of the
clinical effectiveness and cost-effectiveness of the addition of MALDI-TOF MS are known, the best choice
for standard practice in any future trial should be more certain.
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Chapter 4 Discussion
Statement of principal findings
Clinical effectiveness
A comprehensive systematic review and meta-analysis (where applicable) were undertaken to evaluate the
clinical effectiveness of three interventions (SeptiFast, SepsiTest and IRIDICA) in conjunction with clinical
assessment for rapidly identifying bloodstream bacteria and fungi in people with suspected sepsis.
For the review of diagnostic test accuracy, 62 studies44–46,48,49–65,67–88,90–99,101,102,104–119 of varying
methodological quality were included. Most of these studies were considered to be at risk of bias
and there are concerns about their applicability. Pooled effects for sensitivity and specificity across
54 studies44–46,59–65,67–88,90–102,104–111,118,119 (comprising 10,010 patients) comparing SeptiFast with blood culture
found that the specificity of SeptiFast (0.86, 95% CrI 0.84 to 0.89) is higher than its sensitivity (0.65, 95%
CrI 0.60 to 0.71). Similarly, one study112 that compared SeptiFast with blood culture plus MALDI-TOF MS
found that SeptiFast had higher specificity (0.74, 95% CI 0.64 to 0.85) than sensitivity (0.58, 95% CI 0.30
to 0.86). However, because of the deficiencies in the quality of the included studies, these data may not
be reliable and should be treated with caution. Moreover, the prediction intervals of the pooled estimates
indicate a substantial amount of heterogeneity between studies, particularly for sensitivity. Reasons for the
observed heterogeneity in sensitivity and specificity between studies were explored using metaregression
for several potentially relevant characteristics including age category (adults, and children and neonates),
antibiotic use at the time of blood sampling, community- or health-acquired infection, inclusion/exclusion
of contaminants and patients with febrile neutropenia. There was no evidence to suggest that the pooled
sensitivity and specificity were affected by these subgroups.
Pooled effects for sensitivity and specificity across four studies48,113,118,119 (comprising 460 patients)
comparing SepsiTest with blood culture suggest that SepsiTest has a higher specificity (0.86, 95% CrI 0.78
to 0.92) than sensitivity (0.48, 95% CrI 0.21 to 0.74). Although the pooled estimate indicates low
sensitivity, the associated CrI is large. Comparison with blood culture plus MALDI-TOF MS in a single
study114 also showed higher specificity than sensitivity (0.96, 95% CrI 0.92 to 1.00; and 0.11, 95% CrI
0.00 to 0.23, respectively). Despite substantial amounts of heterogeneity between studies, analyses for
potential causes of this heterogeneity could not be explored because of the small number of studies
included. Owing to the deficiencies in the quality of the included studies, the sensitivity and specificity data
for SepsiTest may not be reliable and should be treated with caution.
The pooled effects for sensitivity and specificity across four studies49,115–117 [comprising 860 patients across
two studies115,117 (data not reported for other studies)] comparing IRIDICA with blood culture suggest that
IRIDICA has a higher specificity (0.84, 95% CrI 0.71 to 0.92) than sensitivity (0.81, 95% CrI 0.69 to 0.90),
although the difference between sensitivity and specificity is small. Despite substantial amounts of
heterogeneity between studies, analyses for potential causes of this heterogeneity could not be explored
owing to the small number of studies included. Owing to the deficiencies in the quality of the included
studies, the sensitivity and specificity data for IRIDICA may not be reliable and should be treated
with caution.
Although 41 studies44–46,59,60,64,66,68,69,72,74,76–78,80,81,84,85,88–90,92–94,96,97,99–101,103–107,110–112,114,116,117,119 across the three
interventions reported data on one or more intermediate (e.g. time to pathogen identification, time to
treatment, test failure rates, duration of stay in hospital or critical care units, and change in antimicrobial
treatment plan) and/or clinical outcome measures (e.g. mortality), the majority of studies reported data for
the whole patient cohort, as opposed to comparative data for the index and reference test. Few clinical
trials have been conducted on the likely impact and safety of acting on the results of the real-time PCR
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assays in patients in any setting, although three RCTs,100,110,112 all of SeptiFast, were identified. One did not
investigate patient outcomes112 and one was predominantly in febrile neutropenia patients and reported
no significant difference in mortality, length of stay (ICU or hospital) or fever duration.110 The third RCT
was published in abstract form only and did not report a difference in mortality.100
Given the potentially fatal consequences of removing treatment from patients with sepsis, it is not
anticipated that negative tests in isolation would be acted on in clinical practice were an intervention
introduced. This is because none of the three tests has the very high sensitivity needed to be used as a
‘rule-out’ test, which would reassure clinicians that a negative result would be associated with a very low
probability of a patient having sepsis. Therefore, the main advantage of the tests in patients who are
receiving broad-spectrum antibiotics would be in providing an earlier indication of the pathogen than
would be achieved by standard methods, and in the potential focusing of antibiotic treatments. If negative
tests are not acted upon, then the numbers of false-positive tests are reduced in populations with a high
incidence of sepsis, such as patients in the ICU. It may be that the benefits of the tests are greater in
high-incidence populations.
In addition, the three interventions provide very limited data regarding antimicrobial sensitivity. Definitive
data on this are needed, to be obtained if possible, using standard culture methods undertaken in parallel
with the interventions.
Cost-effectiveness
A systematic review of the literature was undertaken to identify cost-effectiveness analyses relating to the
interventions. Two of these were within-study analyses, one using propensity scoring to match patients103
and one not.89 The remaining two presented results from modelling studies, with one evaluating
SeptiFast66 and one evaluating an IRIDICA–PLEX-ID hybrid.128 The External Assessment Group noted
limitations of all four studies and constructed a de novo mathematical model, and reported results under a
number of scenarios. In base case 1, only documented statistically significant benefits associated with the
tests were included, resulting in an estimation that all of the interventions provided no benefit. In order to
investigate alternative scenarios, clinicians from the Diagnostic Appraisal Committee and clinicians who are
authors of this report were asked, for each intervention, to provide estimates of the benefits associated
with a positive test; this formed base case 2. At the aggregate level, all of the interventions were estimated
to have cost per QALY gained values < £20,000. However, these results must be taken with caution as the
clinicians noted the difficulty of the task and there was a wide divergence of opinion among the
individual clinicians.
Additional analyses, using the data provided by clinicians, were undertaken to assess whether or not the
estimated results were altered by analysing individual studies that assessed an intervention versus
MALDI-TOF MS, or where two interventions were compared simultaneously within a study. The results
from the studies against MALDI-TOF MS were concordant with those produced in base case 2 for
individual interventions; however, indirectly, SeptiFast appeared to dominate SepsiTest, which did not
occur in base case 2. For trials that assessed SeptiFast and SepsiTest simultaneously, the ICER for SeptiFast
compared with SepsiTest was consistently > £30,000 per QALY, which was concordant with base case 2.
It is commented that the results of the evaluation of SeptiFast with SepsiTest are driven by the relative
costs of each test rather than the diagnostic accuracy, and also the assumed benefits assigned to each
test by the expert clinicians. The External Assessment Group notes that the specificities of the tests are
comparable, but the sensitivity of SeptiFast is estimated to be greater than that for SepsiTest.
To provide potentially useful information to the Diagnostic Appraisal Committee, threshold analyses were
undertaken in relation to 30-day mortalities prevented, reduction in the number of days in the ICU and
reduced antimicrobial costs.
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Strengths and limitations of the assessment
Clinical effectiveness
The strengths of this systematic review are that it was conducted using robust methods, including the
development of a prespecified protocol, comprehensive searching of published and unpublished evidence
(including contact with clinical experts in the field and checking evidence submitted by the companies that
manufacture the tests), study selection (including adjudication by three independent clinical experts), and
data extraction by a minimum of two independent reviewers and a formal assessment of methodological
quality. Statistical evaluation of diagnostic test accuracy was undertaken using statistically rigorous methods,
allowing for the correlation between sensitivity and specificity, and potential between-study heterogeneity.
Reasons for the heterogeneity in sensitivity and specificity between studies were explored using
metaregression and parameter estimates were produced using Markov chain Monte Carlo simulation.
The assessment of methodological quality was generally hampered by the poor quality of reporting in the
included SeptiFast, SepsiTest and IRIDICA studies, with the majority of studies being classified as being at
unclear risk of bias on most assessment domains. Although a number of abstracts were included in the
current systematic review, differences often occur between data reported in conference abstracts and their
corresponding full reports; however, differences in results are usually not very large.41
The pooled estimates of sensitivity and specificity for SeptiFast, SepsiTest and IRIDICA were estimated
assuming that the reference standard was 100% sensitive and specific; however, this is unlikely to be the
case. In practice, a wide range of factors is known to influence the diagnostic accuracy of blood cultures.
For example, this may include antimicrobial treatment prior to blood sampling, low blood sample volumes,
lack of replicate blood culture sets, delays in incubation and contamination during sampling.10,12 As a
result, the reported estimates of sensitivity and specificity are likely to be biased (underestimated)
compared with those that would be obtained using a perfect reference standard. In addition, diagnostic
metrics in the included studies were measured using different units: patients, sample episodes or species/
pathogen level. Such analyses create a ‘unit of analyses’ error and may have contributed to the
heterogeneity in the results.
Although no other systematic reviews or meta-analyses were identified for SepsiTest or IRIDICA,
the present overall findings and conclusion for SeptiFast compared with blood culture were consistent
with the review and meta-analysis by Dark et al.,50 with pooled effects for sensitivity and specificity (across
41 SeptiFast studies, which were also included in the current review) of 0.68 (95% CI 0.63 to 0.73)
and 0.86 (95% CI 0.84 to 0.89), respectively. An earlier systematic review of SeptiFast by Chang et al.151
observed similar specificities (0.92, 95% CI 0.90 to 0.95), but higher sensitivities (0.75, 95% CI 0.65 to
0.83) across 34 SeptiFast studies. That review included a number of studies that were excluded from the
present review because of publication type (foreign language, n= 2) or because they did not meet our
inclusion criterion of ‘suspected sepsis’ (n= 2). In addition, Chang et al.151 pooled studies comparing
SeptiFast results against various reference standards to produce composite overall diagnostic accuracy
metrics. These factors may have contributed to the the fact that diagnostic performance metrics were
higher than those found in the present review and by Dark et al.50
Cost-effectiveness
A systematic review of the cost-effectiveness literature associated with the interventions was undertaken.
The External Assessment Group noted limitations with the identified evidence and therefore constructed
a de novo model. A strength of the modelling work undertaken is that a framework for modelling
interventions that provide rapid information on bloodstream bacteria and fungi has been established.
The framework allows for there to be a benefit associated with false-positive tests and thus explicitly
incorporates the fact that blood culture, with or without MALDI-TOF MS, is an imperfect reference test.
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A fundamental limitation is that there are few robust data to populate the mathematical model. The
External Assessment Group attempted to reduce this limitation by asking clinical experts to provide data to
be used in an evaluation. The robustness of any conclusions is severely limited given the feedback from
clinicians regarding the difficulty of the task and also because of the large heterogeneity of results
produced from individual clinicians, which range from the interventions dominating to the interventions
being dominated.
Further limitations are acknowledged in the model, which was simplistic, although none is expected to
influence the conclusion that until further research is performed no robust assessment of cost-effectiveness
can be made. The limitations of the model include the lack of modelling regarding antimicrobial
stewardship benefits; the cost implications of any service reconfiguration required to move to a 24 hours a
day, 7 days a week, service; any training costs required; any utility differential in survivors with and without
any intervention; the possibility that only a sequencer need be purchased to run SepsiTest; that the
estimates for the sensitivity of MALDI-TOF MS have been used at species level; and that any discounts
associated with undertaking large quantities of tests have been omitted.
Uncertainties
Clinical effectiveness
All of the included studies compared the index test with a reference standard (blood culture with or
without MALDI-TOF MS). No studies were identified that compared all of the index tests of interest directly
with each other (end-to-end studies). In addition, there are very few robust data at present that report the
impact of interventions on hard clinical outcomes such as mortality and reduced length of stay in critical
care or in hospital.
Cost-effectiveness
The key uncertainty relates to the estimated cost-effectiveness of each intervention. The results produced
by the External Assessment Group indicate that at an aggregate level clinicians believe the interventions to
provide information that, if acted on, would improve key patient outcomes of mortality or ICU length of
stay. However, there are no data currently available to support these views and no definitive conclusions
can be provided until further research is undertaken.
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Chapter 5 Conclusion
Implications for service provision
Given the considerable uncertainty in the cost-effectiveness results produced for each intervention,
it is uncertain what the implications in the NHS would entail. Were the interventions deemed to be a
cost-effective use of resources, it is likely that reconfigurations of working practice, such as moving to
a 7-day working schedule, would be required in order that the interventions could provide results more
quickly than under the present system.
Research recommendations
Despite the growing evidence base for all three interventions, a number of key issues need to be
addressed. First, all future clinical studies incorporating SeptiFast, SepsiTest and IRIDICA need to be better
reported, in accordance to the standards for the reporting of diagnostic accuracy studies statement.152
Once robust diagnostic accuracy data have been established, there is a need for a pragmatic trial in which
the results from the interventions are allowed to change patient management and for these results to be
compared with standard practice in order to allow robust estimates of the clinical effectiveness and
cost-effectiveness of an intervention to be estimated. A process evaluation, running alongside such a
pragmatic trial, may also be of value to understand how the tests are used in the NHS. At present, there
are very few data that report the impact of interventions on hard clinical outcomes such as mortality and
reduced length of stay in critical care units. Any such trials should wait until the results from the RAPIDO
trial31 are published in order that key information on the clinical utility of MALDI-TOF MS compared with
blood culture is known. Finally, research into logistical issues, such as the numbers of hospitals serviced by
the machine and the number of days that the machine operates to determine the optimal use of the
interventions in England, is required.
Conclusions
Clinical effectiveness
SeptiFast, SepsiTest and IRIDICA appear to have higher specificity values than sensitivity values. However,
because of the deficiencies in study quality in the included studies, these data may not be reliable and
should be treated with caution. Moreover, there are no head-to-head comparisons of all these tests and
there are few robust data that report the impact of interventions on hard clinical outcomes, such as
mortality and reduced length of stay in critical care units; the data that do exist have not shown any
intervention to produce a statistically significant improvement. In order to produce a definitive conclusion
on the clinical effectiveness of the interventions appropriate studies need to be conducted (see
Research recommendations).
Cost-effectiveness
There is considerable uncertainty associated with all analyses within this assessment and a definitive
estimate of the cost-effectiveness of each intervention cannot be provided. This is largely because of the
limitations of the evidence base. The studies recommended in Research recommendations would reduce
this uncertainty. Threshold analyses have been provided that may allow decision-makers to estimate
whether or not the interventions are likely to meet a level at which the decision-makers would consider the
interventions to be cost-effective.
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Appendix 1 Literature search strategies for the
review of clinical effectiveness: a MEDLINE example
MEDLINE search strategy Details
Database searched Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid MEDLINE
Platform or provider used Ovid SP
Date of coverage 1948 to May 2015
Search undertaken Initial search February 2015
Updated search May 2015
Search strategy
1. exp Sepsis/
2. sepsis.mp.
3. septic?emia.mp.
4. Shock, Septic/
5. ((septic or endotoxic or toxic) adj shock).tw.
6. Bacteremia/
7. bacter?emia.mp.
8. Fungemia/
9. fung?emia.mp.
10. Systemic Inflammatory Response Syndrome/
11. sirs.mp.
12. blood$ infection$.tw.
13. blood poison$.tw.
14. or/1-13
15. septifast.mp.
16. lightcycler.mp.
17. 15 or 16
18. 14 and 17
19. sepsitest.mp.
20. iridica.mp.
21. (plex id or plex-id).mp.
22. or/19-21
23. exp Polymerase Chain Reaction/
24. polymerase chain reaction$.tw.
25. pcr$.mp.
26. Gene Amplification/
27. Nucleic Acid Amplification Techniques/
28. or/23-27
29. Genes, Bacterial/ or Genes, Fungal/
30. (exp bacteria/ or exp Fungi/) and exp Nucleic Acids/
31. ((bacteri$ or fung$) adj3 (dna or gene$ or nucleic acid$)).tw.
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32. blood culture$.tw.
33. or/29-32
34. 14 and 28 and 33
35. 18 or 22 or 34
36. Animals/ not (Humans/ and Animals/)
37. 35 not 36
38. limit 37 to yr=“2006 –Current”
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Appendix 2 The QUADAS-2 tool (adapted) for the
methodological assessment of diagnostic studies51
Quality domain Scoring Summary judgement
Risk of bias
Patient selection
Was a consecutive or random
sample of patients enrolled?
‘Yes’ if states consecutive or random
‘No’ if states another method of patient
sampling/selection
‘Unclear’ if unclear or not reported
Could the selection of patients
have introduced bias?
‘Low risk’ if all domains are ‘yes’
‘High risk’ if one or more domain
is ‘no’
‘Unclear risk’ anything in between
Was a case–control design
avoided?
‘Yes’
‘No’
‘Unclear’ if insufficient information provided
Did the study avoid inappropriate
exclusions?
‘Yes’ if the study provides explicit exclusion
criteria and appropriately select participants
that are typical of patients with bloodstream
infection/suspected sepsis
‘No’ if the study has made inappropriate
exclusions from the group it set out to select
(i.e. unrepresentative of people with
bloodstream infection/suspected sepsis)
‘Unclear’ if insufficient information provided
Index test
Were the index test results
interpreted without knowledge of
the results of the reference
standard?
‘Yes’ if index test was interpreted without
knowledge (blind) of the results of the
reference standard or the index test was
clearly interpreted before the reference
standard was known
‘No’ if results of reference standard were
already known
‘Unclear’ if insufficient details are provided
Could the conduct or
interpretation of the index test
have introduced bias?
‘Low risk’ if all domains are ‘yes’
‘High risk’ if one or more domain
is ‘no’
‘Unclear risk’ anything in between
Reference standard
Is the reference standard likely to
correctly classify the target
condition?
‘Yes’ if clinical standard described and is
consistent with published standard operating
procedures
‘No’ if reference standard falls short of
standard operating procedures
‘Unclear’ if insufficient information provided
Could the conduct or
interpretation of the reference
standard have introduced bias?
‘Low risk’ if all domains are ‘yes’
‘High risk’ if one or more domain
is ‘no’
‘Unclear risk’ anything in betweenWere the reference standard
results interpreted without
knowledge of the results of the
index test?
‘Yes’ if the reference standard was interpreted
blind to the index test or the reference
standard was clearly interpreted before the
index test was known
‘No’ if the results of the index test were
known
‘Unclear’ if insufficient information is provided
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Quality domain Scoring Summary judgement
Flow and timing
Was there an appropriate interval
between index test(s) and
reference standard?
‘Yes’ if reference standard and index tests
performed on blood samples drawn at the
same time
‘No’ if reference standard and index tests not
performed on blood samples drawn at
different times
‘Unclear’ if insufficient information is provided
Could the patient flow have
introduced bias?
‘Low risk’ if all domains are ‘yes’
‘High risk’ if one or more domain
is ‘no’
‘Unclear risk’ anything in between
Did all patients receive a reference
standard?
‘Yes’ if all participants who received the index
test also verified using the reference test
‘No’ if not all (or some) of the participants
who received the index test also underwent
the reference test (partially verified). If all
participants did not receive the reference test,
how many did not (of the total)
‘Unclear’ if insufficient information is provided
Did patients receive the same
reference standard?
‘Yes’ if the same reference test was used
regardless of the index test results
‘No’ if different reference tests are used
depending on results of the index tests. If
different reference tests are used, what were
the reasons and how many participants were
involved?
‘Unclear’ if insufficient information is provided
Were all patients included in the
analysis?
‘Yes’ if all patients who were recruited/
enrolled into the study were included in the
analysis or if sufficient explanation is provided
for any discrepancy
‘No’ if there are participants excluded from the
analysis and no/insufficient explanation is
given for any discrepancy
‘Unclear’ if insufficient information is given to
assess whether or not any patients were
excluded from the analysis
Applicability
Patients
Are there concerns that the
included patients and settings do
not match the review question?
Scored in relation to the description of
included patients
‘Yes’ if the sample is
unrepresentative of people with
bloodstream infection/suspected
sepsis
‘No’ if characteristics of
participants are well described
and typical of patients with
bloodstream infection/suspected
sepsis
‘Unclear’ if characteristics are not
well described
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
Quality domain Scoring Summary judgement
Index test
Is there concern that the index
test, its conduct, or interpretation,
differ from the review question
(i.e. CE protocol followed)?
Scored in relation to the CE mark protocol for
SeptiFast, SepsiTest and IRIDICA
‘Yes’ if CE mark protocol for
SeptiFast, SepsiTest and IRIDICA is
not followed
‘No’ if CE mark protocol for
SeptiFast, SepsiTest and IRIDICA is
followed
‘Unclear’ if insufficient details
provided
Reference standard
Is there concern that the target
condition, as defined by the
reference standard, does not
match the review question?
Scored in relation to description of the
reference standard
‘Yes’ if full details of reference
standard are not provided, for
example the reference standard
may be free of bias but the target
condition that it defines may
differ from the target condition
specified in the review question
‘No’ if full details are provided
‘Unclear’ if insufficient details
provided
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Appendix 3 Clinical effectiveness review: table of
excluded studies with rationale
TABLE 55 Studies excluded from the clinical review
Reference details Reason for exclusion
Clinicaltrials.gov. Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and
Therapeutic Approach for Onco-Hematology Patients Presenting Sepsis. 2010.
URL: http://ClinicalTrials.gov/show/NCT00561639 (accessed April 2016)
Trial record with no study results
Clinicaltrials.gov. Diagnosis of Septicaemia by Detection of Microbial DNA in Blood
in Severe Infections. 2011. URL: http://ClinicalTrials.gov/show/NCT00709358
(accessed April 2016)
Protocol: SeptiFast EVAMICA trial
Clinicaltrials.gov. Value of the LightCycler© SeptiFast Test MGRADE for the
Pathogen Detection in Neutropenic Hematological Patients. 2012. URL: http://
ClinicalTrials.gov/show/NCT01114165 (accessed April 2016)
Trial record of Idelevich et al.a
Clinicaltrials.gov. Evaluation in the Treatment of Nosocomial Sepsis Comparing
Polymerase Chain Reaction with Conventional Blood Culture. 2013. URL: http://
ClinicalTrials.gov/show/NCT01450358 (accessed April 2016)
Replaced (protocol) by full-text paper
reported by Rodrigues et al.b
Clinicaltrials.gov. Optimal Antibiotic Treatment of Moderate to Severe Bacterial
Infections. 2014. URL: http://ClinicalTrials.gov/show/NCT01338116 (accessed
April 2016)
Ongoing SeptiFast trial – estimated
completion January 2017
Abbott Molecular Inc. IRIDICA BAC BSI Assay – Package Insert Ref: 08N22-010.
Des Plaines, IL: Abbott Molecular Inc.; 2014
Replaced (package insert) by full-text
paper reported by Metzgar et al.c
Afsharpaiman S, Mamishi S, Pourakbari B, Siyadati A, Tabatabaee P, Khotaee G.
Diagnosis of bacteremia using universal PCR in febrile ill children. Acta Med Iranica
2007;45:131–8
Cultured samples (positive)
Al-Zahrani AKH, Ghonaim MM, Hussein YM, Eed EM, Khalifa AS, Dorgham LS,
et al. Evaluation of recent methods versus conventional methods for diagnosis of
early-onset neonatal sepsis. J Infect Develop Countries 2015;9:388–93
Not intervention (test) of interest
Arabestani MR, Fazzeli H, Nasr Esfahani B. Identification of the most common
pathogenic bacteria in patients with suspected sepsis by multiplex PCR. J Infect
Develop Countries 2014;8:461–8
Cultured samples (positive)
Avolio M, Diamante P, Zamparo S, Modolo M, Grosso S, Zigante P, et al.
Molecular identification of bloodstream pathogens in patients presenting to the
emergency department with suspected sepsis. Shock 2010;34:27–30
Diagnostic metrics data included in
Avolio et al.d (confirmed by authors)
Avolio M, Diamante P, Zamparo S, Modolo ML, Grosso S, Zigante P, et al.
Evaluation of molecular detection of bloodstream pathogens in 144 patients
arriving in the emergency room with clinical signs of sepsis. Clin Microbiol Infect
2010;16:S533–4
Replaced (abstract) by full-text paper
reported by Avolio et al.e
Baraki H, Al AA, Schilling T, Pichlmaier M, Martens A, Haverich A, et al. Are
universal rRNA gene PCR and sequencing tests an alternative to conventional
culture analysis for infected alloplastic implants? Thorac Cardiovasc Surg
2012;60:114
Specimens from tissue samples only
Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An
antimicrobial stewardship program's impact. Clin Infec Dis 2010;51:1074–80
Cultured samples (positive)
Bernaschi P, Ranno S, Lucignano B, Pizzorno B, Liesenfeld O, Menichella D. Value
of multiplex-PCR (SeptiFast) for the diagnosis of bacterial and fungal pathogens in
newborns and children with suspected sepsis. Clin Microbiol Infect 2010;16:S541
Replaced (abstract) by full-text paper
reported by Lucignano et al.f
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TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Bilkovski R, Sampath R, Huiras M, Durtschi A, Ecker D, Chalfin D, et al. The
Potential Clinical and Economic Value of Rapid Diagnosis of Suspected
Bloodstream Infections using PCR/ESI-MS. 54th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Washington, DC, 5–9 September 2014
Replaced (abstract/poster) by full-text
paper reported by Vincent et al.g
Bingold T, Just L, Roenneberg T, Sartorius S, Hunfeld K, Wissing H. Septifast allows
more rapid detection of liver transplant patients being at risk of sepsis than blood
culture or inflammatory parameters. Infection 2009;37:40
Not target population (patients
scheduled for orthotopic liver
transplant)
Brealey D, Libert N, Pugin J, Chalfin D, Sampath R, Ecker D, et al. RADICAL Study:
Rapid Diagnosis of Suspected Bloodstream Infections using PCR/ESI-MS. 54th
Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington,
DC, 5–9 September 2014
Replaced (abstract/poster) by full-text
paper reported by Vincent et al.g
Burdino E, Milia M, Milano R, Gregori G, Allice T, Ruggiero T, et al. Evaluation of
the SEPTIFAST real-time PCR for rapid identification of blood pathogens in patients
with suspected sepsis: an experience in a northwestern Italy hospital. Clin
Microbiol Infect 2012;18:505
Replaced (abstract) by full-text paper
reported by Burdino et al.h
Cambau E, Courcol R, Veerabudun V, Bretagne S, Durand-Zaleski I, Bastuji-Garin S,
et al. Does Performing DNA Detection in Blood Improves the Microbial Diagnosis of
Severe Bloodstream Infections? First Results of the EVAMICA study. Proceedings
of the 23rd European Congress of Clinical Microbiology and Infectious Diseases,
Berlin, Germany, 27–30 April 2013
Insufficient information to allow
calculation of diagnostic 2 × 2 table
(SeptiFast EVAMICA trial)
Casalta JP, Gouriet F, Roux V, Thuny F, Habib G, Raoult D. Evaluation of the
LightCycler SeptiFast test in the rapid etiologic diagnostic of infectious
endocarditis. Eur J Clin Microbiol 2009;28:569–73
Not target population (patients with
infective endocarditis)
Chaidaroglou A, Manoli E, Gkouziouta A, Gourzi P, Pantou M, Saroglou G, et al.
Clinical impact of a multiplex real-time PCR assay (SeptiFast) for the rapid
detection of pathogens in patients with end-stage heart failure bridged to heart
transplantation with ventricular assist devices. Crit Care 2010;14:S13
Not target population (implantable
ventricular-assist device patients
suspected of infection)
Chaidaroglou A, Manoli E, Gkouziouta A, Aggelaki D, Pantou M, Saroglou G,
et al. The use of a multiplex real-time PCR assay for the detection of bacterial and
fungal bloodstream infections in thoracic allograft recipients. J Heart Lung Transpl
2011;30(Suppl. 1):S146
Not target population (thoracic
allograft recipients)
Chaidaroglou A, Manoli E, Gkouziouta A, Kolovou V, Gourzi P, Pandou M, et al.
The contribution of a multiplex real-time PCR assay (SeptiFast) for the rapid
detection of bacterial and fungal bloodstream infections in patients with end-stage
heart failure bridged to heart transplantation with ventricular assist devices.
Transplantation 2012;94:945
Not target population (implantable
ventricular-assist device patients
suspected of infection)
Chaidaroglou A, Manoli E, Gkouziouta A, Gourzi P, Pantou M, Kolovou V, et al.
The contribution of a multiplex real-time PCR to detect bacterial and fungal
bloodstream infections in a cohort of thoracic allograft recipients. Transplantation
2012;94:77
Not target population (thoracic
allograft recipients)
Chaidaroglou A, Manoli E, Marathias E, Gkouziouta A, Saroglou G, Alivizatos P,
et al. Use of a multiplex polymerase chain reaction system for enhanced
bloodstream pathogen detection in thoracic transplantation. J Heart Lung Transpl
2013;32:707–13
Not target population (thoracic
allograft recipients)
Chan KYY, Lam HS, Cheung HM, Chan AKC, Li K, Fok TF, et al. Rapid
identification and differentiation of Gram-negative and Gram-positive bacterial
bloodstream infections by quantitative polymerase chain reaction in preterm
infants. Crit Care Med 2009;37:2441–7
Cultured samples (positive/negative)
Clerici D, Mancini N, Forno B, Cappelli B, Mastaglio S, Messina C, et al. Molecular
diagnosis by lightcycler? SeptiFast in the preemptive treatment of invasive fungal
infections: a 5 cases report. Haematologica 2009;94:415
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Conen A, Schaub N, Achermann Y, Battegay M, Frei R, Trampuz A. Is multiplex
PCR (SeptiFast) useful for diagnosis of infectious endocarditis? Clin Microbiol Infect
2009;15:S531–2
Not target population (patients with
suspected native or prosthetic valve
infective endocarditis)
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TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Dark P, Dunn G, Chadwick P, Young D, Bentley A, Carlson G, et al. The clinical
diagnostic accuracy of rapid detection of healthcare-associated bloodstream
infection in intensive care using multipathogen real-time PCR technology. BMJ
Open 2011;1:e000181
Replaced (protocol) by full-text paper
reported by Warhurst et al.i
Diamante P, Avolio M, Zamparo S, Grosso S, Tosoni N, Zigante P, et al. [Molecular
diagnosis of sepsis: the experience at the Pordenone hospital.] Riv Ital Medi Lab
2010;6:205–10
Foreign language (Italian)
Disqué C, Kochem AJ, Mühl H, Lorenz MG, Sakka SG. PCR detection of sepsis-inducing
pathogens in blood using SepsiTest™. Int J Med Microbiol 2008;298:7
No outcome data
Disqué C, Sakka S, Wellinghausen N. Klinische Evaluation von SepsiTest™ zum
universellen PCR-Nachweis von bakteriellen Erregern in Vollblut. Der Mikrobiologe
Heft 1 2010;20:13–16
Foreign language (German)
Disqué C, Mühl H, Gebert S, Winter J, Matten J, Wellinghausen N. Microbe
detection in whole blood without blood culture. J Mol Diagn 2010;12:882
Replaced (abstract) by full-text paper
reported by Wellinghausen et al.j
Disqué C, Gebert S, Kochem AJ, Mühl H, Matten J, Sakka SG, et al. A Multicentre
Study of Bacteraemia using a New Commercial Universal 16S rDNA PCR Test. 8th
World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany,
9–13 March 2010
Replaced (abstract) by full-text paper
reported by Wellinghausen et al.j
Disqué C, Mühl H, Keim S, Lorenz MG. Automated extraction of microbial DNA
from whole blood for the universal PCR detection of pathogens. Infection
2011;39:S115–16
No comparator (study investigating
the influence of blood volume)
Disqué C, Linow M, Murphy N. Broad-range microbial DNA isolation from clinical
specimens for universal PCR diagnosis. J Mol Diagn 2012;14:687
Specimens (liquid and tissue) from
different body sites and mixed
population
Disqué C, Keim S, Mühl H, Lorenz MG. DNA extraction from broad range of
micro-organisms for molecular diagnosis. Clin Microbiol Infect 2012;18:775
Specimens (liquid and tissue) from
different body sites and mixed
population)
Draz NI, Taha SE, Abou Shady NM, Abdel Ghany YS. Comparison of broad range
16S rDNA PCR to conventional blood culture for diagnosis of sepsis in the
newborn. Egypt J Med Hum Genet 2013;14:403–11
Not intervention (test) of interest
Dubská L, Vyskocˇilová M, Minaríková D, Jelínek P, Tejkalová R, et al. LightCycler
SeptiFast technology in patients with solid malignancies: clinical utility for rapid
etiologic diagnosis of sepsis. Crit Care 2012;16:404
Not target population (patients with
solid malignancy)
Elwan AE, Zarouk WA. Diagnosis of neonatal bacterial sepsis by polymerase chain
reaction. J Biol Sci 2009;9:533–40
Not intervention (test) of interest
Enomoto M, Morioka I, Morisawa T, Yokoyama N, Matsuo M. A novel diagnostic
tool for detecting neonatal infections using multiplex polymerase chain reaction.
Neonatology 2009;96:102–8
Not intervention (test) of interest
Gosiewski T, Jurkiewicz-Badacz D, Sroka A, Brzychczy-Wloch M, Bulanda M.
A novel, nested, multiplex, real-time PCR for detection of bacteria and fungi in
blood. BMC Microbiol 2014;14:144
Not intervention (test) of interest
Greco R, Clerici D, Mancini N, Clementi M, Lorentino F, Crucitti L, et al. Multiplex
PCR-based assay (SeptiFast) for rapid detection of pathogens in febrile
neutropenia: results in 273 consecutive patients. Bone Marrow Transplant
2012;47:S77–8
Replaced (abstract) by full-text paper
reported by Barbanti et al.k
Greco R, Mancini N, Lorentino F, Crucitti L, Barbanti C, Forcina A, et al. Rapid
molecular detection of pathogens in 1941 blood samples from 516 consecutive
patients with febrile neutropenia. Bone Marrow Transplant 2014;49:S334
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Grif K, Heller I. Improvement of detection of bacterial pathogens in normally sterile
body sites with a focus on orthopedic samples by use of a commercial 16S rRNA
broad-range PCR and sequence analysis. J Clin Microbiol 2012;50:2250–4
Specimens (liquid and tissue) from
different body sites
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TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Haag H, Locher F, Nolte O. Molecular diagnosis of microbial aetiologies using
SepsiTest™ in the daily routine of a diagnostic laboratory. Diagn Microbiol
Infect Dis 2013;76:413–18
Specimens (liquid and tissue) from
different body sites
Halasz E, Petro M, Bojtos I, Myszoglad R, Simon J. Rapid diagnosis of sepsis with
molecular biological methods. Clin Chem Lab Med 2012;50:eA32–3
Insufficient information to allow
calculation of diagnostic 2 × 2 table
(not a diagnostic study)
Halliday CL, Sorrell TC, Chen SCA. Detection of multiple fungal species in blood
samples by real-time PCR: an interpretative challenge. J Clin Microbiol
2014;52:3515–16
Letter/comment with no details of
intervention
Hettwer S, Wilhelm J, Hammer D, Schürmann M, Amoury M, Scheubel S, et al.
Sepsis in the emergency department: pathogen identification by blood cultures
and PCR. Crit Care 2009;13:S154
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Holmes C, Kirk-Granger H, Perera N. The Clinical Usefulness of Multiplex PCR for
the Detection of Bacteria and Fungi in the Blood of Patients with Haematological
Malignancies. Proceedings of the 24th European Congress of Clinical Microbiology
and Infectious Diseases, Barcelona, Spain, 10–13 May 2014
Not target population
(haematological malignancies)
Horvath A, Peto Z, Urban E, Vagvolgyi C, Somogyvari F. A novel, multiplex, real-
time PCR-based approach for the detection of the commonly occurring pathogenic
fungi and bacteria. BMC Microbiol 2013;13:300
Not intervention (test) of interest
Idelevich EA, Niederbracht Y, Tafelski S, Nachtigall I, Berdel WE, Peters G, et al.
Clinical value of the SeptiFast Multiplex PCR test in hematologic patients with
neutropenic fever or sepsis: interim study results. Int J Med Microbiol 2011;301:7
Replaced (abstract) by full-text paper
reported by Idelevich et al.l
Irwin AD, Barton T, Grant A, Williams R, Carrol ED. SepsiTest molecular diagnosis
of bacteraemia in febrile paediatric patients. Clin Microbiol Infect 2012;18:505
Not target population (patients with
increased levels of C-reactive protein)
Jordan JA, Durso MB, Butchko AR, Jones JG, Brozanski BS, Durso MB, et al.
Evaluating the near-term infant for early onset sepsis: progress and challenges to
consider with 16S rDNA polymerase chain reaction testing. J Mol Diagn
2006;8:357–63
Not intervention (test) of interest
Jordana-Lluch E, Carolan HE, Giménez M, Sampath R, Ecker DJ, Quesada D, et al.
Rapid diagnosis of bloodstream infections with PCR followed by mass
spectrometry. PLOS ONE 2013;8:e62108
Not intervention (test) of interest
(used older extraction method on
PLEX-ID system, thus not comparable
to the current IRIDICA platform)
Josefson P, Stralin K, Ohlin A, Ennefors T, Dragsten B, Andersson L, et al.
Evaluation of a commercial multiplex PCR (SeptiFast) in the aetiological
diagnosis of community-acquired bloodstream infections. Clin Microbiol Infect
2010;16:S541–2
Replaced (abstract) by full-text paper
reported by Josefson et al.m
Kalenka A, Timm J, Schmid S, Beck G. Value of LightCycler SeptiFast in detection
of ventilator-associated pneumonia. Intens Care Med 2009;35:S197
Not target population (patients with
suspected ventilator associated
pneumonia)
Kalenka A, Schmid S, Timm J, Beck G. Lightcycler SeptiFast as a tool to enhance
the detection of bacteremia and fungemia in patients with intraabdominal
infection during antimicrobiological therapy. Intens Care Med 2009;35:S196
No comparator (i.e. not vs. blood
culture)
Kaleta EJ, Clark AE, Johnson DR, Gamage DC, Wysocki VH, Cherkaoui A, et al.
Use of PCR coupled with electrospray ionization mass spectrometry for rapid
identification of bacterial and yeast bloodstream pathogens from blood culture
bottles. J Clin Microbiol 2011;49:345–53
Cultured samples (positive)
Karam El Din ZA, Mokhtar E, El-Shereef A, Abd El KA, Al-Tounisy A. Rapid
diagnosis of neonatal sepsis caused by yeast infection. Mycoses 2012;55:75
Not intervention (test) of interest
Kim B, Park S, Kim T, Kim J, Rim D, Choi T, et al. [Clinical efficacy evaluation of
multi-parameter realtime polymerase chain reaction for the central venous
catheter-related blood stream infection.] Infect Chemother 2011;43:240–4
Foreign language (Korean)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Kuhn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A. Molecular diagnosis
of the etiological agents of infectious endocarditis using commercial universal
rRNA gene PCR plus sequencing tests. Infection 2011;39:S124–25
Replaced (abstract) by full-text paper
reported by Kuhn et al.n
Kuhn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A. Evaluation of
commercial universal rRNA gene PCR plus sequencing tests for identification of
bacteria and fungi associated with infectious endocarditis. J Clin Microbiol
2011;49:2919–23
Not target population (patients with
suspected infectious endocarditis and
used valvular and blood samples for
analysis)
Lefort A, Chartier L, Sendid B, Wolff M, Mainardi J, Podglajen I, et al. Diagnosis,
management and outcome of Candida endocarditis. Clin Microbiol Infect
2012;18:E99–109
Not target population (patients with
Candida endocarditis)
Lehmann LE, Alvarez J, Hunfeld KP, Goglio AP, Kost GJ, Louie RF, et al. Model
analysis of clinical utility of PCR in microbiological testing for sepsis. Infection
2009;37:44
Not intervention (test) of interest
Leli C, Cardaccia A, D'Alo F, Ferri C, Bistoni F, Mencacci A. A prediction model for
real-time PCR results in blood samples from febrile patients with suspected sepsis.
J Med Microbiol 2014;63:649–58
Study aim to develop prediction
model from positive SepsitFast results
only
Liberto MC, Puccio R. Applications of LightCycler Staphylococcus M-GRADE assay
to detect Staphylococcus aureus and coagulase-negative staphylococci in clinical
blood samples and in blood culture bottles. Infezioni in Medicina 2006;14:71–6
Not intervention (test) of interest
Liu CL, Ai HW, Wang WP, Chen L, Hu HB, Ye T, et al. Comparison of 16S rRNA
gene PCR and blood culture for diagnosis of neonatal sepsis. Arch Pediatrie
2014;21:162–9
Not intervention (test) of interest
Lodes U, Lippert H. [Molecular biological sepsis diagnostic using multiplex PCR in
surgical intensive care as suitable alternative to conventional microbial culture –
a representative overview.] Zentralbl Chir 2011;136:135–42
Foreign language (German)
Markota A, Golle A, Sinkovic A. Polymerase chain reaction analysis in patients with
sepsis. Intens Care Med 2013;39:S453
Diagnostics metrics data (from
patients and samples) included in a
full-text study by Markota et al.o
Martinez MDM, Arredondo AR, Alvarez EM, Prieto AMP, Caballero MP, Mari JMN.
Lightcycler septifast trading system in molecular microbiological diagnosis of
neonatal sepsis. J Matern-Fetal Neonat Med 2010;23(Suppl. 1):156
Coagulase-negative staphylococci
detection only
Mencacci A, Leli C, Montagna P, Cardaccia A, Meucci M, Bietolini C, et al.
Diagnosis of infective endocarditis: comparison of the LightCycler SeptiFast
real-time PCR with blood culture. J Med Microbiol 2012;61:881–3
Not target population (patients with
suspected infective endocarditis)
Mencacci A, Leli C, Cardaccia A, Meucci M, Moretti A, D'Alo F, et al. Procalcitonin
predicts real-time PCR results in blood samples from patients with suspected
sepsis. PLOS ONE 2012;7:e53279
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Merisescu M, Luminos M, Jugulete G, Florea D, Streinu-Cercel A. Molecular
diagnosis of severe bacterial sepsis in children. Crit Care 2012;16:67
Cultured samples (blood and/or fluids)
Merisescu M, Jugulete G, Streinu-Cercel A, Luminos M. Plex Id role in the
diagnosis of acute bacterial sepsis with E-coli in children. Pediatr Crit Care Med
2014;15(Suppl. 1):150–1
Klebsiella pneumoniae detection only
(no details on sample type, comparator
methods or useable outcome data)
Meyer T, Franke G, Polywka S, Lutgehetmann M, Gbadamosi J, Magnus T, et al.
Improved detection of bacterial central nervous system infections by use of a
broad-range PCR assay. J Clin Microbiol 2014;52:1751–3
Specimens from cerebrospinal fluid
samples
Molina JM, Cordoba J, Ramirez P, Gobernado M. [Automatic detection of bacterial
and fungal infections in blood.] Enferm Infect Microbiol Clin 2008;26(Suppl. 9):75–80
Foreign language (Spanish)
Mongelli G, Romeo MA, Denaro C, Gennaro M, Fraggetta F, Stefani S. An added
value of multi-pathogen probe-based real-time PCR SeptiFast in the rapid
diagnosis of bloodstream infections in patients with bacteremia. J Med Microbiol
2015;64:670–5
Not target population (febrile
patients with suspected bacteraemia)
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TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Moore MS, McCann CD, McCarroll M, May L, Jordan JA. Direct detection of
bacteria from blood of ED and ICU patients being evaluated for bloodstream
infection. J Mol Diagn 2014;16:727
Not intervention (test) of interest
Mundy L, Hiller JE. Rapid Molecular Assays for the Diagnosis of Sepsis and
Identification of Sepsis Causing Pathogens. Adelaide, SA: Adelaide Health
Technology Assessment (AHTA). Horizon Scanning Prioritising Summary. 2010.
URL: www.horizonscanning.gov.au/internet/horizon/publishing.nsf/Content/
C8A5BA60BD01A93ECA257757000A2015/$File/Volume_27_June_2010_sepsis.
pdf (accessed April 2016)
Review
Niederbracht Y, Idelevich EA, Penner H, Berdel WE, Peters G, Silling G, et al.
Applicability of a commercial multiplex PCR test for identification of true blood
stream infections with coagulase-negative staphylococci in neutropenic
hematological patients. Int J Med Microbiol 2013;303:13
Coagulase-negative staphylococci
detection only
Nieman A, Rozemeijer W, de Jong E, Beishuizen B, van Agtmael M, Savelkoul P,
et al. Molecular detection of bacterial bloodstream infections: validation of the
SepsiTest™ assay. Ned Tijdschr Med Microbiol 2010;18:109
Preclinical validation study
Nieman A, De Jong E, Beishuizen B, Koek A, Savelkoul PH, Schade RP. Molecular
detection of bacterial bloodstream infections: the SepsiTest assay. Clin Microbiol
Infect 2011;17:S729
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Novak-Frazer L, Rautemaa-Richardson R, Denning D, Bowyer P. Multiplex PCR for
the rapid diagnosis of skin/soft tissue and bloodstream infections. Clin Microbiol
Infect 2012;18:122–3
Specimens from whole blood and
wound swabs (and insufficient
information to allow calculation of
diagnostic 2 × 2 table)
Ohlin A, Backman A, Ewald U, Schollin J, Bjorkqvist M. Diagnosis of neonatal
sepsis by broad-range 16S real-time polymerase chain reaction. Neonatology
2012;101:241–6
Not intervention (test) of interest
Orszag P, Disqué C, Keim S, Lorenz M, Wiesner O, Hadem J, et al. Monitoring of
patients supported by extracorporeal membrane oxygenation for systemic
infections by broad-range rRNA gene PCR amplification and sequence analysis.
J Clin Microbiol 2013;52:307–11
Not target population (patients
supported by extracorporeal
membrane oxygenation)
Ortiz Ibarra F, Reyna J, Trevino P, Fernandez L, Lara G, Valenzuela E, et al.
A standardized protocol for the multiplex PCR technique Septifast Roche for
neonatal samples with suspected sepsis. Crit Care 2012;16:79
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Palomares JC, Puche B, Martos A, Lucena F, Marin M, Martin-Mazuelos E. Rapid
molecular diagnosis of severe sepsis in patients with SIRS. Clin Microbiol Infect
2009;15:S529–30
Replaced (abstract) by full-text paper
reported by Palomares et al.p
Pleskova T, Greplova K, Bacikova L, Dubska L. What is the added value of
molecular microbiology in sepsis? Clin Chem Lab Med 2011;49:S610
Cultured samples (positive) and
unclear if cancer patients have sepsis
Popov DA, Vostrikova TI. [The first experience of application of PCR techniques in
real-time mode to diagnose bacteriemia during postoperational period in
cardiosurgery patients.] Klin Labor Diagn 2011;8:49–52
Foreign language (Russian)
Raineri SM, Canzio D, Sarno C, Cascio ND, Mineo G, Chiaramonte R, et al.
LightCycler SeptiFast in early diagnosis of sepsis: our experience. Crit Care
2009;13:S153
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Ratanarat R, Cazzavillan S, Ricci Z, Rassu M, Segala C, de Cal M, et al. Usefulness
of a molecular strategy for the detection of bacterial DNA in patients with severe
sepsis undergoing continuous renal replacement therapy. Blood Purificat
2007;25:106–11
Not intervention (test) of interest
Reier-Nilsen T, Farstad T, Nakstad B, Lauvrak V, Steinbakk M. Comparison of broad
range 16S rDNA PCR and conventional blood culture for diagnosis of sepsis in the
newborn: a case control study. BMC Pediatr 2009;9:5
Not intervention (test) of interest
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TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Rogina P, Skvarc MM, Stubljar DD. Diagnostic utility of broad range bacterial 16S rRNA
gene PCR with degradation of human and free bacterial DNA in bloodstream infection
is more sensitive than an in-house developed PCR without degradation of human and
free bacterial DNA.Mediators Inflamm 2014;2014:108592
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Sahre H, Vogel S, Park JW, Weber S. [Sepsis-diagnostics with help of SeptiFast®-
systems: experience on a internal intensive care unit.] Infection 2007;35:9–10
Foreign language (German)
Sakka S, Wellinghausen N, Kochem AJ, Disqué C, Muehl H, Gebert S, et al.
A multicentre study of bacteraemia using a new commercial universal 16S rDNA
PCR test. Inflamm Res 2010;59:s137
Replaced (abstract) by full-text paper
reported by Wellinghausen et al.j
Sampath R. Advanced techniques for detection and identification of viral
contaminants using the Ibis PLEX-ID universal biosensor. Pda J Pharm Sci Tech
2011;65:690
Conference abstract not available
Santolaya ME, Farfan MJ, De La Maza, Farfan MJ. Diagnosis of bacteremia in
febrile neutropenic episodes in children with cancer: microbiologic and molecular
approach. Pediatr Infect Dis J 2011;30:957–61
Not intervention (test) of interest
Schaub N, Boldanova T, Noveanu M, Arenja N, Hermann H, Twerenbold R, et al.
Incremental value of multiplex real-time PCR for the early diagnosis of sepsis in the
emergency department. Swiss Med Wkly 2014;144:w13911
Diagnostic metrics data included in
Schaub et al.
q
Shaat SS, El Shazly SA, Badr Eldin MM, Barakat SS, Hashish MH. Role of
polymerase chain reaction as an early diagnostic tool for neonatal bacterial sepsis.
J Egypt Public Health Assoc 2013;88:160–4
Not intervention (test) of interest
Sitnik R, Marra A, Petroni R, Ramos O, Martino M, Pasternak J, et al. SeptiFast for
diagnosis of sepsis in severely ill patients from a Brazilian Hospital. J Med Diagn
2011;13:736
Replaced (abstract) by full-text paper
reported by Sitnik et al.r
Skvarc M, Stublar D, Rogina P. Broad-range 16S rRNA gene PCR using SepsiTest
in conjunction with valid clinical data and sepsis biomarkers improve sepsis
diagnostics. Int J Med Microbiol 2012;302:6
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Steinmann J, Buer J, Paul A, Saner F, Rath PM. Diagnostic performance of
multiplex PCR for diagnosis of bloodstream infections in liver transplant recipients
with suspected sepsis. Int J Med Microbiol 2011;301:51
Replaced (abstract) by full-text paper
reported by Rath et al.s
Stubljar D, Rogina P, Skvarc M, Pavlovic A. Diagnostic Accuracy of sCD14
(Presepsin) is Comparable to Procalcitonin (PCT) for the Diagnosis of Bacterial
Infections in Critically Ill Patients. Proceedings of the 23rd European Congress of
Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27–30 April 2013
Not intervention (test) of interest
Tafelski S, Nachtigall I, Idelevich E, Silling G, Becker K, Faust J, et al. Impact of
Septi-Fast for Pathogen Detection in Critical-Care Patients with Sepsis: Results from a
Randomized Controlled Clinical Trial. Proceedings of the 23rd European Congress of
Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27–30 April 2013
Replaced (abstract) by full-text paper
reported by Tafelski et al.t
Torres-Martos E, Pérez-Ruiz M, Pedrosa-Corral I, Peña-Caballero M, Jiménez-Valera MM,
Pérez-Ramirez MD, et al. [Evaluation of the LightCycler SeptiFast test in newborns and
infants with clinical suspicion of sepsis.] Enferm Infecc Microbiol Clin 2013;31:375–9
Foreign language (Spanish)
Tsalik EL, Jones D, Nicholson B, Caram LB, Liesenfeld O, Fowler VG, et al.
Detection of bacterial and fungal pathogens associated with sepsis in patients
presenting to the emergency room. Intens Care Med 2009;35:S196
Insufficient information to allow
calculation of diagnostic 2 × 2 table
Vrsajkov V, Pejakovic J, Dragic Z, Radanovic B. Pathogen identification in septic
patients: clinical importance of PCR and blood cultures. Intens Care Med
2014;40(Suppl. 1):259
Not intervention (test) of interest
Warhurst G, Dunn G, Chadwick P, Blackwood B, McAuley D, Perkins GD, et al.
Rapid detection of health-care-associated bloodstream infection in critical care
using multipathogen real-time polymerase chain reaction technology: a diagnostic
accuracy study and systematic review. Health Technol Assess 2015;19(35)
Replaced (Health Technology
Assessment monograph) by full-text
journal paper reported by
Warhurst et al.i
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TABLE 55 Studies excluded from the clinical review (continued )
Reference details Reason for exclusion
Zerweck A, Raepple D, Finck A, Finke J, Bertz H. PCR-based molecular diagnostic
tool (Septifast) in septic patients undergoing induction therapy or stem cell
transplantation in haematological malignancies. Bone Marrow Transplant
2010;45:S228
Not target condition (patients
undergoing induction therapy and
or stem cell transplantation)
Ziegler I, Josefson P, Olcen P, Molling P, Stralin K. Quantitative data from the
SeptiFast real-time PCR is associated with disease severity in patients with sepsis.
BMC Infect Dis 2014;14:155
Diagnostic metrics data (secondary
analysis) included in Josefson et al.m
a Idelevich EA, Niederbracht Y, Tafelski S, Nachtigall I, Berdel WE, Peters G, et al. Clinical Value of the SeptiFast Multiplex
PCR test in hematologic patients with neutropenic fever or sepsis: interim study results. Int J Med Microbiol 2011;301:7.
b Rodrigues C, Dos Santos MS, Filho HHC, Charbel CE, da Silva LCS, Rossi F, et al. Rapid molecular test (SeptiFast) reduced
time for adjustment of antibiotic treatment in comparison with conventional blood cultures in critically ill sepsis patients:
a randomized controlled clinical trial (preliminary results). Crit Care 2013;17:P26.
c Metzgar D, Frinder M, Rothman R, Peterson S, Carroll KC, Zhang S, et al. Ibis Biosciences, 2015 (unpublished).
d Avolio M, Diamante P, Modolo M, De Rosa R, Stano P, Camporese A. Direct molecular detection of pathogens in blood
as specific rule-in diagnostic biomarker in patients with presumed sepsis: our experience on a heterogeneous cohort of
patients with signs of infective systemic inflammatory response syndrome. Shock 2014;42:86–92.
e Avolio M, Diamante P, Zamparo S, Modolo M, Grosso S, Zigante P, et al. Molecular identification of bloodstream
pathogens in patients presenting to the emergency department with suspected sepsis. Shock 2010;34:27–30.
f Lucignano B, Ranno S., Liesenfeld O, Pizzorno B, Putignani L, Bernaschi P, et al. Multiplex PCR allows rapid and accurate
diagnosis of bloodstream infections in newborns and children with suspected sepsis. J Clin Microbiol 2011;49:2252–8.
g Vincent J-L, Brealey D, Libert N, Abidi N, O'Dwyer M, Zacharowski K, et al. RApid Diagnosis of Infection in the critiCALly
ill (RADICAL), a multicenter study of molecular detection in bloodstream infections, pneumonia and sterile site infections.
Crit Care Med 2015;43:2283–91.
h Burdino E, Ruggiero T, Allice T, Milia M, Gregori G, Milano R, et al. Combination of conventional blood cultures and the
SeptiFast molecular test in patients with suspected sepsis for the identification of bloodstream pathogens. Diagn Microbiol
Infect Dis 2014;79:287–92.
i Warhurst G, Maddi S, Dunn G, Ghrew M, Chadwick P, Alexander P, et al. Diagnostic accuracy of SeptiFast
multi-pathogen real-time PCR in the setting of suspected healthcare-associated bloodstream infection. Intens Care
Med 2015;41:86–93.
j Wellinghausen N, Kochem A-J, Disqué C, Mühl H, Gebert S, Winter J, et al. Diagnosis of bacteremia in whole-blood
samples by use of a commercial universal 16S rRNA gene-based PCR and sequence analysis. J Clin Microbiol
2009;47:2759–65.
k Barbanti MC, Greco R, Mancini N, Orsini A, Crucitti L, Forcina A, et al. Improving the diagnostic algorithm for sepsis:
adjuvant role of SeptiFast in 491 consecutive hematological patients. Bone Marrow Transplant 2015;50:S405.
l Idelevich EA, Silling G, Niederbracht Y, Penner H, Sauerland MC, Tafelski S, et al. Impact of multiplex PCR on
antimicrobial treatment in febrile neutropenia: a randomized controlled study. Med Microbiol Immunol
2015;204:582–92.
m Josefson P, Stralin K, Ohlin A, Ennefors T, Dragsten B, Andersson L, et al. Evaluation of a commercial multiplex PCR test
(SeptiFast) in the etiological diagnosis of community-onset bloodstream infections. Eur J Clin Microbiol Infect Dis
2011;30:1127–34.
n Kuhn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A. Evaluation of commercial universal rRNA gene PCR plus
sequencing tests for identification of bacteria and fungi associated with infectious endocarditis. J Clin Microbiol
2011;49:2919–23.
o Markota A, Seme K, Golle A, Poljak M, Sinkovicˇ A. SeptiFast real-time PCR for detection of bloodborne pathogens in
patients with severe sepsis or septic shock. Collegium Antropol 2014;38:829–33.
p Palomares J, Puche B, Martos A, Lucena F, Marin E, Martin-Mazuelos E. Rapid Molecular Diagnosis of Severe Sepsis in
Patients with Symptoms of Severe Sepsis. 19th European Congress of Clinical Microbiology and Infectious Diseases,
Helsinki, Finland, 18–19 May 2009.
q Schaub N, Boldanova T, Noveanu M, Arenja N, Hermann H, Twerenbold R, et al. Incremental value of multiplex real-time
PCR for the early diagnosis of sepsis in the emergency department. Swiss Med Wkly 2014;144:w13911.
r Sitnik R, Marra AR, Petroni RC, Ramos OP, Martino MD, Pasternak J, et al. SeptiFast for diagnosis of sepsis in severely ill
patients from a Brazilian hospital. Einstein (Sao Paulo) 2014;12:191–6.
s Rath P, Saner F, Paul A, Lehmann N, Steinmann E, Buer J, et al. Multiplex PCR for rapid and improved diagnosis of
bloodstream infections in liver transplant recipients. J Clin Microbiol 2012;50:2069–71.
t Tafelski S, Nachtigall I, Adam T, Bereswill S, Faust J, Tamarkin A, et al. Randomized controlled clinical trial evaluating
multiplex polymerase chain reaction for pathogen identification and therapy adaptation in critical care patients with
pulmonary or abdominal sepsis. J Int Med Res 2015;43:364–77.
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Appendix 4 Study and population characteristics
of the included studies
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Appendix 5 Diagnostic test accuracy,
additional information
TABLE 59 Deviance information criterion for SeptiFast compared with blood culture. Standard model (without
covariate adjustment) and metaregression models (with covariates indicating subgroups)
Model DICa
Covariate adjustment
Standard model 630.10
Age categories 624.55
Febrile neutropenia 630.78
Clinical setting 630.26
Inclusion/exclusion of contaminants 631.43
DIC, deviance information criterion.
a Note that lower values of DIC are favourable, suggesting a more parsimonious model.
TABLE 60 Coefficient estimates for metaregression model adjusting for the proportion of patients receiving
antibiotics prior to blood draw
Model parameter Regression coefficient, median (95% CrI), logit scale
Sensitivity –0.17 (–1.16 to 0.78)
Specificity –0.58 (–1.24 to 0.10)
Note that the regression terms are considered to significantly affect sensitivity and/or specificity if the CrIs exclude zero
(on the logit scale).
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Appendix 6 Literature search strategies for the
review of cost-effectiveness: a MEDLINE example
MEDLINE search strategy Details
Database searched Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid MEDLINE
Platform or provider used Ovid SP
Date of coverage 1948 to May 2015
Search undertaken Initial search February 2015
Updated search May 2015
Search strategy
1. exp Sepsis/
2. sepsis.mp.
3. septic?emia.mp.
4. Shock, Septic/
5. ((septic or endotoxic or toxic) adj shock).tw.
6. Bacteremia/
7. bacter?emia.mp.
8. Fungemia/
9. fung?emia.mp.
10. Systemic Inflammatory Response Syndrome/
11. sirs.mp.
12. blood$ infection$.tw.
13. blood poison$.tw.
14. or/1-13
15. septifast.mp.
16. lightcycler.mp.
17. 15 or 16
18. 14 and 17
19. sepsitest.mp.
20. iridica.mp.
21. (plex id or plex-id).mp.
22. or/19-21
23. exp Polymerase Chain Reaction/
24. polymerase chain reaction$.tw.
25. pcr$.mp.
26. Gene Amplification/
27. Nucleic Acid Amplification Techniques/
28. or/23-27
29. Genes, Bacterial/ or Genes, Fungal/
30. (exp bacteria/ or exp Fungi/) and exp Nucleic Acids/
31. ((bacteri$ or fung$) adj3 (dna or gene$ or nucleic acid$)).tw.
32. blood culture$.tw.
33. or/29-32
34. 14 and 28 and 33
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35. 18 or 22 or 34
36. Animals/ not (Humans/ and Animals/)
37. 35 not 36
38. limit 37 to yr=“2006 -Current”
39. exp “Costs and Cost Analysis”/
40. Economics/ (26570)
41. exp Economics, Hospital/
42. exp Economics, Medical/
43. Economics, Nursing/
44. exp models, economic/
45. Economics, Pharmaceutical/
46. exp “Fees and Charges"/
47. exp Budgets/
48. budget$.tw.
49. ec.fs.
50. cost$.ti.
51. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
52. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
53. (price$ or pricing$).tw.
54. (financial or finance or finances or financed).tw.
55. (fee or fees).tw.
56. (value adj2 (money or monetary)).tw.
57. quality-adjusted life years/
58. (qaly or qalys).af.
59. (quality adjusted life year or quality adjusted life years).af.
60. or/39-59
61. 38 and 60
62. 38 not 61
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Appendix 7 Population of key parameters by
clinical estimates: reproduction of the correspondence
sent to the clinical experts
Confidential until published 
The task for the clinical expert is to provide a midpoint estimate together with a range for the 
variables shown in Tables 1 and 2. We would like this estimate provided in terms of a single positive 
test result.  Tables 1 and 2 differ in that the Table 1assumes that the results from standard blood 
culture process are concordant with the positive test result, whereas Table 2 assumes that the results 
from the standard blood culture process are negative. It is acknowledged that blood culture results 
would not be known when the result from the rapid test becomes available, but it was believed that 
formulating the question in this manner would make the task easier for the clinician, and these data 
can be weighted by rates of true positives and false positives by the researchers. 
 
Illustrative examples are provided. For example, If you believed that the information provided by a 
positive SeptiFast result would produce a net average reduction in ICU length of stay of 0.1 days 
compared with not having the information from SeptiFast then -0.1 would be entered into the top left 
cell. Were it believed that a positive MALDI-TOF MS test would be associated with a net average 
reduction of 0.001 in 30-day mortality then -0.001 would be entered into the bottom right cell.  If it is 
believed that the answers differ for subgroups, such as children and neonates, people who are 
immunocompromised, those with recent antibiotic use, and people with suspected health care 
acquired infection and suspected community acquired infection, then please duplicate the tables with 
appropriate data. 
 
In order to aid clinical judgement data that may be considered useful is contained following Table 2 
although the generalisability of the data to treatment in England in 2015 needs to be assessed. These 
data have been split into two categories, data obtained from systematic reviews, and additional data. 
The data from the systematic reviews were identified either through the review of diagnostic accuracy 
undertaken by ScHARR or by a review undertaken by the NICE Guideline Development Group when 
constructing the draft guidelines on antimicrobial stewardship. 
 
The additional data has been sourced from studies identified within the cost effectiveness searches 
undertaken by ScHARR. These were supplemented by citation searching. As such, the results cannot 
be classed as derived from a systematic review. 
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Table 1: Template to be completed by the clinical expert. Assuming that the result from 
the blood culture process is positive and in agreement with the test 
 LightCycler 
SeptiFast Test 
MGRADE 
SepsiTest IRIDICA BAC 
BSI 
MALDI-TOF MS 
Average net effect on ICU 
length of stay 
    
Average net effect on 
hospital length of stay 
    
Average net effect on the 
cost of antimicrobials 
    
Net effect on 30-day 
mortality 
    
 
 
Table 2: Template to be completed by the clinical expert. Assuming that the result from 
the blood culture process is negative 
 LightCycler 
SeptiFast Test 
MGRADE 
SepsiTest IRIDICA BAC 
BSI 
Average net effect on ICU 
length of stay 
   
Average net effect on 
hospital length of stay 
   
Average net effect on the 
cost of antimicrobials 
   
Net effect on 30-day 
mortality 
   
 
Information that may be considered useful:  
Data from systematic reviews 
• From an RCT1 the mean time to SeptiFast result was 15.9 hours compared with 38.1 hours for 
blood culture plus MALDI-TOF MS. No data from RCTs on the timings of a result being 
known were available for SepsiTest or IRIDICA BAC BSI. The same RCT 1  reports the mean 
time spent in ICU as 34 days for the SeptiFast and 32 days for blood culture plus MALDI-
TOF MS. This was not statistically significant. 
 
• An RCT2 of de-escalation of antimicrobials recruiting 116 patients with severe sepsis reported 
statistically significantly greater rates of superinfection in the de-escalation group (27% vs 
11%; p-value = 0.03) and in the mean number of antibiotic days (9 vs 7.5; p-value = 0.03). 
There was a non-statistically significant increase in median duration of ICU stay (9 days vs 8 
days; p-value = 0.71) in the de-escalation arm 
 
Additional data 
• A paper3 reports the implementation of an evidence-based intervention that integrated 
MALDI-TOF MS, rapid antimicrobial susceptibility testing, and near–real-time antimicrobial 
stewardship practices. Comparison of results before and after were made. The mean hospital 
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length of stay after blood stream infection onset in the pre-intervention group survivors (n = 
100) was 9.9 versus 8.1 days in the intervention group (n=101; p-value=.01). Within a 
multivariate model receiving active antibiotic therapy at 48 hours was associated with a 
hazard ratio for discharge of 2.90 (95% CI 1.15-7.33; p-value = 0.02) and the intervention 
was associated with a hazard ratio for discharge of (95% CI 1.01-1.88; p-value = 0.04). Total 
hospitalisation costs was $45,709 in the pre-intervention cohort vs $26,162 in the 
intervention.  
 
• A further paper reporting a pre–post quasi-experimental study analysed the impact of 
MALDI-TOF MS with an antimicrobial stewardship team.4 The intervention (n = 256) 
decreased time to organism identification (84.0 vs 55.9 hours, p-value  < .001), and improved 
time to effective antibiotic therapy (30.1 vs 20.4 hours, p-value = .021), optimal antibiotic 
therapy (90.3 vs 47.3 hours, p-value  < .001) and length of ICU stay (14.9 vs 8.3 days, p-value 
= .014) compared with pre-intervention (n=245). 30-day all-cause mortality was lower in the 
intervention arm compared with pre-intervention (12.73 vs 20.3%. p-value  = .021) as was 
length of hospitalisation (14.2 vs 11.4 days, p-value  = .066) 
 
• An Italian observational, propensity matched analysis5 comparing a retrospective cohort with 
a prospective cohort (using SeptiFast) in haematological patients – typically acute myeloid 
leukaemia. Propensity matching was undertaken for: definitive blood culture; positive blood 
cultures; negative blood cultures; (and patients with positive SeptiFast and patients with 
negative SeptiFast results. No differences were observed in the length of stay or in changes in  
management. The mortality difference in the original propensity score matching was not 
significant 8.24 vs 13.48 p = 0.39). However, in a more stringently matched group SeptiFast 
was reported to have better mortality rates (3.13% compared with 14.71% p-value =0.04). 
There were lower costs (€431; p-value = 0.05) in the prospective cohort compared with the 
retrospective cohort. 
 
• One study6 aimed to evaluate the economic impact of SeptiFast via a cost-minimisation study. 
48 patients were in the SeptiFast group with 54 in control. The paper concluded that there was 
a 94.6% chance of cost savings associated with use of SeptiFast when samples were run per 
batch. A large proportion of these savings were from reduced ICU length of stay although this 
could be heavily confounded by the demographic and clinical data of the SeptiFast and 
control groups. For example, there were 20 patients with heart surgery in the control and 2 in 
the SeptiFast group, and 4 polytrauma / head injuries in the control group compared with 20 
in the SeptiFast group. 
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• A prospective, observational trial in 2 German university hospitals, 1 Spanish, 1 American 
and 1 Italian tertiary hospital compared the use of SeptiFast with Blood Culture.7 This study 
estimated that if SeptiFast had been used then there would have been 22.8 days reduction in 
inadequate treatment per 100 tests. The results for those in ICU alone were taken and it was 
estimated that the SeptiFast could have presented 5 mortalities from 221 investigated sepsis 
episodes within 30 days of discontinuing antimicrobial treatment.8. However, the data relating 
inadequate treatment to mortality were taken from studies published in 2000 or earlier.9,10 
 
• A study in Texas compared the outcomes of 112 patients with antibiotic-resistant Gram-
negative bacteraemia, during January 2009 – November 2011 with 157 patients during 
February 2012 to June 2013 post intervention following the introduction of an intervention 
(MALDI-TOF MS and antimicrobial stewardship).11 Time to initiation of active treatment 
was 90 hours pre-intervention and 32 hours post intervention (p<0.001). There were 33 (21%) 
and 10 (9%) all-cause mortalities observed in the pre-intervention cohort and the intervention 
cohort respectively. In multivariate logistic regression the intervention was a significant 
predictor of survival (OR=0.28, 0.12-0.71; p-value =0.008). A significant reduction in 
average total hospital costs was observed from $78,991 to $52,693. 
 
• A paper by Martiny et al.,12 reports that the use of MALDI-TOF MS resulted in the 
modification of in treatment in 21/157 adults and 1/40 paediatrics 
 
• A Spanish retrospective matched cohort study13 attempted to determine the attributable 
mortality and excess length of stay associated with inadequate empirical antimicrobial therapy 
between 1997 – 2006. Therapy was considered inadequate when no effective drug against the 
isolated pathogen(s) was included in the empirical antibiotic treatment within the first 24 
hours of admission to the ICU, or the doses and pattern of administration were not in 
accordance with current medical standards. From 87 matched pairs 59 (67.8%) died in the 
inadequate group compared with 25 (28.7%) in the control group. Removing pairs with 
nosocomial infection still showed a 31.4% excess in mortality (65.7% vs 34.3%).  In those 
without a nosocomial infection there was a significant reduction in the length of stay in ICU 
associated with adequate treatment (7 vs 9 days; p-value = 0.02) 
 
• Using a generalised linear model, adjusted for confounders, Zilberberg et al.,14 estimated that 
the excess length of hospitalisation was 7.7 days (95% CI 0.6-13.5) and attributable costs 
were $13,398 (95% CI $1,060-$26,736) when a patient had inadequate antifungal treatment. 
Inadequate antifungal treatment was defined as treatment delay of ≥24 hours from 
Candidemia onset or inadequate dose of antifungal agent active against the pathogen. 
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• Arnold et al.,15 attempted to estimate from 167 consecutive patients the costs of inappropriate 
treatment of Candidemia, which was defined as delayed antifungal therapy >24 hours from 
culture collection. 22 patients had appropriate therapy, 145 did not. Length of stay was shorter 
in the appropriately treated group (7 vs 10.4 days; p-value = 0.037) and the costs were lower 
($15,832 vs $33,021; p-value <0.001) 
 
• Morrell et al.,16 retrospectively analysed 157 consecutive patients over a 4-year period with a 
candida bloodstream infection of which 50 (32%) died during hospitalisation. The number of 
people without a delay in antifungal treatment (>12 hours) was 9, whilst 148 patients had 
delayed treatment. Adjusted odds ratio associated with delay in antifungal treatment was 2.09 
(95% CI 1.53-2.84). Delay in antifungal treatment was also associated with a longer duration 
within ICU (9.4 days vs 0.4 days; p-value = 0.019).  
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Appendix 8 Results from the threshold analyses
The threshold analyses are divided into three categories based on the number of samples assumed torequire analysing per day (2.4, 17 or 68). In each category each intervention is compared with both
blood culture and MALDI-TOF MS. In these analyses it is assumed that the comparator has already been
purchased and that the intervention will require purchasing.
Assuming 2.4 samples a day require analysing
Threshold analyses for SeptiFast versus blood culture
0
0.0
0.2
0.1
0.3
0.4
0.5
0.6
0.7
20 40 60 80 100 120 140 160
Per 100 tests
(λ = £20,000)
Per 100 positive tests
(λ = £20,000)
Per 100 tests
(λ = £30,000)
Per 100 positive tests
(λ = £30,000)
Net reduction in ICU length of stay (days)
N
et
 r
ed
u
ct
io
n
 in
 3
0-
d
ay
 m
o
rt
al
it
y 
(l
iv
es
)
FIGURE 24 Threshold analyses for SeptiFast vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and 2.4 samples need to
be analysed per day.
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FIGURE 25 Threshold analyses for SeptiFast vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and
2.4 samples need to be analysed per day.
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Threshold analyses for SeptiFast versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 26 Threshold analyses for SeptiFast vs. MALDI-TOF MS using net reduction in mortality and net reduction
in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and 2.4 samples need
to be analysed per day.
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FIGURE 27 Threshold analyses for SeptiFast vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and
2.4 samples need to be analysed per day.
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Threshold analyses for SepsiTest versus blood culture
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FIGURE 28 Threshold analyses for SepsiTest vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be purchased and 2.4 samples
need to be analysed per day.
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FIGURE 29 Threshold analyses for SepsiTest vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be
purchased and 2.4 samples need to be analysed per day.
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Threshold analyses for SepsiTest versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 30 Threshold analyses for SepsiTest vs. MALDI-TOF MS using net reduction in mortality and net reduction
in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be purchased and 2.4
samples need to be analysed per day.
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FIGURE 31 Threshold analyses for SepsiTest vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be
purchased and 2.4 samples need to be analysed per day.
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Threshold analyses for IRIDICA versus blood culture
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FIGURE 32 Threshold analyses for IRIDICA vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and 2.4 samples need to
be analysed per day.
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FIGURE 33 Threshold analyses for IRIDICA vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and
2.4 samples need to be analysed per day.
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Threshold analyses for IRIDICA versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 34 Threshold analyses for IRIDICA vs. MALDI-TOF MS using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and 2.4 samples need to
be analysed per day.
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FIGURE 35 Threshold analyses for IRIDICA vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and
2.4 samples need to be analysed per day.
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Assuming 17 samples a day require analysing
Threshold analyses for SeptiFast versus blood culture
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FIGURE 36 Threshold analyses for SeptiFast vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and 17 samples need to
be analysed per day.
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FIGURE 37 Threshold analyses for SeptiFast vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and
17 samples need to be analysed per day.
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Threshold analyses for SeptiFast versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 38 Threshold analyses for SeptiFast vs. MALDI-TOF MS using net reduction in mortality and net reduction
in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and 17 samples need
to be analysed per day.
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FIGURE 39 Threshold analyses for SeptiFast vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and
17 samples need to be analysed per day.
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Threshold analyses for SepsiTest versus blood culture
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FIGURE 40 Threshold analyses for SepsiTest vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be purchased and 17 samples
need to be analysed per day.
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FIGURE 41 Threshold analyses for SepsiTest vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be
purchased and 17 samples need to be analysed per day.
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Threshold analyses for SepsiTest versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 42 Threshold analyses for SepsiTest vs. MALDI-TOF MS using net reduction in mortality and net reduction
in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be purchased and 17
samples need to be analysed per day.
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FIGURE 43 Threshold analyses for SepsiTest vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be
purchased and 17 samples need to be analysed per day.
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Threshold analyses for IRIDICA versus blood culture
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FIGURE 44 Threshold analyses for IRIDICA vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and 17 samples need to
be analysed per day.
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FIGURE 45 Threshold analyses for IRIDICA vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and
17 samples need to be analysed per day.
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Threshold analyses for IRIDICA versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 46 Threshold analyses for IRIDICA vs. MALDI-TOF MS using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and 17 samples need to
be analysed per day.
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FIGURE 47 Threshold analyses for IRIDICA vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and
17 samples need to be analysed per day.
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Assuming 68 samples a day require analysing
Threshold analyses for SeptiFast versus blood culture
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FIGURE 48 Threshold analyses for SeptiFast vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and 68 samples need to
be analysed per day.
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FIGURE 49 Threshold analyses for SeptiFast vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and
68 samples need to be analysed per day.
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Threshold analyses for SeptiFast versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 50 Threshold analyses for SeptiFast vs. MALDI-TOF MS using net reduction in mortality and net reduction
in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and 68 samples need
to be analysed per day.
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FIGURE 51 Threshold analyses for SeptiFast vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the SeptiFast machine needs to be purchased and
68 samples need to be analysed per day.
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Threshold analyses for SepsiTest versus blood culture
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FIGURE 52 Threshold analyses for SepsiTest vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be purchased and 68 samples
need to be analysed per day.
0
0
100
200
300
400
500
600
700
10 20 30 40 50 60 70
Per 100 tests
Per 100 positive tests
Net reduction in ICU length of stay (days)
N
et
 r
ed
u
ct
io
n
 in
 a
n
ti
m
ic
ro
b
ia
l c
o
st
 (
£)
FIGURE 53 Threshold analyses for SepsiTest vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be
purchased and 68 samples need to be analysed per day.
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Threshold analyses for SepsiTest versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 54 Threshold analyses for SepsiTest vs. MALDI-TOF MS using net reduction in mortality and net reduction
in ICU length of stay combined. Assuming that the machinery related to SepsiTest needs to be purchased and 68
samples need to be analysed per day.
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FIGURE 55 Threshold analyses for SepsiTest vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that machinery related to SepsiTest needs to be
purchased and 68 samples need to be analysed per day.
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Threshold analyses for IRIDICA versus blood culture
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FIGURE 56 Threshold analyses for IRIDICA vs. blood culture using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and 68 samples need to
be analysed per day.
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FIGURE 57 Threshold analyses for IRIDICA vs. blood culture using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and
68 samples need to be analysed per day.
DOI: 10.3310/hta20460 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 46
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
245
Threshold analyses for IRIDICA versus matrix-absorbed laser desorption/
ionisation time-of-flight mass spectrometry
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FIGURE 58 Threshold analyses for IRIDICA vs. MALDI-TOF MS using net reduction in mortality and net reduction in
ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and 68 samples need to
be analysed per day.
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FIGURE 59 Threshold analyses for IRIDICA vs. MALDI-TOF MS using net reduction in antimicrobial treatment costs
and net reduction in ICU length of stay combined. Assuming that the IRIDICA machine needs to be purchased and
68 samples need to be analysed per day.
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